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Obesity	  and	  breast	  cancer	  are	  two	  disease	  models	  that	  directly	  affect	  the	  United	  States	  
population,	  as	  more	  than	  35%	  of	  the	  adult	  population	  is	  obese	  [8],	  	  and	  more	  than	  200,000	  new	  
cases	  of	  breast	  cancer	  are	  diagnosed	  in	  the	  United	  States	  per	  year.	  [34].	  Several	  diseases	  are	  
associated	  with	  obesity	  including,	  cardiovascular	  disease,	  insulin	  resistance,	  increased	  
inflammation	  and	  increased	  cancer	  risk	  [9,10].	  Therefore	  it	  essential	  to	  understand	  the	  risks	  
associated	  with	  obesity	  as	  well	  as	  to	  investigate	  possible	  preventive	  and/or	  therapeutic	  
treatment	  strategies.	  
Rhodiola	  crenulata	  is	  a	  Tibetan	  plant	  that	  has	  been	  used	  in	  Eastern	  traditional	  medicine	  
to	  relieve	  depression,	  anxiety,	  fatigue	  and	  to	  aid	  in	  high	  altitude	  biological	  adjustment	  [1].	  
Studies	  have	  also	  suggested	  that	  treatment	  with	  Rhodiola	  sp.	  and	  their	  components	  can	  
improve	  glucose	  homeostasis	  in	  rodent	  models	  of	  insulin	  resistance[2-­‐4]	  and	  inhibit	  tumor	  
growth	  in	  various	  rodent	  models	  for	  cancer	  [5-­‐7].	  However,	  these	  studies	  have	  been	  plagued	  by	  
the	  lack	  of	  strong	  mechanistic	  data.	  
The	  overall	  goal	  of	  this	  dissertation	  is	  to	  determine	  the	  mechanism	  by	  which	  R.	  
crenulata	  affects	  glucose	  homeostasis	  in	  female	  mice	  subjected	  to	  Diet	  Induced	  Obesity	  (DIO)	  




Wnt	  signaling	  and	  Estrogen	  receptor	  signaling)	  in	  breast	  cancer	  cells	  in	  vitro.	  In	  the	  work	  
presented	  in	  this	  dissertation,	  we	  tested	  two	  main	  hypotheses;	  1)	  12	  weeks	  of	  treatment	  with	  R.	  
crenulata	  extract	  will	  decrease	  adiposity,	  improves	  glucose	  metabolism	  and	  obesity	  associated	  
inflammation	  in	  female	  mice	  subjected	  to	  a	  high	  fat	  diet	  and	  2)	  R.	  crenulata	  treatment	  will	  
decrease	  Wnt/β−catenin	  signaling	  and	  Estrogen	  Receptor	  (ER)	  signaling	  in	  cancer	  cell	  lines	  in	  
vitro.	  We	  used	  a	  wide	  variety	  of	  in	  vitro	  and	  in	  vivo	  techniques	  to	  test	  our	  hypotheses.	  Our	  
results	  suggest	  that	  that	  R.	  crenulata	  can	  be	  beneficial	  for	  controlling	  insulin	  resistance	  and	  liver	  
inflammation	  in	  a	  model	  for	  diet	  induced	  obesity.	  We	  also	  demonstrate	  two	  critical	  pathways	  in	  
breast	  cancer	  cells	  that	  are	  controlled	  by	  R.	  crenulata.	  We	  show	  that	  treatment	  with	  a	  
hydroalcoholic	  extract	  inhibits	  the	  canonical	  Wnt	  signaling	  pathway,	  which	  could	  explain	  some	  
of	  the	  anti-­‐neoplastic	  observations	  previously	  described	  by	  the	  Schneider	  lab.	  We	  also	  confirm	  
that	  this	  R.	  crenulata	  extract	  contains	  estrogenic	  compounds;	  however	  despite	  this	  estrogenic	  
activity,	  R.crenulata	  controlled	  proliferation	  and	  decreased	  tumorsphere	  growth	  and	  survival	  
when	  cultures	  were	  treated	  for	  a	  longer	  period	  of	  time.	  Optimistically,	  the	  results	  from	  these	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In	  2012,	  over	  35%	  of	  the	  adult	  population	  in	  the	  United	  States	  of	  America	  had	  a	  body	  
mass	  index	  (BMI)	  higher	  than	  30,	  which	  is	  considered	  obese	  [1]	  [2].	  By	  2030,	  it	  is	  predicted	  that	  
over	  53%	  of	  the	  population	  will	  be	  obese	  [3].	  Obesity	  is	  a	  severe	  epidemic	  that	  leads	  to	  the	  
predisposition	  of	  several	  metabolic	  diseases	  such	  as	  cardiovascular	  diseases,	  insulin	  resistance	  
and	  type	  2	  diabetes	  as	  well	  as	  increased	  inflammation	  [4,5].	  Additionally,	  obesity	  is	  linked	  to	  
cancer	  development	  as	  it	  has	  been	  shown	  that	  5.8%	  of	  cancer	  incidences	  in	  the	  US	  in	  2007	  were	  
impacted	  by	  obesity	  [4].	  Therefore,	  it	  is	  essential	  to	  reduce	  and	  control	  obesity	  associated	  
complications	  and	  explore	  novel	  treatment	  agents	  for	  preventive	  and/or	  for	  therapeutic	  
strategies.	  There	  are	  several	  factors	  that	  were	  implicated	  in	  the	  development	  of	  obesity-­‐related	  
diseases,	  including	  adipocyte	  produced	  adipokines,	  fatty	  acids,	  mitochondrial	  dysfunction,	  
endoplasmic	  reticulum	  stress,	  and	  hypoxia	  [6].	  
1.2	  Glucose	  homeostasis	  and	  obesity.	  
Physiologically,	  obesity	  occurs	  by	  an	  increase	  in	  adipocyte	  size	  followed	  by	  an	  increase	  
in	  preadipocyte	  differentiation	  due	  to	  excess	  caloric	  intake.	  Dietary	  fatty	  acids	  and	  excess	  
carbohydrates	  are	  primarily	  stored	  in	  white	  adipose	  tissue	  (WAT)	  as	  triglycerides.	  Due	  to	  the	  
presence	  of	  excess	  glucose,	  its	  normal	  homeostasis	  is	  deranged.	  WAT,	  along	  with	  skeletal	  
muscle	  and	  the	  liver	  are	  the	  three	  major	  organs	  that	  regulate	  glucose	  homeostasis	  in	  the	  body.	  
Under	  normal	  conditions,	  when	  glucose	  levels	  are	  increased	  in	  the	  blood,	  islet	  cells	  in	  the	  
pancreas	  respond	  by	  secreting	  insulin	  into	  the	  blood,	  enhancing	  glucose	  uptake	  by	  the	  body’s	  




concentration.	  Excess	  glucose	  is	  converted	  to	  triglycerides,	  stored	  in	  WAT	  or	  converted	  to	  
glucagon	  and	  stored	  in	  the	  liver.	  Under	  nutrient	  fasting	  conditions,	  the	  pancreas	  responds	  by	  
releasing	  glycogen	  from	  α-­‐cells,	  which	  converts	  glycogen	  to	  glucose	  and	  restores	  blood	  
homeostasis.	  A	  schematic	  of	  normal	  glucose	  homeostasis	  is	  shown	  in	  Figure1.1.	  
	  
	  
Figure	  1.1:	  Schematic	  of	  glucose	  homeostasis	  in	  mammals	  
	  
Derangements	  in	  glucose	  homeostasis	  can	  occur	  several	  ways.	  Tissues	  can	  decrease	  
their	  glucose	  uptake	  by	  reducing	  the	  expression	  of	  glucose	  transporters	  or	  become	  irresponsive	  
to	  insulin	  stimulation.	  In	  the	  pancreas,	  β-­‐cells	  could	  become	  less	  efficient	  in	  producing	  insulin	  as	  
well	  as	  α-­‐cells	  could	  increase	  glucagon	  production	  resulting	  in	  a	  sustained	  hyperglycemic	  state.	  
Hence	  several	  impairments	  result	  in	  the	  glucose	  derangements.	  	  
At	  the	  cellular	  level,	  obesity-­‐induces	  insulin	  resistance	  by	  hindering	  the	  insulin-­‐signaling	  




secrete	  hormones	  that	  can	  affect	  insulin	  sensitivity	  and	  glucose	  uptake.	  Resistin,	  a	  WAT	  
produced	  hormone,	  has	  been	  shown	  to	  suppress	  insulin	  stimulated	  glucose	  uptake	  in	  adipocytes	  
and	  skeletal	  muscle	  cells	  [7].	  In	  addition,	  several	  studies	  have	  implicated	  cytokines	  and	  
adipokines,	  secreted	  as	  a	  result	  of	  obesity,	  in	  the	  regulation	  of	  glucose	  homeostasis.	  
1.3	  Obesity	  associated	  inflammation	  
Obesity	  induced	  inflammation	  is	  a	  special	  type	  of	  inflammation	  resulting	  from	  over	  
nutrition	  and	  activation	  of	  stress	  pathways	  that	  drive	  abnormal	  metabolic	  homeostasis	  (e.g.,	  
high	  levels	  of	  lipid	  and	  glucose).	  The	  inflammation	  associated	  with	  obesity	  is	  classified	  as	  a	  low-­‐
grade	  inflammation	  and	  results	  in	  an	  increase	  in	  pro-­‐inflammatory	  cytokine	  expression	  in	  the	  
blood	  and	  in	  the	  inflamed	  tissue	  (adipose,	  liver	  and	  muscle	  tissues).	  It	  is	  also	  considered	  a	  
chronic	  inflammation	  since	  it	  occurs	  over	  a	  long	  period	  of	  time.	  It	  is	  classically	  marked	  by	  an	  
increase	  in	  macrophage	  and	  neutrophil	  infiltration	  and	  production	  of	  pro-­‐inflammatory	  
cytokines	  such	  as	  IL-­‐6	  and	  TNFα. Cytokines	  are	  key	  players	  in	  the	  process	  of	  inflammation,	  as	  
they	  can	  act	  directly	  on	  cells	  (such	  as	  TNFα	  [8]	  [9])	  as	  well	  as	  regulate	  the	  recruitment,	  
development	  and	  activation	  of	  other	  tissue-­‐resident	  immune	  cells.	  Therefore	  obesity-­‐activated	  
immune	  cells	  contribute	  and	  produce	  mediators	  that	  perturb	  insulin	  sensitivity	  in	  cells.	  The	  main	  
factors	  shown	  to	  play	  a	  role	  in	  this	  interaction	  are	  the	  cytokines	  and	  tissue	  resident	  
macrophages	  and	  neutrophils.	  A	  schematic	  of	  the	  progress	  of	  obesity-­‐induced	  inflammation	  in	  





Figure	  1.2	  Schematic	  of	  the	  progress	  of	  obesity-­‐induced	  inflammation	  in	  the	  adipose	  
tissue.	  Figure	  J	  Clan	  Invest.	  2003;112(12):	  1785-­‐1788.	  doi:10.1172/JCI20514.	  
1.3.1	  Cytokines	  
TNFα	  was	  the	  first	  identified	  pro-­‐inflammatory	  cytokine	  to	  be	  implicated	  in	  the	  
regulation	  of	  obesity-­‐induced	  insulin	  resistance	  [8,9].	  These	  studies	  showed	  that	  TNFα	  treated	  
adipocytes	  had	  a	  dysregulation	  in	  their	  insulin	  signaling	  due	  to	  changes	  in	  the	  transcription	  of	  
insulin	  signaling	  receptor,	  IRS-­‐1,	  and	  glucose	  transporter	  gene	  4,	  Glut	  4	  [8,9].	  Other	  studies	  have	  
shown	  that	  TNFα	  can	  induce	  the	  inhibitory	  phosphorylation	  of	  IRS	  resulting	  in	  a	  decreased	  
insulin	  response	  [10].	  Several	  animal	  studies	  confirmed	  that	  increased	  TNFα	  levels	  induced	  
insulin	  resistance,	  and	  that	  its	  functional	  inhibition	  improved	  obesity-­‐induced	  inflammation	  and	  
insulin	  sensitivity	  [11]	  [12]	  [13]	  [14].	  IL-­‐6	  is	  another	  pro-­‐inflammatory	  cytokine	  that	  is	  involved	  in	  
this	  type	  of	  inflammation.	  It	  is	  now	  considered	  a	  risk	  factor	  for	  the	  development	  of	  T2D	  in	  
humans	  [15].	  A	  study	  shows	  that	  acute	  IL-­‐6	  infusion	  into	  mice	  induced	  spontaneous	  insulin	  
resistance	  independent	  of	  obesity	  [16],	  therefore	  suggesting	  its	  ability	  to	  modulate	  insulin	  
sensitivity	  in	  adipose	  tissue.	  	  Increased	  IL-­‐6	  and	  IL-­‐1β	  levels	  were	  shown	  to	  increase	  hepatic	  




[17],	  hence	  creating	  a	  secondary	  recruitment	  wave.	  Additionally,	  persistent	  IL-­‐6	  expression	  
levels	  induced	  by	  obesity	  have	  been	  shown	  to	  increase	  the	  risk	  of	  hepatic	  cancer	  development	  
[18].	  Anti-­‐inflammatory	  cytokines,	  such	  as	  IL-­‐10	  were	  also	  noted	  in	  obesity-­‐induced	  
inflammation.	  IL-­‐10	  is	  thought	  to	  primarily	  dampen	  the	  immune	  response	  in	  affected	  tissues,	  
since	  it	  is	  a	  potent	  inhibitor	  of	  the	  pro-­‐inflammatory	  cytokines	  and	  chemokines	  [19].	  This	  was	  
obvious	  when	  a	  study	  that	  subjected	  mice	  overexpressing	  IL-­‐10	  to	  HFD,	  showed	  an	  
improvement	  in	  insulin	  sensitivity	  and	  protection	  from	  obesity	  induced	  insulin	  resistance	  
compared	  to	  wild	  type	  animals.	  They	  reinforced	  their	  findings	  by	  injecting	  exogenous	  IL-­‐10	  into	  
their	  wild	  type	  animals	  causing	  a	  decrease	  in	  Adipose	  Tissue	  Macrophages	  (ATM)	  	  and	  pro-­‐
inflammatory	  cytokines;	  further	  implicating	  reduction	  in	  macrophage	  and	  cytokine	  responses	  in	  
the	  amelioration	  in	  insulin	  sensitivity	  [16].	  
As	  mentioned	  earlier,	  cytokines	  also	  increase	  immune	  cell	  recruitment	  and	  activation	  in	  
the	  inflamed	  tissue.	  Two	  major	  components	  of	  the	  innate	  immune	  cells	  are	  implicated	  in	  this	  
process,	  macrophages	  and	  neutrophils.	  
1.3.2	  Macrophages	  
	  The	  main	  role	  of	  macrophages	  is	  to	  protect	  the	  body	  from	  infections	  by	  removing	  
infected	  cells	  via	  phagocytosis	  as	  well	  as	  recruiting	  other	  cells	  using	  cytokines	  [20].	  When	  pro-­‐
inflammatory	  cytokine	  expression	  is	  increased	  secondary	  to	  obesity,	  resident	  tissue	  
macrophages	  such	  as	  ATMs	  and	  Kuffer	  cells	  (in	  livers),	  are	  polarized	  in	  a	  pro-­‐inflammatory	  
fashion,	  termed	  M1	  polarization,	  which	  recruit	  more	  immune	  cells	  [21].	  In	  the	  adipose	  tissue,	  
M1	  polarized	  macrophages	  cluster	  around	  dead	  adipocytes,	  forming	  crown-­‐like	  structures	  
(CLSs),	  to	  extract	  dead	  adipocytes	  from	  the	  rest	  of	  the	  tissue	  [22].	  On	  the	  other	  hand	  




and	  IL-­‐10,	  and	  are	  thought	  to	  play	  different	  roles,	  namely	  in	  dampening	  the	  pro-­‐inflammatory	  
signals,	  tissue	  remodeling	  and	  wound	  healing	  [21]	  [23].	  The	  general	  consensus	  in	  the	  field	  
suggests	  that	  ATMs	  resident	  macrophages	  have	  M2	  polarization	  and	  that	  obesity-­‐induced	  
inflammation	  changes	  its	  polarization	  into	  M1	  state.	  
Macrophages	  were	  first	  implicated	  in	  the	  development	  of	  obesity-­‐induced	  inflammation	  
when	  ATM	  numbers	  were	  noted	  to	  be	  significantly	  higher	  upon	  feeding	  animals	  a	  high	  fat	  diet	  
[24,25],	  also	  correlating	  with	  an	  increase	  in	  insulin	  resistance.	  	  Several	  successive	  studies	  in	  
animal	  models	  and	  humans	  confirmed	  that	  an	  increase	  in	  ATM	  numbers	  is	  a	  hallmark	  of	  obesity-­‐
induced	  inflammation	  and	  weight	  loss	  leads	  to	  decreases	  in	  infiltrated	  ATMs	  [26]	  [22]	  [27].	  
1.3.3	  Neutrophils	  
Neutrophils	  are	  an	  important	  component	  of	  innate	  immunity	  responding	  to	  obesity	  
complications	  [28].	  They	  utilize	  intracellular	  vesicles	  (granules)	  that	  bear	  enzymes	  such	  as	  
neutrophil	  elastase	  [29]	  and	  myeloperoxidase	  [30],	  and	  release	  it	  in	  the	  inflammation	  site	  to	  
break	  down	  extracellular	  matrix	  protein	  [31]	  and	  aid	  in	  combating	  invading	  microbes.	  However,	  
neutrophils	  also	  produce	  large	  amounts	  of	  cytokines	  and	  chemokines,	  including	  TNF-­‐α,	  IL-­‐1β,	  IL-­‐
8	  and	  MIP-­‐1α,	  allowing	  recruitment	  of	  more	  immune	  cells,	  particularly	  macrophages	  [28].	  
Neutrophils	  have	  been	  implicated	  in	  the	  development	  of	  obesity-­‐induced	  inflammation	  
[30]	  [32].	  They	  invade	  liver	  and	  adipose	  tissue	  early	  in	  the	  obesity	  process	  [29],	  and	  similarly	  to	  
their	  response	  to	  microbes,	  neutrophils	  secrete	  macrophage-­‐recruiting	  cytokines,	  creating	  a	  
secondary	  recruitment	  of	  immune	  cells.	  Neutrophil	  released	  enzymes	  also	  play	  a	  role	  in	  obesity-­‐
induced	  insulin	  resistance,	  specifically	  neutrophil	  elastase.	  In	  one	  study	  that	  used	  high	  fat	  diet	  
feeding	  to	  induce	  inflammation	  it	  was	  demonstrated	  that	  neutrophil	  elastase	  degrades	  IRS-­‐1	  




inhibition	  of	  neutrophil	  elastase	  improves	  obesity-­‐induced	  insulin	  resistance	  and	  inflammation	  
in	  the	  adipose	  and	  liver	  tissue	  [29].	  Another	  study	  suggested	  that	  the	  imbalance	  between	  
neutrophil	  elastase	  and	  its	  inhibitor	  α1-­‐antitrypsin,	  which	  is	  produced	  by	  the	  liver,	  is	  responsible	  
for	  causing	  insulin	  sensitivity	  and	  inflammation	  [33].	  
1.4	  Breast	  cancer	  
Breast	  cancer	  is	  the	  most	  common	  type	  of	  cancer	  among	  women.	  It	  has	  been	  estimated	  
that	  each	  year	  more	  than	  200,000	  new	  cases	  are	  diagnosed	  in	  the	  United	  States	  [34].	  In	  2013,	  
approximately	  40,000	  deaths	  occurred	  due	  to	  this	  disease	  [35].	  	  Breast	  cancer	  incidence	  has	  
been	  steadily	  increasing	  and	  mortality	  rates	  decreasing	  over	  the	  past	  10	  years	  largely	  due	  to	  the	  
improvement	  in	  public	  awareness	  and	  early	  detection	  methods	  such	  as	  mammography	  
screening	  [36].	  Several	  risk	  factors	  have	  been	  found	  to	  contribute	  to	  breast	  cancer	  development	  
including	  alcohol	  consumption	  [37],	  family	  history	  [38],	  early	  menarche	  and	  late	  menopause	  
[39],	  circulating	  hormone	  levels	  [40],	  inflammation	  [41],	  diet	  [42]	  and	  body	  mass	  index	  (BMI)	  
[42,43],	  
1.4.1	  Breast	  cancer	  development	  
Breast	  cancer	  is	  a	  collection	  of	  diseases	  characterized	  by	  an	  abnormal	  proliferation	  of	  
the	  epithelium	  in	  the	  breast.	  Breast	  tumors	  typically	  start	  in	  the	  epithelium	  of	  the	  mammary	  
gland,	  consisting	  of	  lobules	  and	  ducts,	  when	  an	  epithelial	  cell	  acquires	  a	  genetic	  mutation	  
allowing	  it	  to	  survive	  at	  a	  higher	  rate	  than	  other	  cells	  in	  the	  tissue.	  Up	  to	  this	  point,	  the	  tissue	  is	  
benign	  and	  is	  termed	  hyperplasia.	  As	  more	  mutations	  are	  acquired	  over	  time,	  cell	  proliferation	  
increases	  and	  nuclear	  morphology	  changes.	  With	  increased	  mutations,	  local	  tumors	  form	  in	  the	  
tissue	  (in	  situ),	  invade	  and	  eventually	  metastasize	  to	  other	  organs.	  An	  example	  of	  ductal	  





Figure	  1.3	  Schematic	  of	  ductal	  carcinoma	  progression.	  Adapted	  from	  
http://aegiscreative.com/wp-­‐content/uploads/2014/01/Figure-­‐1.png	  
1.4.2	  Breast	  cancer	  types	  and	  treatment	  
Tumors	  are	  pathologically	  categorized	  by	  the	  expression	  or	  absence	  of	  certain	  protein	  
markers,	  including	  estrogen	  receptors	  (ER+/	  ER-­‐),	  progesterone	  receptors	  (PR+/PR-­‐),	  and	  human	  
epidermal	  growth	  factor	  receptor	  2	  (HER2+/HER2-­‐)	  [44,45].	  These	  markers	  assist	  in	  tailoring	  
breast	  cancer	  treatments	  and	  in	  prognosis	  predictions.	  Among	  the	  subgroups	  of	  breast	  cancer	  is	  
Triple	  Negative	  Breast	  Cancer	  (TNBC)(ER-­‐,	  PR-­‐	  Her2-­‐),	  which	  is	  considered	  one	  of	  the	  most	  
aggressive	  forms	  of	  breast	  cancer	  since	  it	  lacks	  expression	  of	  these	  three	  receptors,	  making	  it	  
challenging	  to	  target	  therapeutically	  [44]	  [46].	  
Upon	  characterization	  of	  the	  malignant	  tumor,	  a	  combination	  of	  treatments	  is	  given	  to	  
affected	  individuals.	  Current	  treatment	  options	  consist	  of	  surgery,	  which	  can	  be	  a	  complete	  
removal	  of	  the	  breast	  (mastectomy)	  or	  breast-­‐conserving	  surgery	  (also	  known	  as	  partial	  
mastectomy,	  quadrantectomy,	  and	  lumpectomy).	  For	  the	  latter	  options	  the	  tumor	  and	  margins	  
consisting	  of	  normal	  tissue	  around	  the	  tumor	  are	  removed.	  Radiation	  therapy	  is	  typically	  used	  
post-­‐surgery,	  aimed	  to	  kill	  left	  over	  cancer	  cells	  at	  the	  tumor	  location	  and	  it	  has	  been	  shown	  to	  
reduce	  reoccurrence	  rates	  by	  50%	  [47,48].	  Systemic	  therapies	  are	  also	  another	  treatment	  option	  
that	  can	  be	  combined	  with	  the	  other	  therapies	  and	  several	  treatment	  strategies	  have	  been	  
developed	  over	  time.	  Initially,	  chemotherapeutics	  were	  used	  based	  on	  tumor	  size	  and	  cellular	  




therapy,	  such	  as	  Tamoxifen,	  targets	  the	  estrogen	  receptor,	  which	  is	  upregulated	  in	  ER+	  
subtypes.	  Humanized	  antibodies,	  such	  as	  Herceptin,	  can	  target	  the	  HER2	  receptor	  in	  HER2+	  
subtypes.	  Some	  drawbacks	  have	  been	  observed	  with	  these	  therapies	  like	  nausea	  and	  vomitting	  
occur	  in	  patients,	  additionally,	  cancer	  cells	  can	  develop	  resistance	  to	  targeted	  therapies.	  Hence,	  
novel	  therapeutic	  approaches	  to	  either	  reduce	  the	  side	  effects	  or	  improve	  patient	  prognosis	  
would	  be	  beneficial.	  
1.5	  The	  WNT	  signaling	  pathway	  
Several	  signaling	  pathways	  have	  been	  implicated	  in	  driving	  proliferation	  of	  normal	  
mammary	  epithelial	  and	  cancer	  cells,	  maintaining	  their	  stem	  cell	  characteristics	  and	  survival	  by	  
activating	  embryonic	  and	  developmental	  signaling	  pathways.	  The	  Wnt	  signaling	  pathway	  is	  an	  
excellent	  example.	  Activation	  of	  Wnt	  signaling	  occurs	  when	  Wnt	  ligands	  bind	  to	  Frizzled	  (FZD)	  
receptors	  in	  conjunction	  with	  one	  of	  the	  LDL	  receptor-­‐related	  proteins	  (LRP5	  or	  LRP6).	  	  Receptor	  
activation	  leads	  to	  increased	  nuclear	  β-­‐catenin	  levels	  and	  its	  translocation	  to	  the	  nucleus,	  	  where	  
it	  forms	  a	  complex	  with	  the	  TCF/LEF1	  family	  of	  HMG	  box	  transcription	  factors	  and	  stimulates	  the	  
expression	  of	  specific	  target	  genes.	  Wnt	  signaling	  can	  be	  antagonized	  by	  secreted	  frizzled-­‐
related	  proteins	  (SFRPs)	  that	  mimic	  WNT	  co-­‐receptor	  FZD.	  The	  Wnt/β-­‐catenin	  signaling	  pathway	  
is	  a	  critical	  pathway	  that	  has	  been	  implicated	  in	  several	  functions	  in	  relation	  with	  obesity	  and	  its	  
complications.	  It	  has	  been	  shown	  to	  regulate	  adipogenesis	  in	  a	  paracrine	  and	  autocrine	  manner	  
and	  to	  control	  adipocyte	  differentiation	  [49]	  [6]	  [50]	  [51],	  as	  have	  the	  the	  Wnt	  regulators,	  SFRPs	  
[52]	  [53].	  	  Other	  studies	  have	  also	  shown	  how	  Wnts	  and	  SFRPs	  influence	  inflammation	  [53]	  [54-­‐
56].	  	  Current	  research	  is	  aimed	  at	  trying	  to	  inhibit	  these	  pathways	  to	  affect	  a	  cure.	  Interestingly,	  





The	  number	  of	  individuals	  who	  have	  adopted	  complementary	  and	  alternative	  medicine	  
is	  gradually	  increasing	  as	  an	  approach	  to	  benefit	  personal	  health	  and	  complement	  conventional	  
medicine.	  	  Various	  plants	  used	  in	  traditional	  medicine	  have	  been	  demonstrated	  to	  have	  anti-­‐
oxidative,	  anti-­‐cancer	  and	  immune-­‐modulatory	  effects	  [57]	  [58]	  [59]	  [60].	  Several	  active	  
components	  have	  been	  identified	  and	  characterized	  from	  these	  plants,	  and	  have	  been	  termed	  
nutraceuticals.	  Alternative	  means	  to	  manage	  and	  prevent	  diseases	  has	  been	  a	  motive	  to	  explore	  
nutraceuticals	  and	  understand	  how	  cellular	  changes	  are	  mediated,	  which	  lead	  to	  an	  overall	  
improvement	  in	  the	  presented	  symptoms.	  Nutraceuticals	  are	  typically	  non-­‐toxic,	  which	  gives	  it	  
an	  advantage	  over	  synthetic	  drugs,	  however	  improper	  use	  could	  lead	  to	  serious	  clinical	  
complications	  [61].	  Therefore,	  investigations	  of	  the	  mechanism	  of	  action,	  side	  effects	  and	  
targets	  of	  these	  plants	  are	  needed	  in	  order	  to	  better	  dietary	  supplement	  recommendations,	  
more	  effective	  disease	  prevention	  and	  treatment	  strategies.	  
1.7	  Rhodiola	  crenulata	  
Rhodiola	  sp.	  is	  a	  perennial	  herbaceous	  plant	  growing	  primarily	  in	  dry	  sandy	  ground	  at	  
high	  altitudes	  in	  the	  arctic	  areas	  of	  Europe	  and	  Asia,	  and	  more	  than	  70	  species	  have	  been	  
reported	  to	  exist	  [62].	  Rhodiola	  sp.	  roots	  have	  been	  traditionally	  used	  to	  increase	  physical	  
endurance,	  reduce	  fatigue,	  prevent	  high	  altitude	  sickness,	  and	  to	  relieve	  depression	  [63].	  It	  has	  
been	  reported	  that	  Rhodiola	  sp.	  has	  adaptogenic,	  anti-­‐hypoxic,	  and	  anti-­‐carcinogenic	  properties	  
[64-­‐66],	  in	  addition	  to	  learning	  and	  memory	  enhancements	  [63].	  
1.7.1	  Rhodiola	  sp.	  studies	  with	  obesity	  and	  its	  complications	  
Interestingly,	  Rhodiola	  sp.	  have	  been	  used	  traditionally	  to	  treat	  diabetes	  [67].	  Several	  




lower	  blood	  glucose	  levels.	  	  In	  a	  clinical	  study	  with	  27	  type	  2	  diabetic	  patients,	  R.	  crenulata	  tea	  
treatment	  for	  12–24	  months	  significantly	  lowered	  blood	  glucose	  concentration,	  and	  improved	  
liver	  and	  kidney	  functions.	  R.	  crenulata	  and	  R.	  rosea	  have	  also	  been	  shown	  to	  have	  amylase	  and	  
glucosidase	  inhibitory	  activity,	  suggesting	  that	  these	  plants	  might	  have	  the	  ability	  to	  reduce	  
complex	  sugars	  in	  the	  small	  intestine	  [68].	  Extracts	  or	  isolated	  components	  from	  R.	  rosea	  have	  
been	  implicated	  in	  glucose	  metabolism	  enhancement	  in	  various	  cell	  types	  and	  tissues.	  For	  
instance,Rhodiola	  rosea	  increases	  essential	  energy	  metabolites,	  including	  adenosine	  
triphosphate	  (ATP)	  and	  creatine	  phosphate,	  in	  the	  muscle	  and	  brain	  mitochondria	  of	  mice	  made	  
to	  swim	  to	  their	  limit	  [69].	  Salidroside,	  a	  major	  component	  of	  Rhodiola	  sp.,	  has	  been	  shown	  to	  
stimulate	  glucose	  uptake	  in	  skeletal	  muscle	  cells	  and	  3T3L1	  cells	  by	  activating	  AMP-­‐activated	  
protein	  kinase	  [70,71].	  Additionally,	  R.	  crenulata	  has	  been	  shown	  to	  inhibit	  adipogenesis	  in	  
vitro[72]	  and	  has	  been	  shown	  to	  reduce	  blood	  triglyceride	  levels	  in	  vivo	  [73].	  	  Lastly,	  a	  diabetic	  
rat	  model	  treated	  with	  R.	  crenulata	  has	  been	  shown	  to	  decrease	  fasting	  insulin	  levels,	  serum	  
triglycerides	  and	  free	  fatty	  acids	  [73].	  To	  date,	  it	  is	  unclear	  by	  which	  mechanism	  whole	  Rhodiola	  
sp.	  root	  extract	  ameliorates	  glucose	  metabolic	  disorders	  and	  insulin	  sensitivity.	  
1.7.2	  Rhodiola	  anti-­‐neoplastic	  studies	  
Over	  the	  past	  decade	  several	  studies	  have	  documented	  that	  Rhodiola	  sp,	  also	  has	  
properties	  that	  could	  be	  used	  towards	  the	  prevention	  or	  treatment	  of	  cancer.	  Rhodiola	  rosea	  
was	  shown	  to	  decrease	  DNA	  damage	  in	  bone	  morrow	  cells	  from	  mice	  in	  response	  to	  the	  
mutagen	  N-­‐nitroso-­‐N-­‐methylurea	  [74].	  It	  has	  been	  shown	  to	  increase	  cell	  death	  in	  several	  
cancer	  cell	  lines	  (i.e.	  HL-­‐60	  cells)[75].	  Also,	  R.	  rosea	  and	  salidroside,	  have	  been	  shown	  to	  induce	  
autophagy	  in	  bladder	  cancer	  cell	  lines	  [66].	  In	  humans,	  R.rosea	  has	  been	  shown	  to	  improve	  




increase	  as	  well	  as	  improve	  T-­‐cell	  immunity	  [76].	  In	  our	  lab,	  we	  have	  previously	  demonstrated	  R.	  
crenulata’s	  ability	  to	  decrease	  tumor	  growth	  in	  mice	  harboring	  a	  syngeneic	  triple	  negative	  
mesenchymal-­‐	  like	  breast	  tumor[77],	  decrease	  cancer	  stem	  cell	  characteristics	  in	  vitro	  	  
(tumorsphere	  formation	  and	  invasion)	  and	  increase	  sensitivity	  to	  anoikis	  (cell	  death	  in	  response	  
to	  loss	  of	  attachment)[78].	  
Many	  plant	  supplements/phytochemicals	  have	  been	  shown	  to	  have	  estrogenic	  activity,	  
however	  it	  is	  currently	  unknown	  whether	  Rhodiola	  sp.	  exhibits	  estrogenic	  effects.	  A	  unique	  
abstract	  suggested	  that	  R.	  rosea	  was	  able	  to	  bind	  to	  the	  estrogen	  receptor	  [79],	  but	  no	  effects	  
on	  transcriptional	  activation	  were	  described.	  This	  is	  an	  important	  question	  because	  if	  R.	  rosea	  is	  
estrogenic,	  then	  women	  who	  have	  had	  ER+	  breast	  cancer	  should	  be	  advised	  not	  to	  supplement	  
with	  it	  to	  alleviate	  depression.	  Therefore,	  we	  were	  interested	  in	  determining	  whether	  R.	  
crenulata	  exhibits	  estrogenic	  activity	  in	  vivo	  or	  in	  vitro.	  
1.8	  Statement	  of	  thesis	  
The	  overall	  goal	  of	  the	  dissertation	  work	  outlined	  here	  was	  to	  provide	  new	  insights	  on	  
how	  R.	  crenulata	  enhances	  glucose	  homeostasis	  under	  DIO	  conditions,	  and	  uncover	  possible	  
mechanisms	  of	  R.	  crenulata’s	  anti-­‐neoplastic	  characteristics.	  R.	  crenulata	  roots	  have	  been	  used	  
in	  Eastern	  medicine	  for	  more	  than	  100	  years	  to	  alleviate	  high	  altitude	  sickness	  and	  fatigue	  
without	  causing	  negative	  side	  effects.	  With	  that	  promising	  prospective,	  we	  thought	  it	  would	  be	  
beneficial	  to	  understand	  how	  R.crenulata	  influences	  the	  observed	  improvements	  in	  these	  two	  
disease	  states.	  In	  this	  dissertation	  I	  focused	  on	  two	  conditions:	  obesity	  and	  its	  complications	  and	  
breast	  cancer.	  
In	  chapter	  2,	  we	  describe	  and	  characterize	  how	  diet-­‐induced	  obesity	  (DIO)	  affected	  mice	  




inflammation,	  it	  still	  remained	  unknown	  how	  DIO	  obesity	  affected	  adipogenesis	  and	  
inflammation	  in	  Sfrp	  1	  knock	  out	  mouse	  model.	  We	  report	  that	  loss	  of	  Sfrp1	  exacerbates	  weight	  
gain,	  glucose	  homeostasis	  and	  inflammation	  in	  mice	  in	  response	  to	  diet	  induced	  obesity	  (DIO).	  
Sfrp1-­‐/-­‐	  mice	  fed	  a	  high	  fat	  diet	  (HFD)	  exhibited	  an	  increase	  in	  body	  mass	  accompanied	  by	  
increases	  in	  body	  fat	  percentage,	  visceral	  WAT	  mass,	  and	  adipocyte	  size.	  	  Moreover,	  Sfrp1	  
deficiency	  increases	  the	  mRNA	  levels	  of	  key	  de	  novo	  lipid	  synthesis	  genes	  (Fasn,	  Acaca,	  Acly,	  
Elovl,	  Scd1)	  and	  the	  transcription	  factors	  that	  regulate	  their	  expression	  (Lxr-­‐,	  Srebp1,	  Chreb,	  and	  
Nr1h3)	  in	  WAT.	  Also,	  fasting	  glucose	  levels	  were	  elevated,	  glucose	  clearance	  was	  impaired,	  
hepatic	  gluconeogenesis	  regulators	  were	  aberrantly	  upregulated	  (G6pc	  and	  Pck1),	  and	  glucose	  
transporters	  were	  repressed	  (Slc2a2	  and	  Slc2a4)	  in	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD.	  Additionally,	  we	  
observed	  increased	  steatosis	  in	  the	  livers	  of	  Sfrp1-­‐/-­‐	  mice.	  When	  there	  is	  an	  expansion	  of	  adipose	  
tissue	  there	  is	  a	  sustained	  inflammatory	  response	  accompanied	  by	  adipokine	  dysregulation,	  
which	  leads	  to	  chronic	  subclinical	  inflammation.	  Thus,	  we	  assessed	  the	  inflammatory	  state	  of	  
different	  tissues	  and	  revealed	  that	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD	  exhibited	  increased	  macrophage	  
infiltration	  and	  expression	  of	  pro-­‐inflammatory	  markers	  including	  Il-­‐6.	  	  Our	  findings	  
demonstrate	  that	  the	  expression	  of	  Sfrp1	  is	  a	  critical	  factor	  required	  for	  maintaining	  appropriate	  
cellular	  signaling	  in	  response	  to	  the	  onset	  of	  obesity.	  
In	  chapter	  3,	  we	  describe	  the	  protective	  effect	  of	  R.	  crenulata	  hydroalcaholic	  treatment	  
on	  mice	  being	  fed	  a	  HFD	  for	  12	  weeks.	  Our	  results	  show	  that	  R.	  crenulata	  enhanced	  insulin	  
sensitivity	  in	  an	  obese	  mouse	  model	  and	  decreased	  liver	  inflammation.	  These	  observations	  
suggest	  a	  possible	  mechanism	  to	  explain	  how	  R.	  crenulata	  affects	  insulin	  sensitivity,	  and	  
suggests	  that	  R.	  crenulata	  is	  a	  candidate	  for	  the	  attenuation	  of	  liver	  inflammation.	  Additionally,	  
we	  describe	  how	  glucose	  homeostasis	  is	  affected	  by	  R.	  crenulata	  treatment	  in	  the	  extreme	  




In	  chapter	  4,	  we	  reveal	  the	  inhibition	  of	  WNT/	  β-­‐catenin	  signaling	  by	  R.	  crenulata	  in	  the	  
triple	  negative	  breast	  cancer	  cell	  line,	  MDA-­‐MB-­‐231.	  As	  mentioned	  earlier,	  the	  lab	  had	  
previously	  shown	  that	  R.	  crenulata	  inhibits	  migration	  and	  increases	  sensitivity	  to	  cell	  death	  in	  
TNBC	  cell	  lines	  [78],	  and	  we	  sought	  to	  identify	  the	  mechanism	  by	  which	  it	  imparts	  these	  effects.	  
We	  demonstrate	  that	  R.	  crenulata	  inhibits	  the	  canonical	  WNT	  signaling	  pathway	  in	  MDA-­‐MB-­‐
231	  cells	  by	  showing	  reduced	  β-­‐catenin	  transcriptional	  activity	  and	  function.	  We	  further	  show	  
that	  R.	  crenulata	  inhibits	  β-­‐catenin	  activity	  even	  when	  β-­‐catenin	  accumulation	  is	  induced	  ligand	  
independently,	  and	  that	  it	  prevents	  β-­‐catenin	  nuclear	  localization.	  Our	  data	  convincingly	  show	  
that	  R.	  crenulata	  inhibits	  a	  critical	  pathway,	  WNT/	  β-­‐catenin	  signaling,	  in	  a	  triple	  negative	  breast	  
cancer	  cell	  line	  and	  suggests	  a	  likely	  mechanism	  by	  which	  R.	  crenulata	  inhibits	  invasion	  and	  
increases	  sensitivity	  to	  death.	  
In	  chapter	  5,	  we	  describe	  R.	  crenulata	  estrogenic	  activity	  on	  ER+	  breast	  cancer	  cell	  line	  
(MCF7)	  over	  time	  in	  vitro,	  and	  how	  it	  affects	  normal	  mammary	  epithelial	  ER	  target	  gene	  
expression	  in	  vivo.	  We	  show	  an	  initial	  activation	  of	  ER	  transcriptional	  activity	  by	  dual	  reporter	  
assay,	  qPCR	  and	  proliferation	  of	  MCF7	  cells	  in	  response	  to	  24	  hours	  of	  R.	  crenulata	  treatment.	  
However,	  upon	  longer	  treatment	  basal	  and	  R.	  crenulata	  induced	  transcriptional	  activity	  was	  
suppressed.	  Additionally,	  there	  was	  a	  decrease	  in	  cell	  doubling	  times	  and	  a	  decrease	  in	  
tumorsphere	  formation.	  In	  association	  with	  these	  changes,	  ERα	  transcript	  levels	  were	  decreased	  
and	  active	  β−catenin	  levels	  were	  reduced	  in	  the	  cells	  treated	  for	  2	  weeks.	  Finally,	  we	  show	  no	  
change	  in	  estrogen	  targets	  in	  normal	  mammary	  cells	  in	  vivo.	  These	  data	  suggest	  that	  the	  R.	  
crenulata	  extract	  contains	  components	  with	  estrogenic	  activity.	  	  However,	  R.	  crenulata	  
treatment	  could	  still	  be	  as	  protective	  in	  ER+	  breast	  cancer	  cells,	  as	  longer	  treatment	  reduced	  the	  




tumorsphere	  formation.	  	  Furthermore,	  administration	  of	  20	  mg/kg/day	  R.	  crenulata	  to	  mice	  did	  
not	  have	  an	  observable	  effect	  on	  mammary	  epithelial	  ERα	  target	  gene	  expression	  in	  vivo.	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MICE	  DEFICIENT	  IN	  SFRP1	  EXHIBIT	  INCREASED	  ADIPOSITY,	  DYSREGULATED	  GLUCOSE	  
METABOLISM,	  AND	  ENHANCED	  MACROPHAGE	  INFILTRATION	  
The	  work	  presented	  in	  this	  chapter	  was	  done	  in	  collaboration	  with	  Kelly	  Gauger	  (Gregory),	  
Elizabeth	  M.	  Henchey,	  Josephine	  Wyman,	  Brooke	  Bentley,	  Melissa	  Brown,	  Akihiko	  Shimono,.	  
Parts	  of	  this	  chapter	  are	  taken	  from	  the	  original	  research	  article:	  Gauger	  KJ,	  Bassa	  LM,	  Henchey	  
EM,	  Wyman	  J,	  Bentley	  B,	  et	  al.	  (2013)	  Mice	  Deficient	  in	  Sfrp1	  Exhibit	  Increased	  Adiposity,	  
Dysregulated	  Glucose	  Metabolism,	  and	  Enhanced	  Macrophage	  Infiltration.	  PLoS	  ONE	  8(12):	  
e78320.	  doi:10.1371/journal.pone.0078320	  
2.1	  Introduction	  	  
Obesity	  is	  a	  severe	  epidemic	  that	  causes	  predisposition	  to	  several	  metabolic	  diseases	  
such	  as	  cardiovascular	  diseases	  and	  type-­‐2	  diabetes.	  It	  is	  caused	  by	  an	  increase	  in	  adipocyte	  size	  
and	  eventually	  an	  increase	  in	  preadipocyte	  differentiation	  due	  to	  excess	  diet	  intake	  [1,2].	  In	  
2010,	  the	  United	  States	  of	  America	  CDC	  reported	  that	  35.7%	  of	  adult	  Americans	  are	  obese	  and	  
17%	  of	  children	  are	  obese	  as	  well	  [3].	  	  This	  epidemic	  resulted	  in	  the	  push	  for	  more	  research	  
aimed	  at	  exploring	  adipocyte	  differentiation	  and	  metabolism	  in	  order	  to	  further	  the	  
understanding	  of	  molecular	  mechanisms,	  which	  regulate	  adipocyte	  biology	  in	  order	  to	  develop	  
potential	  therapeutic	  targets.	  	  
Dietary	  fatty	  acids	  are	  primarily	  stored	  in	  white	  adipose	  tissue	  (WAT)	  as	  triglycerides	  and	  
excess	  carbohydrates	  are	  converted	  to	  fats	  via	  de	  novo	  lipogenesis	  [4].	  Most	  cells	  perform	  de	  
novo	  lipogenesis,	  but	  adipocytes	  and	  hepatocytes	  are	  especially	  well	  adapted	  to	  the	  process.	  
The	  genes	  involved	  in	  de	  novo	  lipogenesis	  are	  controlled	  by	  two	  master	  transcription	  regulator	  
proteins	  which	  are	  regulated	  by	  either	  glucose	  (Carbohydrate	  Response	  Element	  Binding	  Protein	  
-­‐ChREBP)	  or	  insulin	  (Sterol	  Response	  Element	  Binding	  Protein	  1-­‐	  SREBP1).	  Increased	  de	  novo	  
lipogenesis	  during	  adipogenesis	  is	  associated	  with	  improved	  insulin	  sensitivity	  [5],	  but	  the	  




increase	  in	  serum	  triglycerides	  and	  adipocyte	  accumulation	  causing	  steatosis	  and	  nonalcoholic	  
fatty	  liver	  disease	  [6].	  
Immune	  cells	  and	  other	  tissues	  produce	  cytokines,	  whereas	  WAT	  produce	  adipokines,	  
such	  as	  adiponectin,	  Interleukin-­‐6	  (IL-­‐6)	  and	  tumor	  necrosis	  factor	  (TNFα)	  [7]	  as	  well	  as	  
hormones	  including	  leptin,	  estrogen	  and	  resistin.	  	  All	  of	  these	  factors	  play	  a	  variety	  of	  roles	  
through	  different	  signaling	  pathways,	  including	  the	  Wnt/β-­‐catenin	  signaling	  pathway,	  in	  multiple	  
tissues.	  The	  physiological	  roles	  affected	  ranging	  from	  promoting	  or	  inhibiting	  adipogenesis,	  
regulating	  the	  immunoresponse	  and	  insulin	  sensitization.	  Activation	  Wnt	  signaling	  occurs	  when	  
Wnt	  ligands	  bind	  to	  Frizzled	  (FZD)	  receptors	  in	  conjunction	  with	  one	  of	  the	  LDL	  receptor-­‐related	  
proteins	  (LRP5	  or	  LRP6).	  	  Receptor	  activation	  leads	  to	  increased	  nuclear	  β-­‐catenin	  levels	  where	  it	  
complexes	  with	  the	  TCF/LEF1	  family	  of	  HMG	  box	  transcription	  factors	  and	  stimulates	  the	  
expression	  of	  specific	  target	  genes.	  Wnt/β-­‐catenin	  signaling	  has	  been	  shown	  to	  regulate	  
adipogenesis	  in	  a	  paracrine	  and	  autocrine	  manner	  and	  to	  control	  adipocyte	  differentiation	  
[8,9,10].	  	  While	  Wnt6,	  Wnt10a	  and	  Wnt10b	  have	  been	  shown	  to	  inhibit	  preadipocyte	  
differentiation	  [8,9,10],	  Wnt5b	  and	  Wnt4	  promote	  adipogenesis	  [11,12].	  
Wnt	  activity	  is	  blocked	  by	  two	  different	  general	  strategies:	  dickkopfs	  (DKKs)	  and	  
secreted	  frizzled-­‐related	  proteins	  (SFRPs),	  which	  serve	  as,	  decoy	  LRP	  and	  FZD	  receptors	  
respectively	  [13,14].	  There	  are	  five	  members	  of	  the	  SFRP	  family	  of	  proteins	  in	  both	  human	  and	  
mouse	  genomes	  (SFRP1and	  5)	  with	  SFRP1,	  SFRP2	  and	  SFRP5	  forming	  a	  subfamily	  based	  on	  
sequence	  similarity	  [15].	  	  These	  proteins	  contain	  a	  cysteine-­‐rich	  domain	  that	  is	  homologous	  to	  
the	  Wnt-­‐binding	  domain	  of	  FZD	  receptor	  proteins	  [16].	  	  However,	  SFRPs	  do	  not	  contain	  a	  
transmembrane	  domain	  and	  therefore	  reside	  in	  the	  extracellular	  compartment	  where	  they	  
antagonize	  Wnt	  signaling	  by	  binding	  to	  Wnt	  ligands	  and	  prevent	  ligand-­‐receptor	  interactions	  




SFRP	  family	  members	  are	  involved	  in	  the	  regulation	  of	  adipogenesis.	  	  In	  vitro,	  treatment	  
with	  recombinant	  SFRP1	  or	  SFRP2	  protein	  in	  3T3-­‐L1	  preadipocytes	  inhibits	  the	  antiadipogenic	  
Wnt/β-­‐catenin	  signal	  and	  induces	  preadipocyte	  differentiation	  [18].	  In	  mice,	  Sfrp1	  expression	  
increases	  during	  adipogenesis	  and	  in	  response	  to	  HFD.	  In	  humans,	  elevated	  SFRP1	  levels	  are	  
observed	  in	  mildly	  obese	  individuals	  and	  are	  reduced	  in	  response	  to	  extreme	  body	  weight	  in	  
morbidly	  obese	  humans	  [18].	  	  The	  role	  of	  Sfrp5	  in	  obesity	  has	  been	  debated,	  as	  some	  groups	  
have	  seen	  Sfrp5	  expression	  increase	  with	  obesity	  and	  a	  protective	  effect	  against	  diet	  induced	  
obesity	  (DIO)	  when	  Sfrp5	  was	  eliminated	  [18,19,20],	  while	  others	  have	  observed	  that	  deletion	  of	  
Sfrp5	  exacerbates	  obesity	  and	  insulin	  resistance	  [21].	  
Increased	  obesity	  has	  been	  shown	  to	  increase	  pro-­‐inflammatory	  cytokine	  production	  
and	  macrophage	  infiltration	  and	  studies	  have	  shown	  the	  involvement	  of	  SFRP1	  and	  Wnt5a	  in	  the	  
inflammatory	  response.	  Specifically,	  Wnt5a	  is	  secreted	  by	  activated	  antigen	  presenting	  cells	  in	  
rheumatoid	  arthiritis	  joints	  and	  promotes	  the	  production	  cytokines	  including	  Interleukin	  (IL)-­‐1,	  
IL-­‐6	  and	  IL-­‐8	  through	  the	  Fzd5-­‐	  CamKII	  noncononical	  Wnt	  signaling	  pathway	  [22,23].	  	  SFRP1	  has	  
been	  shown	  to	  inhibit	  this	  process	  [24,25]	  and	  has	  also	  been	  shown	  to	  block	  leukocyte	  
activation	  and	  cytokine	  production	  in	  vitro	  [26]	  as	  well	  as	  decrease	  neutrophil	  infiltration	  in	  
ischemic	  tissue	  in	  vivo	  [27].	  Thus,	  SFRP1	  plays	  an	  important	  role	  in	  modulating	  the	  inflammatory	  
response.	  
Considering	  the	  involvement	  of	  SFRP1	  in	  adipogenesis	  and	  inflammation,	  we	  sought	  to	  
determine	  the	  effects	  of	  diet-­‐induced	  obesity	  (DIO)	  in	  the	  Sfrp1-­‐/-­‐	  mouse	  model.	  Our	  data	  
reveal	  that	  Sfrp1-­‐/-­‐	  mice	  exhibit	  increased	  adipocity	  in	  WAT,	  hepatic	  steotosis,	  glucose	  
homeostasis	  irregularities	  and	  increased	  inflammatory	  responses.	  These	  novel	  findings	  suggest	  




2.2	  Materials	  and	  Methods	  
2.2.1	  Animals	  
This	  study	  was	  carried	  out	  in	  strict	  accordance	  with	  the	  recommendations	  in	  the	  Guide	  
for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  of	  the	  National	  Institutes	  of	  Health.	  The	  protocol	  
was	  approved	  by	  the	  Baystate	  Medical	  Center	  Institutional	  Animal	  Care	  and	  Use	  Committee	  
(Permit	  Number:	  283237).	  	  Female129/C57Blk6	  control	  mice	  (n=20)	  and	  129/C57Blk6	  Sfrp1-­‐/-­‐	  
mice	  (n=20)	  were	  individually	  housed	  in	  plastic	  cages	  with	  food	  and	  water	  provided	  
continuously,	  and	  maintained	  on	  a	  12:12	  light	  cycle.	  	  Mice	  (n=10/genotype)	  were	  placed	  on	  
either	  a	  normal	  diet	  [(ND)	  Harlan	  Teklad	  global	  18%	  protein	  rodent	  diet	  (#2018)	  containing	  2.8%	  
fat,	  18.6%	  protein]	  or	  placed	  on	  a	  high	  fat	  diet	  [(HFD)	  Bio-­‐Serv	  (#F1850)	  containing	  36.0	  %	  fat,	  
36.2%	  carbohydrate,	  and	  20.5%	  protein]	  starting	  at	  10	  weeks	  of	  age	  for	  12	  weeks.	  Body	  weight	  
was	  recorded	  every	  three	  days	  and	  body	  composition	  was	  monitored	  with	  an	  Echo	  MRI-­‐100	  
(Echo	  Model	  Systems,	  Houston	  TX)	  prior	  to	  initiating	  the	  study,	  6	  weeks	  after	  putting	  the	  mice	  
on	  the	  diet,	  and	  at	  the	  end	  of	  the	  study.	  Upon	  completion	  of	  metabolic	  measurements,	  mice	  
were	  euthanized	  by	  CO2	  followed	  by	  cervical	  dislocation	  and	  bled	  by	  cardiac	  puncture.	  	  
Mammary	  glands	  (3rd,	  4th,	  and	  5th	  inguinal	  glands),	  white	  adipose	  tissue	  [(WAT)	  gonadal,	  renal,	  
mesenteric,	  and	  scapular	  fat	  pads],	  brown	  adipose	  tissue	  (BAT),	  liver,	  pancreas,	  spleen,	  ovary,	  
kidney,	  bone,	  intestines	  and	  muscle	  were	  harvested,	  weighed	  and	  fixed	  in	  buffered	  formalin.	  In	  
addition,	  mammary	  glands,	  WAT,	  BAT,	  and	  livers	  were	  flash	  frozen.	  
2.2.2	  Adipocyte	  size	  
The	  mean	  adipocyte	  size	  of	  the	  gonadal	  fat	  pad	  was	  determined	  by	  computer-­‐assisted	  
image	  analysis	  of	  adipose	  tissue	  sections	  stained	  with	  hematoxylin	  and	  eosin.	  Briefly,	  




CellProfiler	  software	  (The	  Broad	  Institute).	  	  Cells	  were	  identified	  and	  false	  positives	  were	  
removed	  by	  setting	  appropriate	  threshold.	  Images	  were	  then	  converted	  to	  a	  binary	  black	  and	  
white	  image,	  membranes	  were	  shrunk	  to	  a	  skeleton	  (1	  pixel	  wide),	  and	  then	  images	  were	  
inverted.	  	  Adipocytes	  were	  identified	  by	  software	  pixels	  were	  recorded	  and	  converted	  to	  
microns.	  False	  positive	  areas	  (area	  below	  100	  µm2)	  were	  discarded.	  
2.2.3	  Glucose	  tolerance	  test	  
Glucose	  tolerance	  tests	  (GTTs)	  were	  carried	  out	  2,	  6,	  and	  12	  weeks	  after	  animals	  were	  
placed	  on	  the	  ND	  or	  HFD.	  Briefly,	  mice	  were	  fasted	  for	  16	  hours,	  weighed,	  and	  their	  fasting	  
glucose	  levels	  were	  measured	  from	  1-­‐2	  µl	  of	  blood	  obtained	  from	  the	  tail	  vein	  using	  a	  
glucometer	  (OneTouch	  Ultra;	  Lifescan,	  Milpitas,	  CA).	  Mice	  were	  injected	  with	  glucose	  (2	  g	  of	  D-­‐
glucose	  per	  kg	  of	  body	  weight)	  in	  the	  interperitoneal	  cavity	  and	  blood	  glucose	  levels	  were	  
assessed	  15,	  30,	  60,	  90,	  and	  120	  minutes	  after	  injection.	  
2.2.4	  Analysis	  of	  serum	  insulin	  
At	  the	  time	  of	  GTT	  analysis,	  blood	  was	  also	  collected	  from	  the	  tail	  vein	  into	  microfuge	  
tubes	  before	  glucose	  injection	  and	  15	  minutes	  following	  injection.	  	  	  Serum	  was	  collected	  after	  
centrifugation	  at	  1,500	  x	  g	  for	  15	  min	  at	  4°C.	  	  Insulin	  levels	  were	  assessed	  by	  ultrasensitive	  ELISA	  
with	  mouse	  insulin	  standard	  according	  to	  the	  manufacturer’s	  instructions	  (Crystal	  Chem	  Inc,	  
Downers	  Grove	  IL).	  	  
2.2.5	  RNA	  Isolation	  and	  Real-­‐Time	  PCR	  analysis	  
Total	  RNA	  was	  extracted	  from	  gonadal	  fat	  pad	  and	  liver	  of	  mice	  in	  each	  treatment	  group	  
(n=6)	  as	  described	  previously	  [28].	  	  Relative	  levels	  of	  the	  mRNA	  expression	  of	  target	  genes	  were	  




La	  Jolla,	  CA)	  and	  all	  values	  were	  normalized	  to	  the	  amplification	  of	  β-­‐Actin	  and	  calculated	  using	  
the	  2-­‐(ΔΔCt)	  method.	  The	  PCR	  primer	  sequences	  are	  described	  in	  Table	  1	  and	  Table	  S1.	  The	  assays	  
were	  performed	  using	  the	  1-­‐Step	  Brilliant	  SYBRIII	  Green	  RT-­‐PCR	  Master	  Mix	  Kit	  (Stratagene)	  
containing	  200	  nM	  forward	  primer,	  200	  nM	  reverse	  primer,	  and	  100	  ng	  total	  RNA.	  The	  
conditions	  for	  cDNA	  synthesis	  and	  target	  mRNA	  amplification	  were	  performed	  as	  follows:	  1	  cycle	  
of	  50°C	  for	  30	  min;	  1	  cycle	  of	  95°C	  for	  10	  min;	  and	  35	  cycles	  each	  of	  95°C	  for	  30	  s,	  55°C	  for	  1	  
min,	  and	  72°C	  for	  30	  s.	  
2.2.6	  Immunohistochemistry	  
Immunohistochemistry	  (IHC)	  was	  performed	  on	  a	  DakoCytomation	  autostainer	  using	  the	  
Envision	  HRP	  Detection	  system	  (Dako,	  Carpinteria,	  CA).	  Each	  tissue	  block	  was	  sectioned	  at	  4	  µm	  
on	  a	  graded	  slide,	  deparaffinized	  in	  xylene,	  rehydrated	  in	  graded	  ethanols,	  and	  rinsed	  in	  Tris-­‐
phosphate-­‐buffered	  saline	  (TBS).	  Heat	  induced	  antigen	  retrieval	  was	  performed	  in	  a	  microwave	  
at	  98ºC	  in	  0.01	  M	  citrate	  buffer.	  After	  cooling	  for	  20	  minutes,	  sections	  were	  rinsed	  in	  TBS	  and	  
subjected	  to	  primary	  antibodies	  1:100	  [Glut4	  (Novus	  Biologicals,	  Littleton,	  CO)	  and	  F4/80	  (AbD,	  
Serotec,	  Hercules,	  CA)]	  for	  45	  minutes.	  	  Immunoreactivity	  was	  visualized	  by	  incubation	  with	  
chromogen	  diaminobenzidine	  (DAB)	  for	  5	  minutes.	  Tissue	  sections	  were	  counterstained	  with	  
hematoxylin,	  dehydrated	  through	  graded	  ethanols	  and	  xylene,	  and	  cover-­‐slipped.	  	  Images	  were	  
captured	  with	  an	  Olympus	  BX41	  light	  microscope	  using	  SPOT	  Software	  5.1	  (SPOT™Imaging	  
Solutions,	  Detroit,	  MI).	  
2.2.7	  Analysis	  of	  hepatic	  steatosis	  
Formalin	  fixed	  livers	  were	  paraffin-­‐embedded	  and	  sections	  were	  cut	  on	  a	  Leica	  




eosin	  (H&E)	  per	  standard	  protocol.	  	  Frozen	  sections	  were	  used	  for	  the	  detection	  of	  lipid.	  	  Freshly	  
dissected	  liver	  was	  cryoprotected	  in	  30%	  sucrose	  overnight	  and	  then	  flash	  frozen	  in	  Tissue-­‐Tek	  
OCT	  compound	  (Sakura).	  Cryosections	  10	  µm	  thick	  were	  processed	  for	  Oil	  Red	  O	  staining	  in	  a	  
0.3%	  solution	  of	  Oil	  Red	  O	  (Sigma,	  St.	  Louis,	  MO)	  in	  60%	  isopropanol	  for	  15	  min.	  	  After	  washes	  in	  
60%	  isopropanol,	  sections	  were	  counterstained	  with	  Mayer’s	  hematoxylin.	  Images	  were	  
captured	  with	  an	  Olympus	  BX41	  light	  microscope	  using	  SPOT	  Software	  5.1	  (SPOT™Imaging	  
Solutions).	  
2.2.8	  Statistical	  Analysis	  
Results	  were	  analyzed	  using	  a	  two-­‐way	  ANOVA	  with	  Sfrp1	  loss	  and	  HFD	  treatment	  as	  the	  
main	  effects	  unless	  otherwise	  stated.	  Post	  hoc	  tests,	  where	  appropriate,	  were	  performed	  by	  
Bonferroni’s	  t	  test.	  Bonferroni’s	  t	  test	  uses	  the	  mean	  square	  error	  from	  the	  ANOVA	  table	  as	  a	  
point	  estimate	  of	  the	  pooled	  variance	  (Graphpad	  Prism,	  San	  Diego,	  CA).	  Group	  means	  were	  
compared	  using	  Student’s	  t-­‐tests	  (Graphpad	  Prism)	  and	  results	  with	  P<0.05	  were	  considered	  
significant.	  Multilevel	  mixed-­‐effects	  linear	  regression	  was	  used	  to	  compare	  genotype	  and	  diet	  
groups	  on	  mean	  change	  in	  insulin	  secretion	  from	  0-­‐15	  minutes,	  accounting	  for	  any	  within-­‐
subject	  correlation	  of	  repeated	  measurements	  of	  mice	  at	  2,	  6	  and	  12	  weeks.	  Grubb’s	  test	  was	  
used	  on	  all	  data	  to	  identify	  statistical	  outliers	  (http://www.graphpad.com/quickcalcs).	  Statistical	  
outliers	  were	  identified	  in	  some	  data	  sets,	  but	  the	  overall	  results	  were	  not	  altered	  by	  omission.	  
A	  few	  samples	  were	  lost	  during	  processes;	  therefore,	  there	  are	  some	  unequal	  sample	  sizes.	  
2.2.9	  Islet	  Isolation	  
Age	  matched	  male	  129/C57Blk6	  control	  mice	  (n=3)	  and	  129/C57Blk6	  Sfrp1-­‐/-­‐	  mice	  (n=3)	  




Corporation,	  Indianapolis,	  IN)	  was	  injected	  to	  fully	  distend	  the	  donor	  pancreas.	  After	  digestion,	  
islets	  were	  gradient	  purified	  and	  then	  handpicked.	  Cells	  were	  cultured	  with	  RPMI-­‐1640	  solution	  
with	  10%	  heat-­‐inactivated	  fetal	  bovine	  serum	  and	  1%	  penicillin-­‐streptomycin	  (RPMI-­‐1640,	  FBS	  
and	  P-­‐S	  all	  from	  Mediatech,	  Inc.	  Manassas,	  VA)	  in	  a	  5%	  CO2	  incubator	  overnight.	  
2.2.10	  Glucose	  Stimulated	  Insulin	  Secretion	  Assay	  
Islets	  were	  equilibrated	  in	  low	  glucose	  solution	  (2.8	  mM)	  for	  one	  hour.	  Ten	  size-­‐matched	  
islets	  (in	  triplicate	  samples)	  were	  placed	  in	  12	  µm	  Millicell	  Cell	  Culture	  PCF	  inserts	  (Millipore	  
Corporation,	  Burlington,	  MA)	  in	  24	  well	  plates.	  Fresh,	  low	  glucose	  solution	  was	  added	  for	  2	  
hours	  followed	  by	  moving	  the	  insert	  with	  the	  islets	  into	  high	  glucose	  solution	  (16.7	  mM)	  for	  2	  
hours.	  Insulin	  secretion	  was	  determined	  by	  ELISA	  (Mercodia,	  Winston	  Salem,	  NC)	  according	  to	  
the	  manufacturer’s	  instruction.	  
2.2.11	  Islet	  Quantification	  and	  IHC	  
Formalin	  fixed	  pancreas	  was	  paraffin-­‐embedded	  and	  subjected	  to	  H&E	  staining	  
(n=6/treatment	  group).	  Sections	  were	  viewed	  were	  captured	  with	  an	  Olympus	  BX41	  light	  
microscope	  and	  the	  total	  number	  of	  islets	  per	  tissue	  section	  were	  counted.	  IHC	  was	  performed	  
as	  described	  in	  the	  main	  body	  of	  the	  research	  article.	  Tissue	  was	  incubated	  with	  primary	  
antibodies	  1:100	  [C-­‐peptide	  (Cell	  Signaling,	  Danverse,	  MA)	  and	  Glucagon	  (Cell	  Signaling)	  for	  45	  
minutes.	  Images	  were	  captured	  with	  an	  Olympus	  BX41	  light	  microscope	  using	  SPOTSOFTWARE.	  
2.2.12	  Insulin	  tolerance	  test	  
Mice	  were	  fasted	  for	  4	  hours,	  weighed,	  and	  their	  fasting	  blood	  glucose	  levels	  were	  
measured	  from	  the	  tail	  vein	  using	  a	  glucometer	  (OneTouch	  Ultra;	  Lifescan,	  Milpitas,	  CA).	  Mice	  




of	  insulin	  per	  kg	  of	  body	  weight	  in	  the	  interpretational	  cavity	  and	  blood	  glucose	  levels	  were	  
assessed	  15,	  30,	  60,	  90,	  and	  120	  minutes	  after	  injection.	  
2.3	  Results	  
2.3.1	  Loss	  of	  Sfrp1	  exacerbates	  weight	  gain	  and	  adiposity	  in	  mice	  fed	  a	  HFD	  	  
Since	  it	  has	  previously	  been	  shown	  that	  Sfrp1	  levels	  are	  reduced	  in	  the	  adipose	  tissue	  of	  
severely	  obese	  mice	  and	  humans	  [18],	  we	  chose	  to	  evaluate	  the	  effects	  of	  diet-­‐induced	  obesity	  
(DIO)	  in	  Sfrp1-­‐/-­‐	  mice.	  	  Control	  and	  Sfrp1-­‐/-­‐	  mice	  were	  fed	  either	  a	  high	  fat	  diet	  (HFD)	  or	  a	  
normal	  diet	  (ND)	  for	  10	  weeks	  after	  reaching	  12	  weeks	  of	  age.	  Both	  control	  and	  Sfrp1-­‐/-­‐	  mice	  
fed	  a	  HFD	  gained	  weight	  as	  expected	  (Fig.	  2.1A,	  left	  panel),	  with	  a	  more	  rapid	  increase	  in	  Sfrp1-­‐
/-­‐	  mice	  when	  compared	  to	  control	  mice.	  	  A	  two-­‐way	  ANOVA	  revealed	  a	  significant	  effect	  on	  final	  
body	  weight	  in	  response	  to	  Sfrp1	  deficiency	  (F1,	  36=7.95;	  P<0.01)	  and	  the	  HFD	  (F1,	  36=17.04;	  
P<0.001),	  but	  there	  was	  no	  interaction	  between	  these	  two	  main	  effects	  (F1,	  36=2.07;	  P<0.05)	  
(Fig.	  2.1A,	  left	  panel).	  	  Body	  fat	  analysis	  demonstrated	  that	  body	  fat	  percentage	  is	  affected	  by	  
Sfrp1	  loss	  (F1,	  36=45.25;	  P<0.0001)	  at	  the	  time	  the	  study	  was	  initiated,	  but	  there	  is	  
understandably	  no	  diet	  effect	  (F1,	  36=0.12;	  P>0.05)	  or	  interaction	  between	  the	  two	  main	  effects	  
(F1,	  36=3.67;	  P>0.05)	  (Fig.	  2.1B,	  0	  Weeks).	  On	  the	  other	  hand,	  at	  the	  later	  time	  points,	  body	  fat	  
percentage	  was	  affected	  by	  both	  Sfrp1	  loss	  (6	  weeks:	  F1,	  35=16.05;	  P<0.001;	  12	  weeks:	  F1,	  
35=8.03;	  P<0.01)	  and	  the	  HFD	  (6	  weeks:	  F1,	  35=63.83;	  P<0.0001;	  12	  weeks:	  F1,	  35=59.31;	  
P<0.0001),	  but	  there	  was	  no	  interaction	  between	  the	  two	  main	  effects	  (6	  weeks:	  F1,	  35=3.37;	  
P>0.05;	  12	  weeks:	  F1,	  35=0.51;	  P>0.05)	  (Fig	  2.1B	  6	  &12	  weeks).	  	  Evaluation	  of	  fat	  depot	  weight	  
at	  the	  end	  of	  the	  study	  demonstrated	  that	  in	  response	  to	  a	  HFD,	  there	  was	  a	  significant	  increase	  
in	  the	  white	  adipose	  tissue	  (WAT)	  from	  Sfrp1-­‐/-­‐	  mice,	  both	  the	  visceral	  gonadal	  fat	  pad	  and	  in	  




and	  5th	  inguinal	  mammary	  glands	  and	  also	  did	  not	  change	  the	  weight	  of	  brown	  adipose	  tissue	  
(BAT)	  (Fig.	  2.1C).	  Additionally,	  organ	  weight	  was	  recorded	  in	  animals	  on	  both	  diets	  and	  there	  
were	  no	  significant	  changes	  in	  response	  to	  Sfrp1	  deficiency	  (Fig.	  2.S1).	  	  Measurement	  of	  the	  
adipocytes	  comprising	  the	  gonadal	  fat	  pad	  demonstrated	  that	  there	  is	  a	  significant	  increase	  in	  
adipocyte	  size	  from	  Sfrp1-­‐/-­‐	  mice	  compared	  to	  control	  mice	  fed	  a	  Fig.	  2.1D).	  	  Taken	  together	  





Figure	  2.1.	  	  Effects	  of	  high-­‐fat	  diet-­‐induced	  obesity	  on	  weight	  gain	  and	  adiposity.	  	  (A)	  Left	  
panel,	  the	  body	  weight	  of	  control	  and	  Sfrp1-­‐/-­‐	  mice	  put	  on	  a	  ND	  and	  HFD	  was	  monitored	  
every	  3	  days	  after	  being	  put	  on	  the	  diet	  and	  changes	  are	  displayed	  graphically	  as	  percent	  
initial	  body	  weight.	  	  	  Right	  panel,	  Final	  body	  weight	  after	  12	  weeks	  on	  the	  diet.	  	  (B)	  Body	  




weeks),	  and	  at	  the	  end	  of	  the	  study	  (12	  weeks)	  and	  fat	  mass	  was	  normalized	  to	  body	  
weight	  and	  expressed	  as	  percent	  body	  fat.	  (C)	  Average	  weight	  of	  upper	  mammary	  glands	  
(3rd	  &	  4th	  inguinal),	  lower	  mammary	  gland	  (5th	  inguinal),	  gonadal	  fat	  pad,	  renal	  fat	  pad,	  
mesenteric	  fat	  pad,	  scapular	  fat	  pad,	  and	  brown	  adipose	  tissue	  harvested	  from	  mice	  fed	  
a	  HFD	  for	  12	  weeks.	  (D)	  Upper	  panel,	  Representative	  images	  of	  H&E	  staining	  of	  gonadal	  
fad	  pads	  dissected	  from	  mice	  fed	  a	  HFD	  for	  12	  weeks.	  	  Lower	  panel,	  Quantification	  of	  
gonadal	  adipocyte	  size.	  (*p<0.05,**p<0.01,	  ***p<0.001	  significantly	  different	  from	  
control	  mice	  fed	  a	  ND	  using	  Bonferroni’s	  t	  test	  after	  a	  two-­‐way	  ANOVA;	  #p<0.05, 
##p<0.01, ###p<0.001	  significantly	  different	  from	  control	  mice	  fed	  a	  HFD	  using	  student’s	  t	  
test.)	  	  
	  
Figure	  2.S1.	  Tissue	  Weights	  (A)	  Final	  organ	  weights	  from	  control	  and	  Sfrp1-­‐/-­‐	  fed	  a	  ND	  for	  
12	  weeks.	  (B)	  Final	  organ	  weights	  from	  control	  and	  Sfrp1-­‐/-­‐	  fed	  a	  HFD	  for	  12	  weeks.	  
2.3.2	  Glucose	  clearance	  and	  insulin	  secretion	  is	  deregulated	  in	  Sfrp1-­‐/-­‐	  mice	  in	  response	  to	  
DIO	  	  
To	  explore	  glucose	  homeostasis	  and	  insulin	  release,	  a	  glucose	  tolerance	  test	  (GTT)	  was	  
performed	  at	  3	  different	  time	  points	  within	  the	  study	  (Fig	  2.2A).	  	  At	  all	  three	  time	  points	  (2,	  6,	  
and	  12	  weeks),	  Sfrp1-­‐/-­‐	  mice	  on	  a	  HFD	  showed	  significantly	  delayed	  glucose	  clearance	  in	  
response	  to	  a	  1	  time	  glucose	  bolus	  compared	  to	  all	  other	  groups	  (Fig.	  2.2A).	  Fasting	  glucose	  was	  




three	  time	  points,	  there	  was	  a	  significant	  effect	  on	  blood	  glucose	  levels	  in	  response	  to	  both	  
Sfrp1	  loss	  (2	  weeks:	  F1,	  35=36.16;	  P<0.0001;	  6	  weeks	  F1,	  35=21.67;	  P<0.0001;	  12	  weeks:	  F1,	  
35=18.5;	  P<0.0001)	  and	  at	  2	  weeks	  and	  12	  weeks,	  there	  was	  an	  effect	  in	  response	  to	  the	  HFD	  (2	  
weeks:	  F1,	  35=13.67;	  P<0.0001;	  6	  weeks	  F1,	  35=2.47;	  P>0.05;	  12	  weeks:	  F1,	  35=6.73;	  P<0.05).	  	  
However,	  there	  were	  no	  interactions	  between	  the	  main	  effects	  (2	  weeks:	  F1,	  35=0.75;	  6	  weeks:	  
F1,	  35=1.38,	  P<0.05;	  12	  weeks:	  F1,	  35=0.689;	  P<0.05)	  (Fig.	  2.2B).	  	  	  
We	  next	  measured	  insulin	  secretion	  via	  ELISA	  throughout	  the	  study	  (Fig.	  2.2C).	  	  Analysis	  
of	  the	  data	  revealed	  that	  the	  mean	  change	  in	  insulin	  secretion	  was	  significantly	  higher	  in	  mice	  
fed	  a	  ND	  compared	  to	  mice	  fed	  a	  HFD	  after	  adjusting	  for	  genotype.	  	  Likewise,	  mean	  change	  was	  
significantly	  higher	  in	  control	  mice	  compared	  to	  Sfrp1-­‐/-­‐	  mice	  after	  adjusting	  for	  diet.	  	  
Interestingly,	  there	  was	  also	  a	  significant	  interaction	  between	  the	  main	  effects	  on	  insulin	  
change.	  	  The	  effect	  of	  Sfrp1	  loss	  on	  lowering	  the	  change	  in	  insulin	  was	  present	  only	  in	  mice	  fed	  a	  
HFD.	  	  In	  mice	  fed	  a	  ND,	  there	  was	  no	  difference	  in	  insulin	  change	  between	  control	  and	  Sfrp1-­‐/-­‐	  
mice	  (Table	  2.2).	  This	  hyperinsulinemic	  response	  in	  Sfrp1-­‐/-­‐	  mice	  was	  mimicked	  ex	  vivo	  in	  
pancreatic	  islets.	  	  Specifically,	  a	  two-­‐way	  ANOVA	  revealed	  that	  there	  was	  a	  significant	  effect	  on	  
insulin	  secretion	  in	  response	  to	  both	  Sfrp1	  deficiency	  (F1,	  8=12.13;	  P<0.01)	  as	  well	  as	  glucose	  
stimulation	  (F1,	  8=32.43;	  P<0.001),	  and	  there	  was	  also	  an	  interaction	  between	  these	  main	  
effects	  (F1,	  8=9.99;	  P<0.05).	  	  (Fig.	  2.S2A).	  Interestingly,	  the	  HFD	  did	  not	  affect	  the	  quantity	  of	  
glucagon	  expressing	  alpha	  cells	  in	  pancreatic	  islets	  (Fig.	  2.S2B).	  	  The	  total	  number	  of	  islets/slide	  
was	  affected	  by	  Sfrp1	  loss	  (F1,	  19=4.44;	  P<0.05),	  but	  not	  the	  HFD	  (F1,	  19=4.44;	  P<0.05),	  and	  
there	  was	  a	  significant	  interaction	  between	  the	  two	  main	  effects	  (Fig.	  2.S2C).	  Hyperglycemia	  in	  
the	  presence	  of	  high	  insulin	  might	  also	  suggest	  either	  enhanced	  insulin	  tolerance	  or	  a	  secretion	  
of	  inactive	  insulin.	  	  An	  insulin	  tolerance	  test	  (ITT)	  suggested	  that	  Sfrp1-­‐/-­‐	  mice	  may	  not	  be	  




rate	  similar	  to	  the	  control	  animals	  on	  a	  high	  fat	  diet	  (Fig.	  2.S2E).	  Finally,	  immunohistochemical	  
detection	  of	  C-­‐peptide	  in	  pancreatic	  islets	  confirmed	  that	  the	  insulin	  secreted	  by	  Sfrp1-­‐/-­‐	  mice	  
on	  a	  HFD	  is	  indeed	  cleaved	  and	  active	  (Fig.	  2.S2D).	  
2.3.3	  DIO	  misregulates	  the	  expression	  of	  regulatory	  gluconeogenesis	  enzymes	  and	  glucose	  
transporters	  in	  Sfrp1-­‐/-­‐	  mice	  
Glucose	  is	  internally	  produced	  in	  the	  liver	  by	  way	  of	  gluconeogenesis.	  Wnt	  signaling	  
regulates	  gluconeogenesis	  by	  controlling	  the	  expression	  of	  glucose-­‐6-­‐phosphatase	  (G6pc),	  and	  
the	  rate-­‐limiting	  enzyme,	  PEP	  carboxykinase	  (Pck1)	  [29].	  Therefore,	  we	  measured	  the	  mRNA	  
levels	  of	  G6pc	  and	  Pck1	  in	  the	  livers	  of	  our	  animals	  (Fig.	  2.2D).	  We	  observed	  an	  aberrant	  
response	  in	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD	  in	  that	  despite	  the	  elevated	  glucose	  levels	  in	  these	  animals,	  
they	  exhibited	  a	  significant	  increase	  in	  the	  expression	  of	  both	  G6pc	  and	  Pck1	  compared	  with	  
Sfrp1-­‐/-­‐	  mice	  fed	  a	  ND.	  Canonical	  Wnt	  signaling	  has	  been	  shown	  to	  upregulate	  the	  expression	  of	  
these	  enzymes	  [30]	  and	  real-­‐time	  PCR	  analysis	  of	  several	  Wnt	  ligand	  transcripts	  revealed	  that	  
the	  Wnt3a	  ligand	  is	  significantly	  elevated	  in	  response	  to	  a	  HFD	  in	  Sfrp1-­‐/-­‐	  mice	  (Fig.	  2.S3B).	  	  
Glucose	  clearance	  is	  due	  to	  several	  glucose	  transporters	  in	  the	  muscle,	  liver	  and	  fat	  
tissues,	  which	  carry	  the	  circulating	  glucose	  from	  the	  blood	  stream	  into	  cells	  for	  energetic	  storage	  
and	  so	  we	  examined	  the	  expression	  of	  glucose	  transporter	  2	  (Slc2a2	  aka	  Glut2)	  in	  the	  liver.	  As	  
expected,	  control	  mice	  fed	  a	  HFD	  expressed	  elevated	  levels	  of	  Slca2	  when	  compared	  with	  
control	  mice	  fed	  a	  ND.	  	  However,	  the	  expression	  of	  Slca2	  was	  significantly	  reduced	  in	  Sfrp1-­‐/-­‐	  
mice	  fed	  a	  HFD	  compared	  to	  ND	  fed	  mice.	  Similarly,	  in	  the	  gonadal	  fat	  pad,	  the	  transcript	  and	  
protein	  levels	  of	  glucose	  transporter	  4	  (Slc2a4	  aka	  Glut4)	  were	  significantly	  lower	  in	  Sfrp1-­‐/-­‐	  
mice	  fed	  a	  HFD	  (FIg.	  2.2E).	  Glucose	  transporter	  4	  is	  also	  responsible	  for	  insulin	  stimulated	  
glucose	  transport	  into	  the	  muscle	  and	  immunohistochemical	  analysis	  revealed	  that	  HFD	  fed	  




that	  Sfrp1	  deficiency	  results	  in	  a	  multifactorial	  effect,	  which	  includes	  misregulated	  
gluconeogenesis,	  with	  a	  slightly	  compromised	  ability	  to	  clear	  glucose,	  resulting	  in	  impaired	  





Figure	  2.2.	  	  Aberrant	  glucose	  homeostasis	  and	  insulin	  secretion	  observed	  in	  Sfrp1-­‐/-­‐	  mice.	  	  
(A)	  Glucose	  tolerance	  test	  (GTT)	  was	  performed	  at	  three	  separate	  time	  points	  during	  the	  
study	  (2	  weeks,	  6	  weeks,	  and	  12	  weeks).	  After	  a	  16-­‐18	  h	  fast,	  mice	  were	  injected	  with	  2	  
g/kg	  BW	  glucose	  and	  blood	  glucose	  levels	  were	  monitored	  for	  2	  h.	  (B)	  Blood	  glucose	  




before	  (0	  min)	  and	  after	  (15	  min)	  glucose	  injection.	  	  (D)	  For	  real-­‐time	  PCR	  analysis	  of	  
G6pc,	  Pck1,	  and	  Slca2	  gene	  expression,	  total	  RNA	  was	  isolated	  from	  liver	  of	  mice	  in	  each	  
treatment	  group	  (n=6).	  The	  results	  shown	  represent	  experiments	  performed	  in	  duplicate	  
and	  normalized	  to	  the	  amplification	  of	  β-­‐actin	  mRNA.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  
relative	  expression	  with	  respect	  to	  ND	  fed	  mice.	  	  (E)	  Left	  panel,	  For	  real-­‐time	  PCR	  
analysis	  of	  Slca4	  gene	  expression,	  total	  RNA	  was	  isolated	  from	  the	  gonadal	  fad	  pad	  from	  
mice	  in	  each	  treatment	  group	  (n=6).	  Real-­‐time	  PCR	  analysis	  was	  carried	  out	  as	  described	  
above.	  	  Right	  panel,	  gonadal	  fat	  pad	  sections	  were	  subjected	  to	  immunohistochemical	  
analysis	  and	  stained	  for	  Slc2a4	  (brown	  chromogen)	  and	  representative	  images	  were	  
captured	  at	  100X	  are	  displayed	  for	  mice	  in	  each	  treatment	  group	  (scale	  bar	  200	  µm).	  (F)	  
Muscle	  sections	  were	  stained	  for	  Slc2a4	  and	  200X	  images	  were	  captured	  as	  described	  
above	  (scale	  bar	  100	  µm).	  (*p<0.05,**p<0.01,	  ***p<0.001	  significantly	  different	  from	  
control	  mice	  fed	  a	  ND	  using	  Bonferroni’s	  t	  test	  after	  a	  two-­‐way	  ANOVA;	  #p<0.05, 






Figure	  2.S2.	  Assessment	  of	  pancreatic	  function	  and	  morphology	  in	  response	  to	  DIO	  and	  
Sfrp1	  deficiency.	  (A)	  Functional	  analysis	  of	  islets	  derived	  from	  control	  and	  Sfrp1-­‐/-­‐	  mice	  
was	  determined	  by	  glucose	  stimulated	  insulin	  secretion	  (GSIS).	  An	  Insulin	  ELISA	  was	  used	  
to	  measure	  the	  concentration	  of	  insulin	  in	  the	  media	  of	  cultured	  islets	  stimulated	  with	  




were	  subjected	  to	  immunohistochemical	  analysis	  and	  stained	  for	  Glucagon	  (brown	  
chromogen)	  and	  representative	  images	  were	  captured	  at	  200X	  are	  displayed	  for	  mice	  in	  
each	  treatment	  group	  (scale	  bar	  100	  μm).	  (C)	  H&E	  stained	  pancreas	  slides	  were	  viewed	  
at	  40X	  and	  the	  total	  number	  of	  islets	  per	  tissue	  section	  was	  counted.	  (D)Pancreas	  
sections	  were	  subjected	  to	  immunohistochemical	  analysis	  and	  stained	  for	  C-­‐peptide	  
(brown	  chromogen)	  and	  representative	  images	  were	  captured	  at	  200X,	  are	  displayed	  for	  
mice	  in	  each	  treatment	  group	  (scale	  bar	  100	  μm).	  (E)	  Insulin	  tolerance	  test	  (ITT)	  was	  
performed	  at	  the	  end	  of	  the	  study.	  After	  a	  4	  h	  fast,	  mice	  were	  injected	  with	  0.8	  U/kg	  BW	  
insulin	  and	  blood	  glucose	  levels	  were	  monitored	  for	  2	  hours.	  (**p<0.01,	  significantly	  
different	  from	  control	  mice	  fed	  a	  ND	  using	  Bonferroni’s	  t	  test	  after	  a	  two	  way	  ANOVA.)	  
	  
Figure	  2.S3.	  Effect	  of	  Sfrp1	  deficiency	  on	  Wnt	  ligand	  expression	  in	  the	  liver.	  
	  Total	  RNA	  from	  the	  liver	  was	  used	  for	  real-­‐time	  PCR	  analysis	  of	  Wnt3a,	  Wnt5b,	  and	  
Wnt10a	  gene	  expression	  in	  mice	  from	  each	  treatment	  group	  (n=6).	  The	  results	  shown	  
represent	  experiments	  performed	  in	  duplicate	  and	  normalized	  to	  the	  amplification	  of	  β-­‐
actin	  mRNA.	  (A)	  Data	  depict	  relative	  mRNA	  expression	  in	  ND	  fed	  control	  and	  Sfrp1-­‐/-­‐	  
mice.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  relative	  expression	  with	  respect	  to	  ND	  fed	  
control	  mice.	  (B)	  Data	  depict	  relative	  mRNA	  expression	  in	  HFD	  fed	  control	  and	  Sfrp1-­‐/-­‐	  
mice.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  relative	  expression	  with	  respect	  to	  ND	  fed	  
control	  mice.	  (#p<0.05,	  ##p<0.01,	  significantly	  different	  from	  respective	  ND	  fed	  mice	  
using	  student’s	  t	  test.)	  
2.3.4	  Sfrp1-­‐/-­‐	  fed	  HFD	  mice	  exhibit	  hepatic	  steatosis. 
Considering	  that	  we	  observed	  significant	  Sfrp1	  dependent	  changes	  in	  the	  gluconeogenic	  
transcripts	  in	  the	  liver,	  and	  non-­‐alcoholic	  fatty	  liver	  disease	  is	  tightly	  associated	  with	  obesity	  and	  




Although	  we	  did	  not	  observe	  any	  significant	  differences	  in	  gross	  liver	  weight	  (Fig.	  2.S1),	  we	  did	  
observe	  increased	  liver	  steatosis	  in	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD.	  This	  is	  clearly	  illustrated	  by	  oil	  red	  O	  
staining	  of	  frozen	  liver	  sections,	  which	  have	  noticeably	  more	  lipid	  accumulation	  compared	  to	  
control	  HFD	  fed	  mice	  (Fig.	  2.3A).	  These	  findings	  support	  the	  notion	  that	  the	  observed	  hepatic	  
steatosis	  is	  a	  direct	  result	  of	  the	  HFD	  on	  other	  tissues	  rather	  then	  an	  effect	  of	  Sfrp1	  loss	  on	  the	  
misregulation	  of	  lipogenesis	  in	  the	  liver.	  	  
2.3.5	  Sfrp1	  depletion	  increases	  the	  expression	  of	  hepatic	  pro-­‐inflammatory	  cytokines	  	  
The	  accumulation	  of	  fat	  in	  the	  liver	  is	  also	  accompanied	  by	  steatohepatitis,	  progressive	  
inflammation	  of	  the	  liver.	  	  Thus,	  we	  looked	  at	  the	  effect	  of	  DIO	  on	  inflammation	  in	  our	  animal	  
models.	  No	  histological	  signs	  of	  inflammatory	  infiltrate	  were	  observed	  in	  any	  of	  the	  livers	  
regardless	  of	  treatment	  group	  (data	  not	  shown).	  A	  two-­‐way	  ANOVA	  revealed	  that	  there	  were	  no	  
effects	  on	  Tnf-­‐α	  or	  Il-­‐1β	  mRNA	  expression	  in	  response	  to	  Sfrp1	  loss	  (Tnf-­‐α:	  F1,	  20=0.8272;	  
P>0.05;	  Il-­‐1β:	  F1,	  20=0.51;	  P>0.05)	  or	  the	  HFD	  (Tnf-­‐α:	  F1,	  20=0.8841	  P>0.05;	  Il-­‐1β:	  F1,	  20=0.12;	  
P>0.05).	  There	  was	  also	  no	  interaction	  between	  theses	  two	  main	  effects	  (Tnf-­‐α:	  F1,	  20=0.09	  
P>0.05;	  Il-­‐1β:	  F1,	  20=1.83;	  P>0.05).	  	  However,	  a	  two-­‐way	  ANOVA	  showed	  that	  Il-­‐6	  mRNA	  
expression	  levels	  were	  significantly	  affected	  by	  Sfrp1	  loss	  (F1,	  20=25.01;	  P<0.0001),	  though	  
there	  was	  no	  effect	  in	  response	  to	  the	  HFD	  (F1,	  20=3.44;	  P>0.05)	  and	  there	  was	  no	  interaction	  
between	  the	  main	  effects	  (F1,	  20=0.25;	  P>0.05).	  We	  next	  measured	  the	  mRNA	  levels	  of	  the	  pro-­‐
inflammatory	  adipokine	  Visfatin	  (Nampt),	  as	  it	  potently	  induces	  the	  production	  of	  Il-­‐6	  [32].	  A	  
two-­‐way	  ANOVA	  revealed	  a	  significant	  effect	  on	  Nampt	  expression	  in	  response	  to	  Sfrp1	  loss	  (F1,	  
20=31.78;	  P<0.0001)	  and	  the	  HFD	  (F1,	  20=31.86;	  P<0.0001),	  as	  well	  as	  a	  significant	  interaction	  





Figure	  2.3.	  	  Hepatic	  steatosis	  and	  inflammation	  exhibited	  by	  Sfrp1-­‐/-­‐	  mice.	  	  (A)	  Steatosis	  is	  
distinguished	  by	  Oil	  Red	  O	  staining	  of	  lipids.	  Images	  were	  captured	  at	  400X	  and	  
represent	  control	  mice	  and	  Sfrp1-­‐/-­‐	  mice	  on	  a	  HFD	  (scale	  bar	  50	  µm).	  (B)	  H&E	  staining	  of	  
livers	  and	  captured	  as	  described	  above.	  	  (C)	  Total	  RNA	  from	  the	  livers	  in	  each	  group	  (n=6)	  




expression.	  	  The	  results	  shown	  represent	  experiments	  performed	  in	  duplicate	  and	  
normalized	  to	  the	  amplification	  of	  β-­‐actin	  mRNA.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  
relative	  expression	  with	  respect	  to	  ND	  fed	  mice.	  (D)	  Real-­‐time	  PCR	  analysis	  of	  liver	  Il-­‐6,	  
Tnf-­‐α,	  Il-­‐1β,	  and	  Nampt	  gene	  expression	  was	  carried	  out	  as	  described	  above.	  Bars	  
represent	  mean	  ±	  SEM	  of	  the	  difference	  in	  fold	  change	  compared	  with	  control	  ND	  fed	  
mice.	  (*p<0.05,	  **p<0.01,	  ***p<0.001	  significantly	  different	  from	  control	  mice	  fed	  a	  ND	  
using	  Bonferroni’s	  t	  test	  after	  a	  two-­‐way	  ANOVA;	  #p<0.05, ##p<0.01, ###p<0.001	  
significantly	  different	  from	  respective	  ND	  fed	  mice	  using	  student’s	  t	  test.)	  
2.3.6	  Loss	  of	  Sfrp1	  increases	  de	  novo	  lipogenesis	  in	  the	  gonadal	  fat	  pad	  	  
We	  demonstrate	  that	  mice	  deficient	  in	  Sfrp1	  exhibit	  an	  increase	  in	  visceral	  fat	  pad	  
weight,	  with	  the	  gonadal	  fat	  pad	  showing	  the	  highest	  significance	  (Fig.	  2.1C).	  Therefore,	  to	  
elucidate	  the	  contributing	  factors	  leading	  to	  the	  increased	  adiposity,	  we	  took	  a	  closer	  look	  at	  the	  
gonadal	  fat	  pad	  de	  novo	  lipogenesis	  gene	  expression	  profile.	  Real-­‐time	  PCR	  analysis	  revealed	  
that	  the	  mRNA	  transcript	  levels	  of	  several	  de	  novo	  lipogenesis	  genes	  (Acaca,	  Acly,	  Fasn,	  Elov16,	  
and	  Scd1)	  were	  affected	  by	  loss	  of	  Sfrp1.	  Specifically,	  a	  two-­‐way	  ANOVA	  revealed	  that	  there	  was	  
a	  significant	  effect	  on	  Acaca	  expression	  in	  response	  to	  Sfrp1	  loss	  (F1,	  17=27.30;	  P<0.0001)	  and	  
the	  HFD	  (F1,	  17=20.46;	  P<0.001),	  as	  well	  as	  a	  significant	  interaction	  between	  these	  two	  main	  
effects	  (F1,	  17=22.14;	  P<0.001).	  	  Similarly,	  Acly	  expression	  was	  affected	  in	  response	  to	  Sfrp1	  loss	  
(F1,15=7.72;	  P<0.05)	  as	  well	  as	  the	  HFD	  (F1,15=16.20;	  P<0.01),	  and	  there	  was	  a	  significant	  
interaction	  between	  these	  two	  main	  effects	  (F1,15=11.13;	  P<0.01).	  Fasn	  expression	  was	  also	  
altered	  in	  response	  to	  Sfrp1	  loss	  (F1,	  16=11.01;	  P<0.01)	  as	  well	  as	  the	  HFD	  (F1,	  16=19.04;	  
P<0.001),	  and	  there	  was	  a	  significant	  interaction	  between	  these	  two	  main	  effects	  (F1,	  16=13.92;	  
P<0.01).	  	  Elov16	  mRNA	  levels	  were	  affected	  by	  to	  Sfrp1	  loss	  (F1,	  18=5.53;	  P<0.05)	  as	  well	  as	  the	  
HFD	  (F1,	  18=6.77;	  P<0.05)	  and	  there	  was	  a	  significant	  interaction	  between	  these	  two	  main	  
effects	  (F1,	  18=4.41;	  P<0.05).	  Lastly,	  Scd1	  expression	  was	  affected	  by	  Sfrp1	  loss	  (F1,	  18=6.42;	  
P<0.05),	  though	  there	  was	  no	  effect	  in	  response	  to	  the	  HFD	  (F1,	  18=0.90;	  P>0.05)	  and	  there	  was	  




Sfrp1-­‐/-­‐	  mice	  were	  fed	  a	  HFD	  and	  insulin	  levels	  increased,	  the	  mRNA	  expression	  of	  these	  genes	  
was	  reduced	  to	  basal	  levels,	  with	  the	  exception	  of	  Scd1	  (Fig.	  2.4A).	  	  We	  next	  sought	  to	  
determine	  whether	  Sfrp1	  loss	  affects	  the	  transcription	  factors	  involved	  in	  regulating	  the	  mRNA	  
expression	  de	  novo	  lipogenesis	  genes.	  These	  transcription	  factors	  control	  the	  de	  novo	  
lipogenesis	  process	  in	  response	  to	  either	  glucose	  levels	  (Chrebp-­‐α,	  Chrebp-­‐β)	  or	  insulin	  (Srebp1).	  
The	  expression	  of	  each	  of	  these	  genes	  is	  significantly	  elevated	  in	  the	  gonadal	  fat	  pad	  of	  Sfrp1-­‐/-­‐	  
mice	  on	  a	  ND	  (Fig.	  2.4B).	  The	  Lxrα	  transcription	  factor	  (Nr1h3)	  is	  known	  to	  regulate	  cholesterol	  
homeostasis	  and	  uptake,	  and	  our	  results	  demonstrate	  that	  there	  is	  a	  significant	  increase	  in	  
expression	  of	  Nr1h3	  mRNA	  in	  ND	  fed	  Sfrp1-­‐/-­‐	  mice	  (Fig.	  2.4B).	  Interestingly,	  canonical	  Wnt	  
signaling	  is	  enhanced	  in	  response	  Fasn	  [33]	  and	  analysis	  of	  Wnt	  ligands	  in	  the	  gonadal	  fat	  pad	  
shows	  that	  Wnt3a	  is	  overexpressed	  in	  Sfrp1-­‐/-­‐	  mice	  (Fig.	  2.S4).	  	  
2.3.7	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD	  exhibit	  enhanced	  macrophage	  infiltration	  and	  cytokine	  
production	  in	  the	  gonadal	  fat	  pad	  
Since	  visceral	  fat	  is	  prone	  to	  inflammation	  and	  Wnts	  have	  been	  shown	  to	  augment	  
macrophage	  cytokine	  production	  [25],	  we	  investigated	  the	  inflammatory	  state	  of	  the	  gonadal	  fat	  
pad.	  We	  first	  looked	  at	  the	  expression	  of	  F4/80	  (macrophage	  marker)	  in	  control	  and	  Sfrp1-­‐/-­‐	  
mice	  in	  response	  to	  a	  HFD	  and	  found	  that	  Sfrp1-­‐/-­‐	  mice	  exhibit	  a	  significant	  increase	  in	  F4/80	  
mRNA	  (Fig.	  2.4C,	  right	  panel).	  The	  F4/80	  protein	  is	  160-­‐kDa	  cell	  surface	  glycoprotein	  and	  under	  
lipolytic	  conditions,	  F4/80	  positive	  macrophages	  cluster	  around	  dying	  adipocytes	  and	  are	  
referred	  to	  as	  Crown-­‐like	  structures	  (CLS).	  	  These	  structures	  are	  frequently	  detected	  in	  fat	  tissue	  
of	  obese	  patients	  and	  are	  associated	  with	  inflammation	  [34,35].	  Our	  images	  reveal	  that	  more	  
CLSs	  are	  present	  in	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD	  (Fig	  2.4C,	  left	  panel)	  and	  quantification	  confirmed	  
that	  these	  observations	  were	  significantly	  different	  from	  control	  animals	  on	  a	  HFD	  (Fig.	  2.4C,	  




Il-­‐1β	  and	  Nampt).	  	  A	  two-­‐way	  ANOVA	  revealed	  that	  Il-­‐6	  mRNA	  expression	  is	  not	  affected	  by	  
Sfrp1	  loss	  (F1,	  13=3.26;	  P>0.05)	  but	  is	  significantly	  affected	  by	  the	  HFD	  (F1,	  13=9.23;	  P<0.01)	  and	  
there	  is	  a	  significant	  interaction	  between	  these	  two	  main	  effects	  (F1,	  13=4.72;	  P<0.05).	  The	  
expression	  of	  Nampt	  is	  affected	  by	  Sfrp1	  loss	  (F1,	  17=9.42;	  P<0.01)	  but	  it	  is	  not	  significantly	  
affected	  by	  the	  HFD	  (F1,	  17=1.26;	  P>0.05)	  and	  there	  is	  no	  significant	  interaction	  between	  these	  
two	  main	  effects	  (F1,	  17=0.65;	  P>0.05).	  Although	  Tnf-­‐α	  was	  not	  affected	  in	  response	  to	  Sfrp1	  
loss	  (F1,	  18=0.82;	  P>0.05)	  or	  in	  response	  to	  the	  HFD	  (F1,	  18=1.04;	  P>0.05),	  there	  is	  a	  significant	  
interaction	  between	  these	  two	  main	  effects	  (F1,	  18=4.48;	  P<0.05).	  	  The	  expression	  of	  Il-­‐1β	  was	  
not	  affected	  by	  Sfrp1	  loss	  (F1,	  20=0.51	  P>0.05)	  or	  the	  HFD	  (F1,	  20=0.12;	  P>0.05)	  and	  there	  was	  





Figure	  2.4.	  	  Analysis	  of	  de	  novo	  lipid	  synthesis	  and	  the	  inflammatory	  signature	  in	  the	  
gonadal	  fat	  pad.	  	  (A)	  Total	  RNA	  from	  the	  gonadal	  fat	  pad	  in	  each	  group	  (n=6)	  was	  utilized	  
for	  real-­‐time	  PCR	  analysis	  of	  Fasn,	  Acly,	  and	  Acaca,	  Elov16,	  and	  Scd1	  gene	  expression.	  	  
The	  results	  shown	  represent	  experiments	  performed	  in	  duplicate	  and	  normalized	  to	  the	  




change	  compared	  with	  control	  ND	  fed	  mice.	  	  (B)	  Real-­‐time	  PCR	  was	  carried	  out	  utilizing	  
RNA	  from	  the	  gonadal	  fat	  pad	  of	  control	  mice	  and	  Sfrp1-­‐/-­‐	  mice	  on	  a	  ND	  to	  measure	  the	  
relative	  mRNA	  expression	  of	  the	  following	  transcription	  factors:	  Srebp1,	  Chrebp-­‐α,	  
Chrebp-­‐β,	  and	  Nr1h3.	  The	  experiments	  were	  carried	  out	  as	  described	  above	  and	  bars	  
represent	  mean	  ±	  SEM	  of	  the	  difference	  in	  fold	  change	  compared	  with	  control	  ND	  fed	  
mice.	  (C)	  Left	  panel,	  Gonadal	  fat	  pad	  sections	  were	  subjected	  to	  immunohistochemical	  
analysis,	  stained	  for	  F4/80	  (brown	  chromogen),	  and	  representative	  images	  were	  
captured	  at	  100X	  are	  displayed	  for	  mice	  in	  each	  treatment	  group	  (scale	  bar	  200	  µm).	  
Right	  upper	  panel,	  gonadal	  fat	  pad	  RNA	  was	  used	  for	  real-­‐time	  PCR	  analysis	  of	  F4/80	  
mRNA,	  experiments	  were	  carried	  out	  as	  described,	  and	  bars	  represent	  mean	  ±	  SEM	  of	  
the	  relative	  expression	  with	  respect	  to	  ND	  fed	  mice.	  	  Right	  lower	  panel,	  The	  total	  
number	  of	  CLSs	  (see	  arrow	  inset)	  was	  counted	  in	  F4/80	  stained	  gonadal	  fat	  pad	  sections	  
(n=4/genotype)	  (D)	  Real-­‐time	  PCR	  analysis	  of	  liver	  Il-­‐6,	  Tnf-­‐α,	  Il-­‐1β,	  and	  Nampt	  gene	  
expression	  was	  carried	  out	  as	  described	  above.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  
difference	  in	  fold	  change	  compared	  with	  control	  ND	  fed	  mice.	  (*p<0.05,	  **p<0.01,	  
***p<0.001	  significantly	  different	  from	  control	  mice	  fed	  a	  ND	  using	  Bonferroni’s	  t	  test	  
after	  a	  two-­‐way	  ANOVA;	  #p<0.05, ##p<0.01,	  significantly	  different	  from	  respective	  ND	  fed	  
mice	  using	  student’s	  t	  test.)	  
	  
Figure	  2.S4.	  Effect	  of	  Sfrp1	  deficiency	  on	  Wnt	  ligand	  expression	  in	  the	  gonadal	  fat	  pad.	  
Total	  RNA	  from	  the	  gonadal	  fat	  pad	  was	  used	  for	  real-­‐time	  PCR	  analysis	  of	  Wnt3a,	  
Wnt5b,	  and	  Wnt10a	  gene	  expression	  in	  mice	  from	  each	  treatment	  group	  (n=6).	  The	  




amplification	  of	  β-­‐actin	  mRNA.	  (A)	  Data	  depict	  relative	  mRNA	  expression	  in	  ND	  fed	  
control	  and	  Sfrp1-­‐/-­‐	  mice.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  relative	  expression	  with	  
respect	  to	  ND	  fed	  control	  mice.	  (B)	  Data	  depict	  relative	  mRNA	  expression	  in	  HFD	  fed	  
control	  and	  Sfrp1-­‐/-­‐	  mice.	  Bars	  represent	  mean	  ±	  SEM	  of	  the	  relative	  expression	  with	  
respect	  to	  ND	  fed	  control	  mice.	  (#p<0.05,	  ##p<0.01,	  significantly	  different	  from	  respective	  
ND	  fed	  mice	  using	  student’s	  t	  test.)	  
2.4	  Discussion	  
The	  present	  study	  demonstrates	  that	  loss	  of	  Sfrp1	  exacerbates	  adiposity,	  weight	  gain,	  
glucose	  homeostasis	  and	  inflammation	  in	  mice	  on	  a	  HFD.	  It	  is	  well	  established	  that	  Wnt	  signaling	  
is	  important	  for	  preadipocyte	  differentiation	  and	  adipogenesis	  [2].	  	  Some	  ligands	  act	  as	  
inhibitors,	  such	  as	  Wnt10a	  and	  Wnt10b	  [8,9],	  and	  other	  ligands	  promote	  adipogenesis	  such	  as	  
Wnt5b	  and	  Wnt4	  [11,12]	  in	  both	  a	  canonical	  and	  non-­‐canonical	  fashion.	  	  We	  looked	  at	  the	  
expression	  of	  Wnt	  ligands	  in	  the	  gonadal	  fat	  pad	  and	  found	  that	  there	  were	  no	  differences	  in	  the	  
expression	  of	  Wnt5b	  or	  Wnt10b	  (Fig.	  2.S4).	  	  However,	  Sfrp1	  loss	  did	  induce	  an	  increase	  in	  Wnt3a	  
expression	  regardless	  of	  diet	  (Fig.	  2.S4).	  Lagathu	  et.	  al.	  have	  previously	  shown	  that	  the	  Sfrp1	  
profile	  expression	  in	  C57/Bl6	  mice	  and	  humans	  exhibit	  a	  bell-­‐shaped	  expression	  pattern	  in	  
response	  to	  a	  HFD	  and	  a	  decrease	  in	  Wnt/β-­‐catenin	  signaling	  [18].	  Since	  we	  observed	  an	  
increase	  in	  Wnt3a	  expression	  in	  the	  gonadal	  fat	  pad,	  we	  hypothesized	  that	  canonical	  Wnt/β-­‐
catenin	  signaling	  would	  be	  increased	  in	  Sfrp1-­‐/-­‐	  mice,	  but	  no	  differences	  were	  detected	  in	  the	  
gonadal	  or	  liver	  tissue	  of	  hallmark	  canonical	  target	  transcripts	  including	  c-­‐Myc,	  Ccdn1	  and	  Axin2	  
(data	  not	  shown).	  However,	  given	  the	  body	  of	  literature	  linking	  Wnt	  signaling	  to	  breast	  cancer	  
[38],	  we	  measured	  the	  expression	  of	  Axin2	  in	  mammary	  tissue	  of	  control	  and	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  
ND	  or	  HFD	  because	  it	  is	  a	  direct	  readout	  of	  Wnt	  signaling.	  	  We	  found	  that	  contrary	  to	  the	  
gonadal	  fat	  pad,	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD	  exhibit	  an	  up-­‐regulation	  of	  Axin2	  expression	  in	  the	  




must	  be	  independent	  of	  Wnt	  signaling	  since	  SFRP1	  affects	  a	  myriad	  of	  cell	  signaling	  pathways	  
such	  as	  regulating	  thrombospondin,	  ADAM	  proteases	  and	  RANKL	  [37,39,40,41,42]	  
To	  determine	  the	  mechanism	  by	  which	  Sfrp1-­‐/-­‐	  mice	  exhibit	  enhanced	  growth	  of	  WAT	  fat	  
depots,	  we	  analyzed	  genes	  involved	  in	  de	  novo	  lipogenesis.	  Lxr-­‐α,	  Srebp1	  and	  Chrebp	  are	  three	  
transcription	  factors	  critical	  for	  regulating	  a	  majority	  of	  target	  genes	  that	  comprise	  this	  pathway	  
[43].	  The	  finding	  that	  the	  expression	  of	  these	  transcription	  factors	  and	  their	  targets	  are	  
upregulated	  in	  Sfrp1-­‐/-­‐	  mice	  suggests	  a	  novel	  pathway	  in	  which	  loss	  of	  Sfrp1	  enhances	  lipogenesis	  
and	  may	  explain	  why	  heavier	  fat	  depots	  are	  observed	  in	  the	  Sfrp1-­‐/-­‐	  animals.	  	  Fatty	  acids	  are	  
critical	  for	  embryonic	  development	  and	  also	  for	  the	  development	  of	  cancer.	  Interestingly,	  
palmitate,	  an	  end	  product	  of	  the	  de	  novo	  lipid	  synthesis,	  is	  an	  important	  regulator	  of	  Wnt	  
signaling	  [33].	  Thus,	  Sfrp1	  deficiency	  in	  some	  tissues	  may	  also	  regulate	  Wnt	  activity	  through	  
indirect	  control	  of	  the	  de	  novo	  lipid	  synthesis	  transcriptional	  machinery.	  	  The	  regulation	  of	  de	  
novo	  lipid	  synthesis	  by	  Sfrp1	  loss	  is	  a	  novel	  observation	  and	  future	  research	  will	  need	  to	  be	  
carried	  out	  to	  determine	  whether	  palmitate	  production	  is	  higher	  in	  the	  tissues	  of	  Sfrp1-­‐/-­‐	  mice.	  
We	  clearly	  demonstrate	  that	  loss	  of	  Sfrp1	  results	  in	  a	  marked	  effect	  on	  fasting	  glucose	  
levels	  and	  glucose	  clearance	  (Fig.	  2.2A&B).	  Increased	  circulating	  glucose	  may	  be	  due	  to	  several	  
factors	  including	  reduced	  insulin	  secretion,	  less	  β cells	  in	  pancreatic	  islets,	  insulin	  resistance,	  an	  
impaired	  cellular	  ability	  to	  uptake	  glucose	  due	  to	  reduced	  glucose	  transporter	  levels,	  or	  
overproduction	  of	  glucose	  in	  the	  liver	  by	  way	  of	  gluconeogenesis.	  	  Initially	  we	  hypothesized	  that	  
Sfrp1-­‐/-­‐	  animals	  produced	  a	  reduced	  amount	  of	  active	  insulin	  because	  our	  insulin	  tolerance	  tests	  
showed	  that	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD	  exhibited	  a	  very	  similar	  level	  of	  insulin	  resistance	  to	  control	  
mice	  fed	  a	  HFD	  (Fig	  2.S2E).	  However,	  our	  insulin	  ELISAs	  revealed	  that	  the	  Sfrp1-­‐/-­‐	  animals	  were	  in	  
fact	  hyperinsulinemic	  on	  the	  HFD	  group	  as	  early	  as	  2	  weeks	  after	  starting	  the	  diet	  (Fig.	  2.2C).	  	  




glucose	  (Fig.	  2.S2A)	  and	  these	  data	  help	  explain	  the	  observed	  elevated	  serum	  insulin	  levels	  in	  
response	  to	  Sfrp1	  loss.	  This	  is	  in	  agreement	  with	  the	  literature,	  as	  both	  Wnt3a	  and	  Wnt5a	  
enhance	  glucose	  stimulated	  insulin	  release	  from	  islet	  cells	  and	  addition	  of	  recombinant	  human	  
SFRP1	  and	  SFRP4	  has	  been	  shown	  to	  inhibit	  insulin	  secretion	  [44].	  We	  also	  took	  a	  closer	  look	  at	  
the	  islets	  and	  the	  insulin	  being	  released	  from	  Sfrp1-­‐/-­‐	  mice	  and	  showed	  that	  insulin	  is	  cleaved	  
properly	  and	  glucagon	  levels	  are	  not	  affected	  in	  response	  to	  Sfrp1	  loss	  (Fig.	  2.S2).	  However,	  
although	  the	  number	  of	  pancreatic	  islets	  was	  increased	  in	  control	  mice	  fed	  a	  HFD	  as	  expected,	  
this	  increase	  did	  not	  occur	  in	  response	  to	  Sfrp1	  deficiency	  (Fig.	  2.S2C)	  which	  could	  render	  Sfrp1-­‐/-­‐	  
mice	  more	  susceptible	  to	  β	  cell	  burn	  out	  and	  further	  metabolic	  disregulation	  recapitulating	  a	  
type-­‐2	  diabetes	  model.	  The	  reduction	  in	  glucose	  transporter	  expression	  (Fig.	  2.2D,	  E	  &	  F)	  also	  
partially	  explains	  the	  observed	  hyperglycemia.	  Additional	  research	  must	  be	  undertaken	  to	  
investigate	  the	  relationship	  between	  Sfrp1	  loss	  and	  metabolic	  syndromes.	  
Obesity	  can	  also	  be	  associated	  with	  hepatosteatosis,	  which	  results	  from	  lipid	  
accumulation	  in	  the	  liver	  and	  associated	  inflammation.	  Loss	  of	  Sfrp1	  results	  is	  hepatosteatosis	  
(Fig.	  2.3A&B),	  which	  has	  been	  mechanistically	  demonstrated	  to	  be	  regulated	  by	  Il-­‐6	  as	  well	  as	  
Ppar-­‐α	  and	  Ppar-­‐γ	  ligands	  leading	  to	  expression	  of	  Fabp1,	  Chrebp	  and	  other	  genes	  involved	  in	  de	  
novo	  lipid	  synthesis	  [45,46].	  	  However,	  Sfrp1	  deficiency	  had	  very	  little	  effect	  on	  de	  novo	  lipid	  
sythesis	  gene	  expression	  in	  the	  liver	  (Fig.	  2.3D)	  suggesting	  that	  the	  accumulated	  lipid	  is	  likely	  
due	  to	  increased	  transport	  and	  accumulation	  of	  lipid	  from	  other	  organs.	  For	  instance,	  lipid	  
accumulation	  can	  also	  occur	  in	  response	  to	  changes	  in	  the	  levels	  of	  insulin	  that	  signal	  through	  
the	  insulin	  receptor	  substrate	  (IRS)	  which	  upregulate	  fatty	  acid	  transport	  proteins	  (FATP)	  that	  
uptake	  and	  store	  circulating	  lipids	  made	  elsewhere	  in	  the	  body	  [47].	  	  Thus,	  the	  systemic	  
hyperinsulinemia	  together	  with	  the	  increased	  Il-­‐6	  expression	  (Fig.	  2.3D)	  may	  also	  be	  driving	  the	  




The	  increased	  macrophage	  infiltration	  and	  pro-­‐inflammatory	  cytokine	  expression	  
observed	  in	  Sfrp1-­‐/-­‐	  mice	  was	  expected	  based	  in	  the	  link	  between	  obesity	  and	  inflammation.	  
Periera	  et.	  al.	  have	  also	  demonstrated	  that	  human	  SFRP1	  plays	  a	  role	  in	  cytokine	  regulation	  by	  
showing	  that	  addition	  of	  recombinant	  human	  SFRP1	  to	  LPS-­‐stimulated	  macrophages	  results	  in	  a	  
reduction	  in	  the	  levels	  of	  Il-­‐6,	  Il-­‐8	  and	  IL-­‐1β [24].	  	  However,	  the	  selective	  upregulation	  of	  Il-­‐6	  
over	  Tnf-­‐α	  and	  Il-­‐1β in	  our	  Sfrp1-­‐/-­‐	  mice	  (Fig.	  2.3D;	  Fig.	  2.4D;	  Fig.	  2.5B)	  differs	  from	  other	  models	  
for	  Wnt	  antagonist	  loss.	  Specifically,	  Sfrp5-­‐/-­‐	  mice	  exhibit	  an	  increase	  in	  the	  levels	  of	  all	  three	  
inflammatory	  cytokines	  [21].	  In	  addition,	  Mori	  et.	  al.	  showed	  that	  a	  compensatory	  increase	  in	  
Sfrp1	  occurs	  in	  Sfrp5	  mutant	  mice	  and	  so	  we	  examined	  the	  levels	  of	  Sfrp5,	  Sfrp4	  and	  Sfrp2	  in	  
gonadal	  adipose	  tissue	  and	  noted	  that	  expression	  of	  Sfrp5	  is	  increased	  in	  Sfrp1-­‐/-­‐	  mice	  fed	  a	  HFD,	  
while	  the	  control	  animals	  demonstrated	  a	  decrease	  in	  Sfrp5	  (data	  not	  shown).	  	  We	  suspect	  that	  
some	  of	  the	  heterotypic	  effects	  that	  we	  observe	  in	  the	  gonadal	  cytokine	  expression	  levels	  may	  
be	  due	  to	  the	  replacement	  and	  slightly	  differential	  activity	  of	  SFRP5.	  	  
Nicotinamide	  Phosphoribosyltransferase	  (Nampt	  aka	  Visfatin	  and	  Pbef)	  is	  an	  adipokine	  
that	  has	  recently	  generated	  excitement	  since	  its	  expression	  has	  strong	  correlation	  with	  obesity	  
and	  type-­‐2	  diabetes	  [47,48,49,50].	  Interestingly,	  Nampt	  has	  also	  been	  shown	  to	  promote	  
glucose-­‐induced	  insulin	  secretion,	  protect	  against	  islet	  death,	  and	  regulate	  Il-­‐6	  as	  well	  as	  Il-­‐17	  
expression	  in	  immune	  cells	  [51,52].	  We	  consistently	  observed	  increased	  tissue	  expression	  of	  
Nampt	  in	  Sfrp1-­‐/-­‐	  mice	  (Fig.	  2.3D;	  Fig.	  2.4D;	  Fig.	  2.5B)	  which	  suggests	  that	  Sfrp1	  may	  be	  
responsible	  for	  controlling	  the	  expression	  of	  Nampt	  and	  that	  this	  upregulation	  may	  explain	  the	  
increased	  insulin	  secretion	  (Fig.	  2.2C)	  and	  Il-­‐6	  expression	  (Fig.	  2.3D;	  Fig.	  2.4D;	  Fig.	  2.5B).	  	  
The	  typical	  western	  diet	  is	  rich	  in	  fat	  and	  carbohydrates	  and	  is	  resulting	  in	  rapid	  overall	  
weight	  gain	  in	  the	  US	  population	  that	  has	  been	  likened	  to	  an	  epidemic.	  Several	  recent	  studies	  




family	  members	  [70].	  Furthermore,	  SNPs	  in	  the	  human	  SFRP1	  gene	  are	  associated	  with	  body	  
composition	  suggesting	  that	  differences	  in	  SFRP1	  expression	  may	  play	  a	  role	  in	  regulating	  waist	  
to	  hip	  ratios	  [71].	  Thus,	  given	  the	  link	  between	  Wnt	  signaling,	  adipogenesis,	  diabetes	  and	  these	  
epidemiological	  studies,	  it	  is	  important	  to	  ascertain	  whether	  SFRP	  family	  members	  are	  critical	  
adipokines	  that	  can	  be	  used	  for	  the	  prevention	  of	  health	  issues	  related	  to	  weight	  gain	  and/or	  to	  
identify	  higher	  risk	  individuals.	  	  This	  study	  focused	  on	  Sfrp1	  as	  it	  is	  expressed	  in	  and	  secreted	  
from	  numerous	  cell	  types.	  This	  research	  is	  important	  because	  it	  supports	  the	  notion	  that	  Sfrp1	  is	  
a	  critical	  secreted	  protein	  that	  is	  capable	  of	  regulating	  weight	  gain,	  glucose	  homeostasis	  and	  
insulin	  production	  through	  distinct	  targets	  on	  various	  cell	  types.	  The	  alteration	  of	  expression	  of	  
other	  secreted	  factors	  such	  as	  Il-­‐6,	  Nampt,	  Tgf-­‐β and	  Serpine1	  are	  likely	  to	  partially	  explain	  the	  
pleiotropic	  effects	  observed	  and	  will	  be	  the	  focus	  of	  future	  studies.	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Table	   2 . 1:	  PCR	  primer	   sequences	   for	   real-­‐time	   PCR	  analysis	  
	  
G6pc	   forward	  
reverse	  
5'- ACACCGACTACTACAGCAACAG -3' 
5'- CCTCGAAAGATAGCAAGAGTA -3' 
Chrebp	  	  α	   forward	  
reverse	  
5'- CGACACTCACCCACCTCTTC -3' 







Chrebp-­‐	  	  β 	  
forward	  
	  
5'- TCTGCAGATCGCGTGGAG -3' 












5'- AGGAGTGTCGACTTCGCAAA -3' 



















5'- GCTGCGGAAACTTCAGGAAAT -3' 
	  




5'-TGTCTCAGCCTCTTCTCATTCC -3 ' 




























5'- GGCAGAAGCCGAGTTCAA -3 ' 

























5'- GGAGCCATGGATTGCACATT -3' 












0.0789	   ng/mL	  
	  
0.022	   ng/mL	  
ND	   0.159	   ng/mL	  *** 0.023	   ng/mL	  
Genotype	   	   	  
Sfrpl	  	  	  -­‐1-­‐	   0.0809	   ng/mL	   0.023	   ng/mL	  
Control	   0.154	   ng/mL	  ** 0.022	   ng/mL	  
Diet/Genotype	   	   	  
HFD!Sfrpl	  	  -­‐1-­‐	   0.007	   ng/mL	  ** 0.032	   ng/mL	  
HFD/Control	   0.147	   ng/mL	   0.031	   ng/mL	  
ND	  /	  Sfrpl	  	  	  -­‐1-­‐	   0.156	   ng/mL	   0.032	   ng/mL	  
ND/Control	   0.161	  ng/	  mL	   0.032	  ng/	  mL	  




RHODIOLA	  CRENULATA	  ATTENUATES	  DIET	  INDUCED	  OBESITY	  LIVER	  INFLAMMATION	  
3.1	  Introduction	  
In	  the	  United	  States,	  more	  than	  35%	  of	  the	  adult	  population	  is	  obese.	  More	  importantly,	  
obesity	  associated	  inflammation	  predisposes	  one	  to	  several	  metabolic	  disorders	  including	  
cardiovascular	  disease,	  non-­‐alcoholic	  fatty	  liver	  (NAFLD)	  and	  type-­‐2	  diabetes	  [1].	  	  
A	  major	  organ	  affected	  by	  obesity-­‐induced	  inflammation	  is	  the	  liver.	  It	  has	  been	  shown	  
that	  increased	  lipid	  deposits	  in	  the	  liver	  leads	  to	  steotosis	  and	  an	  increase	  in	  inflammation	  [2],	  
which	  in	  its	  turn	  decreases	  insulin	  sensitivity	  in	  the	  liver	  [3].	  Both	  macrophages	  [4]	  and	  
neutrophils	  [5]	  have	  been	  reported	  to	  contribute	  to	  liver	  insulin	  resistance.	  	  
Rhodiola	  sp.	  is	  a	  perennial	  herbaceous	  plant	  growing	  primarily	  at	  high	  altitudes	  in	  the	  
arctic	  areas	  of	  Europe	  and	  Asia.	  It	  is	  an	  adaptogen	  [6]	  which	  has	  been	  traditionally	  used	  to	  
increase	  physical	  endurance,	  reduce	  fatigue,	  prevent	  high	  altitude	  sickness,	  and	  relieve	  
depression	  [7].	  Several	  studies	  have	  reported	  that	  Rhodiola	  rosea	  as	  well	  as	  one	  of	  its	  major	  
components,	  salidroside,	  attenuate	  pro-­‐inflammatory	  responses	  in	  inflammation	  associated	  
disease	  models	  for	  Alzheimers	  [8]	  and	  hepatitis	  [9]	  by	  attenuating	  IL-­‐6,	  TNFα and	  IL-­‐1β.	  In	  a	  
diabetic	  rat	  model,	  Rhodiola	  crenulata	  was	  shown	  to	  decrease	  fasting	  insulin	  and	  serum	  
triglyceride	  levels	  as	  well	  as	  improve	  insulin	  resistance	  [10].	  Furthermore,	  in	  a	  clinical	  study	  with	  
type	  2	  diabetic	  patients,	  R.crenulata	  treatment	  for	  12–24	  months	  significantly	  lowered	  blood	  
glucose	  concentration,	  and	  improved	  liver	  and	  kidney	  function	  [11].	  Despite	  these	  encouraging	  
results,	  neither	  study	  assessed	  the	  mechanism	  by	  which	  R.crenulata	  treatment	  improved	  insulin	  
resistance.	  	  
In	  this	  study,	  we	  aimed	  to	  investigate	  the	  effect	  of	  R.	  crenulata	  treatment	  on	  liver	  
inflammation	  following	  placement	  of	  animals	  on	  a	  high	  fat/high	  carb	  diet	  for	  12	  weeks	  to	  induce	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obesity.	  Our	  results	  suggest	  that	  an	  R.	  crenulata	  extract	  protects	  the	  liver	  from	  inflammation	  
associated	  with	  diet-­‐induced	  obesity	  (DIO)	  and	  this	  is	  associated	  with	  improved	  insulin	  
sensitivity.	  
3.2	  Materials	  and	  Methods	  
3.2.1	  Animal	  care	  and	  treatment	  
This	  study	  was	  carried	  out	  in	  strict	  accordance	  with	  the	  recommendations	  in	  the	  
Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  of	  the	  National	  Institutes	  of	  Health.	  
This	  protocol	  was	  approved	  by	  the	  Baystate	  Medical	  Center	  Institutional	  Animal	  Care	  and	  Use	  
Committee	  (IACUC).	  Female129/C57Blk6	  mice	  (n=40)	  were	  individually	  housed	  in	  plastic	  cages	  
with	  food	  and	  water	  provided	  continuously,	  and	  maintained	  on	  a	  12:12	  light	  cycle.	  	  Mice	  (n=10)	  
were	  placed	  on	  either	  a	  normal	  diet	  [(ND)	  Harlan	  Teklad	  global	  18%	  protein	  rodent	  diet	  (#2018)	  
containing	  2.8%	  fat,	  18.6%	  protein]	  or	  placed	  on	  a	  high	  fat	  diet	  [(HFD)	  Bio-­‐Serv	  (#F1850)	  
containing	  36.0	  %	  fat,	  36.2%	  carbohydrate,	  and	  20.5%	  protein]	  starting	  at	  10	  weeks	  of	  age	  for	  12	  
weeks.	  R.crenulata	  root	  extract	  powder	  (Barrington	  Chemical	  Corporation,	  Harrison,	  NY),	  
containing	  a	  total	  of	  132.0	  mg/g	  dry	  weight	  (dw)	  of	  phenolic	  compounds	  (2.07±0.08	  mg/g	  dw	  of	  
Tyrosol,	  Coumaric	  0.33±0.01	  mg/g	  dw,	  and	  6.17±0.31	  of	  Gallic	  acid)	  as	  described	  in	  [12]	  ,	  was	  
dissolved	  in	  10%	  ethanol	  hydroalcaholic	  solution	  and	  filter	  sterilized.	  R.crenulata	  and	  or	  
equivalent	  volume	  of	  vehicle	  treatment	  (10%	  ethanol	  solution)	  was	  supplemented	  in	  the	  water	  
at	  a	  concentration	  depending	  on	  average	  cage	  weight	  knowing	  that	  the	  average	  mouse	  imbibes	  
4.2	  mL/day	  for	  an	  average	  consumption	  of	  20-­‐mg/kg/day	  concentration	  R.	  crenulata.	  Body	  
weight	  was	  recorded	  and	  body	  composition	  was	  monitored	  with	  an	  Echo	  MRI-­‐100	  (Echo	  Model	  
Systems,	  Houston	  TX)	  prior	  to	  initiating	  the	  study	  and	  at	  the	  end	  of	  the	  study.	  Upon	  completion	  
of	  the	  study,	  mice	  were	  euthanized	  by	  CO2	  followed	  by	  cervical	  dislocation.	  The	  total	  body	  and	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liver	  weights	  were	  recorded.	  The	  tissues	  were	  harvested	  and	  fixed	  in	  buffered	  formalin	  or	  flash	  
frozen.	  
3.2.2	  Immunohistochemistry	  (IHC)	  	  
IHC	  was	  performed	  on	  a	  DakoCytomation	  autostainer	  using	  the	  Envision	  HRP	  Detection	  
system	  (Dako,	  Carpinteria,	  CA).	  Each	  tissue	  block	  was	  sectioned	  at	  4	  μm	  on	  a	  graded	  slide,	  
deparaffinized	  in	  xylene,	  rehydrated	  in	  graded	  ethanols,	  and	  rinsed	  in	  Tris-­‐phosphate-­‐buffered	  
saline	  (TBS).	  Heat	  induced	  antigen	  retrieval	  was	  performed	  in	  a	  microwave	  at	  98ºC	  in	  0.01	  M	  
citrate	  buffer.	  After	  cooling	  for	  20	  minutes,	  sections	  were	  rinsed	  in	  TBS	  and	  subjected	  to	  primary	  
Ly6g	  antibody	  (NIMP-­‐R14,	  Santa	  Cruz	  Biotechnology,	  Dallas,	  TX)	  for	  45	  minutes.	  
Immunoreactivity	  was	  visualized	  by	  incubation	  with	  chromogen	  diaminobenzidine	  (DAB)	  for	  5	  
minutes.	  Tissue	  sections	  were	  counterstained	  with	  hematoxylin,	  dehydrated	  through	  graded	  
ethanol	  and	  xylene,	  and	  cover-­‐slipped.	  Images	  were	  captured	  with	  an	  Olympus	  BX41	  light	  
microscope	  using	  SPOT	  Software	  5.1	  (SPOT™	  Imaging	  Solutions,	  Detroit,	  MI).	  Positively	  stained	  
epithelial	  cells	  from	  mammary	  glands	  were	  quantified	  and	  the	  percentage	  of	  positively	  labeled	  
cells	  was	  calculated.	  
3.2.3	  Analysis	  of	  hepatic	  steatosis	  
Frozen	  sections	  were	  used	  for	  the	  detection	  of	  lipid.	  	  Freshly	  dissected	  liver	  was	  
cryoprotected	  in	  30%	  sucrose	  overnight	  and	  then	  flash	  frozen	  in	  Tissue-­‐Tek	  OCT	  compound	  
(Sakura).	  Cryosections	  10	  µm	  thick	  were	  processed	  for	  Oil	  Red	  O	  staining	  in	  a	  0.3%	  solution	  of	  
Oil	  Red	  O	  (Sigma,	  St.	  Louis,	  MO)	  in	  60%	  isopropanol	  for	  15	  min.	  	  After	  washes	  in	  60%	  
isopropanol,	  sections	  were	  counterstained	  with	  Mayer’s	  hematoxylin.	  Images	  were	  captured	  
with	  an	  Olympus	  BX41	  light	  microscope	  using	  SPOTSOFTWARE.	  
	  
62	  
3.2.4	  RNA	  Isolation	  and	  Real-­‐Time	  PCR	  
Total	  RNA	  was	  extracted	  from	  the	  gonadal	  fat	  pad	  and	  liver	  of	  mice	  in	  each	  treatment	  
group	  (n=6)	  as	  described	  previously	  (26).	  	  Relative	  mRNA	  levels	  were	  quantified	  using	  
quantitative	  real-­‐time	  Polymerase	  Chain	  Reaction	  (qPCR)	  (Strategene	  Mx3005P,	  Agilent	  
Technologies,	  La	  Jolla,	  CA).	  	  All	  values	  were	  normalized	  to	  the	  amplification	  of	  β−actin.	  The	  PCR	  
primer	  sequences	  used	  are	  as	  follows:	  Il-­‐6	  forward;	  5’-­‐gctaccaaactgcatataatcagga-­‐3’;	  Il-­‐6	  
reverse;	  5’-­‐ccaggtagctatggtactccagaa-­‐3’	  mKc	  forward;	  5’-­‐caatgagctgcgctgtcagtg-­‐3’;	  mKc	  reverse;	  
5’-­‐cttggggacaccttttagcatc	  -­‐3’	  Mip2	  forward;	  5’-­‐ccaagggttgacttcaagaac-­‐3’;	  Mip2	  reverse;	  5’-­‐
agcgaggcacatcaggtacg	  -­‐3’	  F4/80	  forward;	  5’-­‐ctttggctatgggcttccagtc-­‐3’;	  F4/80	  reverse;	  5’-­‐
gcaaggaggacagagtttatcctg	  -­‐3’	  Cd68	  forward;	  5’-­‐cttctgctgtggaaatgcaa-­‐3’;	  Cd68	  reverse;	  5’-­‐
agaggggctggtaggttgat	  -­‐3’	  Tnfa	  forward;	  5’-­‐tgtctcagcctcttctcattcc-­‐3’;	  Tnfa	  reverse;	  5’-­‐
tgagggtctgggccatagaac	  -­‐3’	  Elane	  forward;	  5’-­‐tgattatccagctcaatggc-­‐3’;	  Elane	  reverse;	  5’-­‐
acatggagttctgtcaccca	  -­‐3’	  Ly6g	  forward;	  5’-­‐tgcgttgctctggagataga-­‐3’;	  Ly6g	  reverse;	  5’-­‐	  
cagagtggggcagatgg-­‐3’	  Cd11b	  forward;	  5’-­‐ctgagaaatgacggtgagga-­‐3’;	  Cd11b	  reverse;	  5’-­‐
cagcaggctttacaaaccaa	  -­‐3’,	  βactin	  forward;	  5’-­‐ctaaggccaaccgtgaaaag-­‐3’;	  βactin	  reverse;	  5’-­‐
accagaggcatacagggaca	  -­‐3’.	  Assays	  were	  performed	  using	  the	  1-­‐step	  2X	  Brilliant	  SYBR	  Green	  qRT-­‐
PCR	  Master	  Mix	  Kit	  (Agilent	  Technologies)	  containing	  200	  nM	  forward	  primer,	  200	  nM	  reverse	  
primer,	  and	  100	  ng	  total	  mRNA.	  The	  conditions	  for	  target	  mRNA	  amplification	  were	  performed	  
as	  follows:	  1	  cycle	  of	  50°C	  for	  30	  min;	  1	  cycle	  of	  95°C	  for	  10	  min;	  35	  cycles	  each	  95°C	  for	  30s,	  
55°C	  for	  1	  min,	  and	  72°C	  for	  30s.	  	  
3.2.5	  Insulin	  tolerance	  test	  
Mice	  were	  fasted	  for	  4	  hours,	  weighed,	  and	  their	  fasting	  blood	  glucose	  levels	  were	  
measured	  from	  the	  tail	  vein	  using	  a	  glucometer	  (OneTouch	  Ultra;	  Lifescan,	  Milpitas,	  CA).	  Mice	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were	  injected	  with	  human	  regular	  insulin	  (Eli	  Lilly,	  Indianapolis,	  IN)	  at	  a	  concentration	  of	  0.8	  unit	  
of	  insulin	  per	  kg	  of	  body	  weight	  in	  the	  interpretational	  cavity	  and	  blood	  glucose	  levels	  were	  
assessed	  15,	  30,	  60,	  90,	  and	  120	  minutes	  after	  injection.	  
3.2.6	  Statistical	  Analysis	  	  
A	  two-­‐way	  ANOVA	  with	  diet	  and	  R.	  crenulata	  treatment	  stimulation	  as	  the	  main	  effect	  
was	  used	  for	  the	  analysis	  of	  the	  percent	  body	  fat	  experiment	  and	  post	  hoc	  tests	  were	  performed	  
by	  Bonferroni’s	  t	  test.	  (Graphpad	  Prism,	  San	  Diego,	  CA).	  Student’s	  t-­‐test	  was	  used	  to	  determine	  
statistical	  significance	  between	  R.crenulata	  and	  vehicle	  treated	  groups.	  In	  all	  cases,	  p	  values	  <	  
0.05	  were	  considered	  statistically	  significant.	  Graphpad	  Prism	  statistical	  analysis	  software	  (San	  
Diego,	  CA)	  was	  used	  in	  this	  analysis	  and	  figure	  generation	  
(http://www.graphpad.com/quickcalcs).	  Statistical	  outliers	  were	  identified	  in	  some	  data	  sets	  by	  
applying	  Grubb’s	  test	  (http://www.graphpad.com/quickcalcs),	  but	  the	  overall	  results	  were	  not	  
altered	  by	  omission.	  A	  few	  samples	  were	  lost	  during	  processes;	  therefore,	  there	  are	  some	  
unequal	  sample	  sizes.	  	  
3.3	  Results	  	  
3.3.1	  R.crenulata	  treatment	  does	  not	  alter	  body	  fat	  percentage	  or	  lipid	  deposits	  in	  livers	  in	  
mice,	  but	  increases	  insulin	  sensitivity	  after	  12-­‐weeks	  of	  HFD	  feeding.	  
Since	  high	  fat	  diet	  (HFD)	  feeding	  for	  12	  weeks	  successfully	  results	  in	  diet	  induced	  obesity	  
(DIO)	  [13],	  we	  subjected	  female	  129/c57bl6	  mice	  to	  a	  HFD	  and	  treated	  with	  a	  hydroalcoholic	  
extract	  of	  R.	  crenulata	  or	  vehicle	  in	  their	  water	  for	  12	  weeks.	  HFD	  successfully	  induced	  obesity	  
regardless	  of	  R.	  crenulata	  treatment,	  shown	  by	  body	  fat	  percentage	  content	  (fig.	  3.1A).	  Next	  we	  
examined	  whether	  there	  were	  differences	  in	  the	  level	  of	  lipid	  deposits	  in	  livers	  of	  HFD	  
R.crenulata	  or	  vehicle	  treated	  mice.	  No	  differences	  in	  liver	  weight	  or	  fat	  deposits	  were	  observed	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as	  shown	  by	  by	  Oil-­‐red-­‐O	  staining	  (fig.	  3.1B	  and	  3.1C).	  At	  12	  weeks	  following	  initiation	  of	  the,	  we	  
performed	  an	  insulin	  tolerance	  test	  to	  determine	  if	  R.	  crenulata	  treatment	  rendered	  an	  
improvement	  in	  insulin	  sensitivity	  in	  mice	  on	  a	  HFD.	  Indeed,	  R.crenulata	  treated	  mice	  
demonstrated	  a	  significant	  improvement	  in	  the	  rate	  of	  glucose	  clearance	  following	  insulin	  
stimulation	  (fig.	  3.1D).	  These	  data	  confirmed	  previous	  results	  that	  show	  that	  R.	  crenulata	  
improves	  insulin	  sensitivity	  under	  conditions	  of	  DIO.	  
	  
	  
Figure	  3.1.	  R.	  crenulata	  treatment	  enhances	  insulin	  sensitivity	  independently	  of	  liver	  
lipid	  deposits.	  A.	  Bars	  represent	  mean	  ±	  SEM	  of	  percent	  body	  fat	  content	  of	  mice	  fed	  a	  
normal	  diet	  (ND)	  or	  a	  high	  fat	  diet	  (HFD)	  and	  ±	  R.	  crenulata	  (n=10,	  **p<0.01,	  *p<0.05.	  
Depicted	  significance	  is	  from	  adjusted	  p	  values	  from	  Bonferroni	  test	  post	  2-­‐way	  ANOVA	  
analysis).	  B.	  Bars	  represent	  mean	  ±	  SEM	  of	  liver	  percent	  body	  weights	  (n=10,	  **p<0.01,	  
Student’s	  t	  test).	  C.	  Image	  representation	  of	  Oil-­‐red-­‐O	  staining	  analysis	  of	  paraffin	  
embedded	  livers	  from	  HFD	  fed	  mice	  treated	  with	  R.	  crenulata	  or	  vehicle	  for	  12	  weeks.	  D.	  
Insulin	  tolerance	  test	  (ITT)	  was	  performed	  at	  the	  end	  of	  the	  study.	  After	  a	  4	  h	  fast,	  mice	  
were	  injected	  with	  0.8U/kg	  BW	  insulin	  and	  blood	  glucose	  levels	  were	  monitored	  for	  2	  
hours.	  (**p<0.01,	  ****p<0.0001,	  Student’s	  t	  test.	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3.3.2	  R.	  crenulata	  treatment	  decreases	  liver	  inflammation	  and	  neutrophil	  infiltration	  in	  mice	  
following	  12-­‐weeks	  on	  a	  HFD.	  
Considering	  that	  obesity	  is	  linked	  to	  liver	  inflammation	  (hepatitis),	  in	  addition	  to	  non-­‐
alcoholic	  fatty	  liver	  disease	  (NAFLD)	  (hepatosteatosis)	  [14]	  and	  R.	  crenulata	  treatment	  can	  
attenuate	  liver	  inflammation	  in	  other	  disease	  models,	  we	  evaluated	  the	  gene	  transcript	  levels	  of	  
pro-­‐inflammatory	  cytokines	  Tnf-­‐α	  and	  Il-­‐6	  and	  macrophage	  markers	  CD68	  and	  F4/80	  in	  our	  
model.	  We	  observed	  a	  significant	  decrease	  in	  the	  mRNA	  transcript	  levels	  of	  Tnf-­‐α,	  Il-­‐6	  and	  Cd68	  
in	  R.crenulata	  treated	  mice,	  suggesting	  an	  improvement	  in	  the	  fatty	  liver	  associated	  
macrophage	  infiltration	  and	  polarization	  (fig.	  3.2A).	  As	  neutrophil	  infiltration	  is	  also	  an	  
established	  aspect	  of	  the	  inflammatory	  response	  to	  NAFLD	  and	  liver	  injury	  [5],	  we	  examined	  the	  
gene	  transcript	  levels	  of	  neutrophil	  chemo-­‐attractants	  Kc	  and	  Mip-­‐2,	  as	  well	  as	  neutrophil	  
markers	  Ly6G,	  Cd11b	  and	  the	  enzyme	  neutrophil	  elastase	  (Elane)	  in	  the	  liver.	  Real-­‐time	  qPCR	  
analysis	  revealed	  that	  there	  was	  a	  significant	  decrease	  in	  each	  of	  the	  genes,	  suggesting	  a	  
decreased	  neutrophil	  infiltration	  response	  upon	  R.crenulata	  treatment	  (fig.	  3.2B).	  We	  confirmed	  
our	  PCR	  results	  with	  IHC	  analysis	  on	  paraffin	  embedded	  liver	  tissue	  using	  an	  anti-­‐Ly6g	  antibody	  
(NIMP-­‐R14),	  which	  will	  predominantly	  stain	  neutrophils	  (fig.	  3.2C).	  Our	  results	  show	  that	  there	  
are	  significantly	  less	  positively	  stained	  cells	  in	  the	  livers	  of	  R.crenulata	  treated	  mice.	  Together,	  




Figure	  3.2.	  R.	  crenulata	  treatment	  decreases	  macrophage	  markers,	  associated	  pro-­‐
inflammatory	  cytokine	  transcripts	  and	  decreases	  neutrophil	  infiltration	  of	  livers	  from	  
HFD	  fed	  mice.	  Total	  RNA	  from	  livers	  of	  HFD	  fed	  mice	  treated	  with	  R.crenulata	  or	  vehicle	  
(n=6)	  was	  subjected	  to	  qPCR	  analysis	  for	  A.	  Tnfα,	  Il-­‐6,	  F4/80	  and	  CD68,	  B.	  Kc,	  Mip-­‐2	  
Elane,	  Ly6G	  and	  Cd11b	  normalized	  to	  β−actin	  mRNA.	  Bars	  graphs	  represent	  the	  analysis	  
result	  expressed	  as	  relative	  expression	  to	  vehicle	  treated	  mice.	  C.	  Image	  representation	  
of	  IHC	  analysis	  with	  neutrophil	  marker	  NIMP-­‐R14	  antibody	  (anti-­‐Ly6g)	  performed	  on	  
paraffin	  embedded	  livers	  from	  HFD	  fed	  mice	  treated	  with	  R.	  crenulata	  or	  vehicle	  for	  12	  
weeks.	  Bar	  graph	  represents	  quantified	  positive	  cells	  in	  each	  treatment	  group	  (n=4)	  	  
3.4	  Discussion	  
R.crenulata	  has	  previously	  been	  shown	  to	  ameliorate	  blood	  glucose	  concentrations	  in	  a	  
clinical	  study	  [11]	  in	  addition	  to	  improving	  the	  homeostasis	  model	  assessment	  of	  insulin	  
resistance	  index	  (HOMA-­‐IR)	  and	  excessive	  hepatic	  triglyceride	  accumulation	  in	  Zucker	  diabetic	  
fatty	  rats	  [10].	  Here	  we	  reveal	  that	  treatment	  with	  a	  hydroalcohlic	  extract	  of	  R.crenulata	  
improves	  insulin	  sensitivity	  in	  a	  mouse	  model	  for	  diet-­‐induced	  obesity	  (fig.	  3.1D).	  This	  
improvement	  happened	  independently	  of	  changes	  in	  fat	  content	  as	  R.	  crenulata	  did	  not	  change	  
the	  diet	  induced	  increase	  in	  percent	  body	  fat.	  	  The	  effect	  of	  R.	  crenulata	  on	  insulin	  sensitivity	  
also	  appeared	  independent	  of	  hepatosteatosis	  as	  no	  difference	  was	  noted	  in	  the	  amount	  of	  lipid	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in	  the	  liver	  in	  response	  to	  treatment.	  These	  data	  suggest	  that	  R.	  crenulata	  changes	  how	  the	  
livers	  responded	  to	  the	  fat	  accumulated	  by	  DIO.	  We	  hypothesized	  that	  R.	  crenulata	  would	  
abrogate	  the	  inflammation	  associated	  with	  fat	  deposition	  in	  the	  liver.	  While	  numerous	  tissues	  
respond	  to	  and	  depend	  upon	  insulin	  action	  to	  utilize	  blood	  glucose,	  we	  specifically	  focused	  on	  
the	  liver	  since	  it	  is	  known	  to	  be	  one	  of	  the	  most	  important	  organs	  for	  blood	  glucose	  regulation	  
and	  as	  an	  organ	  responsible	  for	  processing	  and	  metabolizing	  nutrients,	  it	  is	  likely	  to	  have	  higher	  
exposure	  to	  the	  R.	  crenulata	  extract.	  
	  Macrophages	  play	  an	  important	  role	  in	  the	  process	  of	  NAFLD	  and	  insulin	  resistance	  
[15],	  as	  in	  both	  cases,	  macrophages	  have	  been	  shown	  to	  increase	  the	  pro-­‐inflammatory	  state	  
and	  mediate	  insulin	  resistance.	  It	  has	  been	  shown	  that	  TNFα	  is	  the	  primary	  activator	  of	  
macrophages	  in	  the	  liver	  post	  DIO	  and	  depletion	  of	  liver	  macrophages	  increases	  insulin	  
sensitivity	  [16].	  Furthermore,	  Park	  et	  al.	  showed	  that	  obesity	  can	  increase	  the	  risk	  of	  hepatic	  
cancer	  development	  through	  persistent	  pro-­‐inflammatory	  cytokine	  expression	  (TNFα	  and	  IL-­‐6)	  
[4].	  
	  Research	  has	  shown	  that	  it	  is	  not	  just	  macrophages	  which	  are	  involved	  in	  the	  liver	  
inflammatory	  process,	  but	  neutrophils	  contribute	  as	  well.	  In	  fact,	  neutrophil	  liver	  infiltration	  is	  
thought	  to	  be	  one	  of	  the	  primary	  responders	  to	  liver	  damage	  [5]	  .	  In	  a	  clinical	  study,	  neutrophil	  
to	  lymphocyte	  ratio	  has	  been	  proposed	  as	  a	  marker	  for	  severity	  of	  liver	  steatosis	  and	  fibrosis	  
[17].	  Additionally,	  neutrophils	  have	  been	  shown	  to	  have	  a	  causal	  role	  in	  insulin	  resistance	  via	  
expression	  of	  	  the	  enzyme	  neutrophil	  elastase	  (Elane)	  [18,19].	  Hence	  identifying	  agents	  capable	  
of	  attenuating	  macrophage	  and	  neutrophil	  infiltration	  and	  activation	  is	  of	  interest	  to	  ameliorate	  
the	  inflammatory	  state	  associated	  with	  metabolic	  disease.	  
Several	  natural	  agents	  have	  been	  studied	  for	  possible	  anti-­‐inflammatory	  behavior	  	  
(reviewed	  in	  [20])	  such	  as	  Berberine	  [21],	  Panax	  notoginseng	  saponins	  [22],curcumin	  [23]	  and	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salidroside	  [9]	  They	  have	  been	  used	  successfully	  in	  pro-­‐inflammatory	  disease	  models	  for	  
Alzheimer’s	  disease[8]and	  endotoxemia[24]	  to	  attenuate	  pro-­‐inflammatory	  cytokine	  
expressions	  and	  improve	  responses.	  In	  our	  study	  R.	  crenulata	  attenuated	  DIO	  induced	  liver	  
inflammation	  and	  reduced	  liver	  neutrophil	  infiltration	  (fig.	  3.2).	  This	  attenuation	  of	  liver	  
inflammation	  by	  R.crenulata	  would	  be	  a	  possible	  mechanism	  for	  the	  observed	  increased	  insulin	  
sensitivity.	  
3.5	  Conclusion	  
Our	  results	  show	  that	  treatment	  with	  a	  hydroalcohlic	  extract	  of	  R.crenulata	  decreases	  
DIO	  induced	  insulin	  resistance	  and	  attenuates	  liver	  inflammation	  despite	  not	  having	  an	  effect	  on	  
weight	  gain	  or	  lipid	  deposition	  in	  the	  liver.	  These	  results	  support	  the	  use	  of	  R.crenulata	  as	  a	  
supplement	  to	  attenuate	  some	  of	  the	  most	  deleterious	  metabolic	  effects	  of	  obesity.	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3.7.1	  Unpublished	  data	  
	  
Figure	  3.3	  R.crenulata	  treatment	  had	  an	  early	  favorable	  affect	  on	  glucose	  clearance	  and	  
insulin	  sensitivity,	  however	  it	  is	  lost	  over	  time	  in	  Sfrp1	  -­‐/-­‐	  mice.	  
(A)	  Glucose	  tolerance	  test	  (GTT)	  was	  performed	  at	  three	  separate	  time	  points	  during	  the	  
study	  (2	  weeks,	  6	  weeks,	  and	  12	  weeks).	  After	  a	  16-­‐18	  h	  fast,	  mice	  were	  injected	  with	  2	  
g/kg	  BW	  glucose	  and	  blood	  glucose	  levels	  were	  monitored	  for	  2	  h.	  (B)	  Insulin	  tolerance	  
test	  (ITT)	  was	  performed	  at	  the	  end	  of	  the	  study.	  After	  a	  4	  h	  fast,	  mice	  were	  injected	  
with	  0.8	  U/kg	  BW	  insulin	  and	  blood	  glucose	  levels	  were	  monitored	  for	  2	  hours.	  Since	  the	  














RHODIOLA	  CRENULATA	  INHIBITS	  CANONICAL	  WNT	  SIGNALING	  IN	  THE	  MDA-­‐MB-­‐231	  TRIPLE	  
NEGATIVE	  BREAST	  CANCER	  CELL	  LINE	  
The	  work	  presented	  in	  this	  chapter	  was	  done	  in	  collaboration	  with	  Carmen	  Mora,	  Elizabeth	  
Amaro	  Gonzalez	  	  
4.1	  Background:	  
Breast	  cancer	  is	  a	  collection	  of	  diseases	  characterized	  by	  an	  abnormal	  proliferation	  of	  
the	  epithelium	  in	  the	  breast.	  Tumors	  are	  pathologically	  categorized	  by	  the	  expression	  of	  
hormone	  receptors	  (Estrogen,	  Progesterone)	  or	  growth	  factor	  receptors	  (Her2/Neu).	  	  Among	  
those	  subgroups	  of	  breast	  cancer,	  Triple	  Negative	  Breast	  Cancer	  (TNBC)	  is	  the	  most	  aggressive	  
form	  of	  breast	  cancer	  since	  it	  lacks	  expression	  of	  these	  three	  receptors,	  making	  it	  challenging	  to	  
target	  therapeutically	  [2].	  	  
Cancer	  cells	  maintain	  their	  characteristics	  and	  survival	  by	  activating	  embryonic	  and	  
developmental	  signaling	  pathways.	  Current	  research	  is	  aimed	  at	  trying	  to	  inhibit	  these	  pathways	  
to	  affect	  a	  cure.	  Interestingly,	  a	  number	  of	  phytochemicals	  have	  been	  shown	  to	  alter	  such	  
pathways.	  	  
Rhodiola	  crenulata	  is	  a	  Tibetan	  plant	  that	  has	  been	  used	  in	  Eastern	  traditional	  medicine	  
to	  relieve	  depression,	  anxiety,	  fatigue,	  and	  to	  aid	  in	  high	  altitude	  adjustment	  [3]	  .	  Studies	  have	  
shown	  that	  Rhodiola	  species	  also	  have	  anti-­‐neoplastic	  properties.	  Rhodiola	  rosea,	  the	  most	  
studied	  specie	  of	  Rhodiola,	  and	  its	  active	  component,	  salidroside,	  have	  been	  shown	  to	  increase	  
cell	  death	  in	  HL-­‐60	  leukemia	  cell	  lines	  [4]	  and	  induce	  autophagy	  in	  bladder	  cancer	  cell	  lines	  [5].	  
We	  have	  previously	  demonstrated	  R.	  crenulata’s	  ability	  to	  decrease	  tumor	  growth	  in	  mice	  
harboring	  a	  syngeneic	  triple	  negative	  breast	  tumor	  derived	  from	  a	  p53	  heterozygous	  animal	  [6].	  
Furthermore,	  in	  a	  human	  TNBC	  cell	  line,	  MDA-­‐MB-­‐231,	  we	  have	  shown	  that	  treatment	  with	  R.	  
crenulata	  results	  in	  a	  decrease	  in	  tumorsphere	  formation	  and	  invasion	  in	  vitro,	  as	  well	  as	  an	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increase	  in	  sensitivity	  to	  anoikis	  [1].	  Taken	  together,	  these	  data	  suggest	  that	  R.	  crenulata	  may	  
have	  effective	  anti-­‐neoplastic	  activities	  towards	  aggressive	  breast	  cancer	  sub-­‐types;	  however,	  
the	  mechanism	  remains	  unclear.	  
A	  signaling	  pathway	  that	  is	  implicated	  in	  the	  regulation	  of	  cell	  fate,	  cell	  proliferation,	  
morphology,	  and	  migration	  during	  normal	  development	  is	  the	  canonical	  WNT	  signaling	  pathway	  
[7].	  Dysregulation	  of	  this	  signaling	  pathway	  has	  been	  implicated	  in	  breast	  cancer,	  where	  it	  plays	  
a	  role	  in	  cell	  invasion	  and	  cancer	  stem	  cell	  maintenance	  [8].	  WNT	  ligands,	  secreted	  extracellular	  
proteins,	  bind	  to	  their	  co-­‐receptors	  Frizzled	  proteins	  and	  the	  LDL	  receptor-­‐related	  proteins,	  LRP5	  
or	  LRP6,	  resulting	  in	  the	  activation	  of	  the	  canonical	  WNT/	  β-­‐catenin	  signaling	  pathway.	  	  Receptor	  
activation	  leads	  to	  the	  inhibition	  of	  the	  β-­‐catenin	  phosphorylation	  complex,	  composed	  of	  
GSK3β,	  Axin,	  and	  APC,	  allowing	  increased	  stability	  and	  accumulation	  of	  β-­‐catenin,	  followed	  by	  
its	  nuclear	  localization.	  In	  the	  nucleus,	  β-­‐catenin	  complexes	  with	  the	  transcription	  factors,	  
TCF/LEF,	  and	  initiates	  the	  expression	  of	  specific	  target	  genes,	  such	  as	  Axin2,	  CyclinD1,	  and	  cMyc	  
as	  well	  as	  others	  to	  drive	  stem	  cell	  maintenance,	  invasion,	  and	  proliferation.	  The	  observed	  
effects	  of	  R.	  crenulata	  on	  the	  MDA-­‐MB-­‐231	  aggressive	  cells	  were	  mimicked	  on	  TERT-­‐siSFRP1	  
cells,	  an	  engineered	  cell	  line	  where	  WNT	  inhibitor	  secreted	  frizzeled	  related	  protein	  1	  (SFRP1),	  
expression	  is	  knocked	  down	  and	  has	  been	  shown	  to	  have	  increased	  sensitivity	  to	  WNT/β-­‐catenin	  
signaling	  activation	  [9],	  hence	  suggestion	  the	  implication	  of	  this	  signaling	  pathway.	  Our	  previous	  
studies	  indicated	  that	  R.	  crenulata	  inhibits	  stem-­‐like	  behaviors	  and	  invasion;	  therefore,	  we	  
hypothesized	  that	  R.	  crenulata	  treatment	  would	  inhibit	  the	  WNT/	  β-­‐catenin	  signaling	  pathway	  in	  
MDA-­‐MB-­‐231	  cells.	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4.2	  Materials	  and	  methods:	  
4.2.1	  Treatments	  
R.	  crenulata	  root	  extract	  powder	  (Barrington	  Chemical	  Corporation,	  Harrison,	  NY),	  
containing	  a	  total	  of	  132.0	  mg/g	  dry	  weight	  (dw)	  of	  	  phenolic	  compounds	  (2.07±0.08	  mg/g	  	  dw	  
of	  Tyrosol,	  	  Coumaric	  0.33±0.01	  mg/g	  	  dw,	  and	  6.17±0.31	  of	  	  Gallic	  acid)	  as	  described	  in	  [10],	  
was	  dissolved	  in	  a	  hydroalcoholic	  solution	  (10%	  EtOH	  )	  and	  filter	  sterilized.	  All	  treatments	  were	  
at	  100	  µg/ml	  concentration	  or	  equivalent	  volume	  of	  vehicle	  control	  (10%	  EtOH),	  with	  a	  final	  
Etoh	  concentration	  of	  0.01%,	  and	  cells	  were	  also	  stimulated	  with	  Wnt3a	  conditioned	  media	  
(WNT3a	  expressing	  fibroblasts	  [ATCC	  CRL-­‐2647]),	  media	  from	  control	  vector	  transfected	  cells	  
(ATCC	  CRL-­‐2648)	  or	  1	  µm	  of	  LiCl	  dissolved	  in	  diH2O	  or	  equivalent	  volume	  of	  vehicle,	  for	  24	  hours.	  
Treatment	  dose	  was	  chosen	  based	  on	  previous	  studies	  [6].	  
4.2.2	  Cell	  Culture	  	  
MDA-­‐MB-­‐231	  cells	  (ATCC,	  Manassas,	  VA,	  USA)	  were	  maintained	  at	  37°C	  with	  5%	  CO2	  in	  
Dulbecco’s	  modified	  Eagle’s	  medium	  (DMEM,	  Life	  Technologies,	  Grand	  Island,	  NY)	  
supplemented	  with	  10%	  FBS	  and	  20	  µg/ml	  Gentamycin	  (Life	  Technologies,	  Grand	  Island,	  NY).	  	  
4.2.3	  Cell	  Proliferation	  Assay	  
MDA-­‐MB-­‐231	  cells	  (1x105	  cells/well)	  in	  6	  well	  plates	  (N=3	  per	  group),	  and	  treated	  as	  
described	  above.	  Cells	  were	  collected	  by	  Trypsin	  (Life	  Technologies,	  Grand	  Island,	  NY),	  and	  
counted	  using	  Vi-­‐cell	  cell	  viability	  (Beckman	  Coulter	  Inc,	  Fullerton,	  CA).	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4.2.4	  RNA	  Isolation	  and	  Real-­‐Time	  PCR	  
MDA-­‐MB-­‐231	  cells	  were	  treated	  as	  described	  above	  and	  the	  total	  RNA	  was	  extracted	  as	  
per	  manufacturer’s	  protocol	  (Trizol,	  Life	  Technologies,	  Carlsbad,	  CA).	  Relative	  mRNA	  levels	  were	  
quantified	  using	  quantitative	  real-­‐time	  Polymerase	  Chain	  Reaction	  (qPCR)	  (Strategene	  Mx3005P,	  
Agilent	  Technologies,	  La	  Jolla,	  CA).	  	  All	  values	  were	  normalized	  to	  the	  amplification	  of	  βactin.	  
The	  PCR	  primer	  sequences	  used	  are	  as	  follows:	  Axin2	  forward;5’-­‐TGTGGGCAGTAAGAAACAGC-­‐
3’;Axin2	  reverse;	  5’-­‐GGTTCTCGGGAAATGAGGTA-­‐3’;	  βactin	  forward;	  5’-­‐
GAGGCGTACAGGGATAGC-­‐3’;	  βactin	  reverse;	  5’-­‐ATGGATATCGCC-­‐3’.	  Assays	  were	  performed	  
using	  the	  1-­‐step	  2X	  Brilliant	  SYBR	  Green	  qRT-­‐PCR	  Master	  Mix	  Kit	  (Agilent	  Technologies)	  
containing	  200nM	  forward	  primer,	  200nM	  reverse	  primer,	  and	  100ng	  total	  mRNA.	  The	  
conditions	  for	  target	  mRNA	  amplification	  were	  performed	  as	  follows:	  1	  cycle	  of	  50°C	  for	  30	  min;	  
1	  cycle	  of	  95°C	  for	  10	  min;	  35	  cycles	  each	  95°C	  for	  30s,	  55°C	  for	  1	  min,	  and	  72°C	  for	  30s.	  	  
4.2.5	  Fluorescent	  Immunocytochemistry	  	  
MDA-­‐MB-­‐231	  cells	  (4.5x104	  cells/well)	  were	  plated	  on	  glass	  coverslips	  coated	  with	  
Attachment	  Factor	  1X	  (Life	  Technologies,	  Grand	  Island,	  NY),	  as	  described	  in	  manufacturer’s	  
protocol	  and	  treated	  as	  described	  above.	  	  The	  cells	  were	  fixed	  in	  4%	  paraformaldehyde	  and	  
permeabilized	  with	  0.5%	  TritonX-­‐100.	  Cells	  were	  washed	  three	  times	  with	  1X	  PBS:Glycine	  
(130mM	  NaCl,	  7mM	  Na2HPO4,	  3.5mM	  NaH2PO4,	  100mM	  Glycine),and	  ,	  blocked	  with	  1X	  IF	  Buffer	  
(130mM	  NaCl,	  7mM	  Na2HPO4,	  3.5mM	  NaH2PO4,	  7mM	  NaN3,	  0.1%	  BSA,	  0.2%	  TritonX-­‐100,	  0.05%	  
Tween-­‐20)	  plus	  10%	  goat	  serum;	  followed	  by	  a	  2°	  blocking	  step	  (1X	  IF	  buffer	  plus	  10%	  goat	  
serum	  plus	  20μg/ml	  goat	  anti-­‐mouse	  F(ab’)2]	  for	  30-­‐45min.	  Rabbit	  anti-­‐active	  β-­‐catenin	  (Cell	  
Signaling	  Technology,	  Beverly	  MA)	  was	  diluted	  1:100	  into	  what?	  and	  incubated	  overnight	  at	  4°C.	  
Wells	  were	  washed	  three	  times	  in	  IF	  buffer	  ,	  anti-­‐rabbit	  2°	  antibody	  coupled	  with	  Alexa	  Flour-­‐
	  
75	  
568	  (Molecular	  Probes,	  Invitrogen)	  (1:500	  in	  IF	  buffer)	  was	  incubated	  for	  45-­‐60	  min.	  The	  
coverslips	  were	  washed	  and	  mounted	  with	  Vecta-­‐shield	  Mounting	  Medium	  for	  Fluorescence	  
with	  DAPI	  (Vector	  Laboratories	  Inc.,	  Burlingame,	  CA).	  Images	  were	  captured	  using	  Nikon	  Eclipse	  
TE2000-­‐U	  and	  MetaVueTM	  imaging	  software	  (Universal	  Imaging	  Corporation).	  	  	  
4.2.6	  Western	  Blot	  Analysis	  	  
MDA-­‐MB-­‐231	  cells	  were	  treated	  as	  described	  above	  and	  were	  lysed	  with	  RIPA	  buffer	  
supplemented	  with	  phosphatase	  inhibitors	  and	  protease	  inhibitors	  (Sigma	  Aldrich®,	  St.	  Louis,	  
MO).	  Lysate	  protein	  concentrations	  were	  measured	  by	  a	  BCATM	  Protein	  Assay	  Kit	  (Pierce,	  
Rockford,	  IL),	  50μg/ml	  of	  protein	  was	  run	  on	  a	  10%	  SDS-­‐PAGE	  and	  transferred	  onto	  a	  PVDF	  
membrane	  (Sigma	  Aldrich®,	  St.	  Louis,	  MO).	  Membrane	  was	  blocked	  for	  one	  hour	  with	  5%	  milk	  in	  
TBS-­‐T	  and	  primary	  antibodies	  	  (Rabbit	  non-­‐phospho	  (Active)	  β-­‐catenin	  (Ser33/37/Thr41)	  
(D13A1)	  1:1000	  5%	  BSA	  in	  TBS-­‐T	  (Cell	  Signaling	  Technology,	  Danvers,	  MA);	  Rabbit	  β-­‐actin	  1:2000	  
(Abcam,	  Cambridge,	  MA)	  were	  incubated	  over	  overnight.	  Secondary	  antibody	  [goat	  anti-­‐rabbit	  
IgG-­‐HRP	  1:5000	  (Santa	  Cruz	  Biotechnology,	  Dallas,	  TX)	  was	  incubated	  for	  2	  hours	  at	  room	  
temperature.	  The	  blot	  was	  washed	  and	  developed	  using	  a	  Western	  Blot	  Luminol	  Reagent	  (Santa	  
Cruz	  Biotechnology)	  and	  imaged	  with	  a	  Synopics	  4.2	  MP	  camera	  and	  G:Box	  Chemi-­‐XT4	  GENESys	  
software	  (SYNGENE,	  Frederick,	  MD).	  Image	  J	  software	  was	  used	  for	  band	  density	  quantification.	  	  
4.2.7	  Dual	  reporter	  luciferase	  Assay	  	  
MDA-­‐MB-­‐231	  cells	  were	  transiently	  transfected	  with	  Super8xTOPFlash	  reporter	  
construct	  (graciously	  provided	  by	  Randall	  Moon)	  and	  pRL-­‐CMV	  using	  Lipofectamine	  2000	  (Sigma	  
Aldrich®,	  St.	  Louis,	  MO),	  as	  per	  manufacturer	  instructions.	  Cells	  were	  then	  washed	  with	  1X	  PBS	  
and	  the	  Dual-­‐Luciferase®	  Reporter	  Assay	  System	  (Promega)	  supplied	  protocol	  was	  followed	  for	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lysis	  and	  measurements.	  Recorded	  Firefly	  and	  Renilla	  luciferase	  activity	  was	  measured	  using	  TD-­‐
20/20	  Luminometer	  (Turner	  Designs,	  Sunnyvale,	  CA).	  
4.2.8	  Statistical	  Analysis	  	  
All	  results	  were	  analyzed	  using	  a	  two-­‐way	  ANOVA	  with	  R.	  crenulata	  treatment	  and	  
Wnt3a	  or	  LiCl	  stimulation	  as	  the	  main	  effects.	  Post	  hoc	  tests	  were	  performed	  by	  Bonferroni’s	  t	  
test.	  (Graphpad	  Prism,	  San	  Diego,	  CA).	  Grubb’s	  test	  was	  used	  on	  all	  data	  to	  identify	  statistical	  
outliers	  (http://www.graphpad.com/quickcalcs).	  	  
4.3	  Results	  
4.3.1	  R.	  crenulata	  inhibits	  canonical	  WNT	  signaling	  in	  MDA-­‐MB-­‐231	  cells	  	  
To	  evaluate	  R. crenulata	  treatment	  effects	  on	  β−catenin	  transcription,	  a	  dual	  luciferase	  
reporter	  assay	  was	  performed	  on	  MDA-­‐MB-­‐231	  cells	  expressing	  8xTOPFlash	  reporter	  (β−catenin	  
luciferase	  reporter)	  construct.	  The	  reporter	  construct	  transfected	  cells	  were	  treated	  with	  Wnt3a	  
conditioned	  media	  to	  activate	  the	  WNT	  pathway	  in	  the	  presence	  or	  absence	  of	  R. crenulata.	  	  
Wnt3a	  conditioned	  media	  treatment	  significantly	  increased	  luciferase	  activity,	  significant	  of	  
β−catenin	  transcriptional	  activation.	  However	  the	  Wnt3a	  mediated	  increased	  luciferase	  levels	  
were	  significantly	  repressed	  when	  R. crenulata	  was	  included	  in	  the	  treatment	  	  (Figure	  1A).	  To	  
confirm	  our	  findings	  with	  endogenous	  β−catenin	  transcriptional	  activity,	  we	  performed	  a	  qPCR	  
analysis	  of	  WNT/β−catenin	  signaling	  canonical	  target	  gene,	  Axin2.	  Again,	  Wnt3a	  conditioned	  
media	  treatment	  significantly	  increased	  Axin2	  mRNA	  level;	  and	  this	  increase	  in	  expression	  was	  
repressed	  when	  R. crenulata	  was	  included	  in	  the	  treatment	  (Figure	  1B).	  Together,	  these	  results	  
demonstrate	  that	  R. crenulata	  treatment	  inhibits	  Wnt3a-­‐induced	  β−catenin	  transcriptional	  
activity	  of	  exogenous	  and	  endogenous	  targets.	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β−catenin	  stability	  is	  regulated	  by	  a	  phosphorylation	  at	  (Ser33/37/Thr41),	  and	  once	  that	  
occurs,	  it	  is	  targeted	  for	  degradation.	  	  To	  investigate	  whether	  there	  was	  a	  change	  in	  the	  
β−catenin	  activity,	  we	  probed	  protein	  extracts	  of	  the	  Wnt3a	  and	  R. crenulata	  treated	  cells	  via	  
Western	  blot	  analysis	  with	  a	  non-­‐phospho	  (active)	  β−catenin	  antibody	  	  (Figure	  1C,	  upper	  panel).	  
Densitometry	  analysis	  (Figure	  1C,	  lower	  panel)	  confirmed	  that	  the	  active	  form	  of	  β−catenin	  was	  
significantly	  increased	  by	  Wnt3a	  media	  at	  24	  hours	  and	  reversed	  with	  the	  addition	  of	  R. 
crenulata.	  Hence,	  R. crenulata	  treatment	  results	  in	  the	  abrogation	  of	  Wnt3a-­‐induced	  β−catenin	  
activity.	  It	  is	  Finally,	  we	  evaluated	  whether	  R. crenulata	  could	  inhibit	  WNT/β-catenin	  mediated	  
cellular	  proliferation,	  induced	  by	  our	  Wnt3a	  conditioned	  media,	  as	  WNT	  signaling	  is	  well	  
established	  mitogen	  [11].	  	  Equal	  number	  of	  cells	  were	  incubated	  and	  treated	  Wnt3a	  
conditioned	  media	  and	  in	  the	  presence	  or	  absence	  of	  R. crenulata, and cells were counted 24 
hours later. 	  Total	  cell	  counts	  were	  significantly	  increased	  in	  response	  to	  Wnt3a,	  and	  that	  R. 
crenulata	  treatment	  significantly	  decreased	  this	  Wnt3a	  mediated	  increase	  in	  total	  cell	  number	  
(Figure	  1D).	  Collectively,	  these	  data	  demonstrate	  that	  R. crenulata	  treatment	  inhibits	  canonical	  
WNT	  signaling	  and	  function	  in	  MDA-­‐MB-­‐231	  TNBC	  cells.	  To	  our	  knowledge,	  this	  is	  the	  first	  time	  




Figure	  4.1:	  R.	  crenulata	  inhibits	  canonical	  WNT	  signaling	  in	  MDA-­‐MB-­‐231	  cells	  in	  
response	  to	  Wnt3a	  stimulus	  MDA-­‐MB-­‐231	  cells	  were	  plated	  for	  24	  hours.	  Media	  was	  
replaced	  with	  WNT3a	  conditioned	  media	  or	  media	  from	  control	  vector	  transfected	  cells	  	  
and	  treated	  with	  100ug/ml	  R.	  crenulata	  or	  vehicle	  (10%	  EtOH)	  for	  24	  hours.	  A.	  Bar	  
representation	  of	  luciferase	  reporter	  assay	  mean	  ±	  SEM	  (N=4)	  of	  the	  difference	  in	  fold	  
change	  compared	  with	  control	  vehicle	  treated	  cells	  (**p	  value<	  0.01).	  B.	  Bar	  
representation	  of	  Axin2	  mRNA	  levels	  normalized	  to	  βactin	  mRNA	  in	  response	  to	  R.	  
crenulata	  and	  Wnt3a	  stimulation.	  Bars	  represent	  mean	  ±	  SEM	  Axin2/ βactin	  and	  are	  
expressed	  as	  relative	  expression	  of	  vehicle	  treated	  control	  cells	  (	  *p	  <	  0.05).	  C.	  Upper	  
panel:	  representative	  image	  of	  total	  protein	  lysates	  immuno-­‐blotted	  with	  anti-­‐(Active)	  
β−catenin	  and	  normalizer	  βactin.	  Lower	  panel:	  Bar	  representation	  of	  band	  densities	  
quantified	  and	  normalized	  to	  βactin.	  Bars	  represent	  mean	  and	  ±	  SEM	  of	  N=4	  (****p	  
value	  <	  0.0001).	  D.	  Bar	  representation	  of	  total	  MDA-­‐MB-­‐231	  cells	  after	  treatment	  Bars	  
represent	  the	  mean	  and	  ±	  SEM	  of	  total	  cell	  counts	  (N=3,	  *p	  <	  0.05.	  	  All	  depicted	  
significance	  is	  from	  adjusted	  p	  values	  from	  Bonferroni	  test	  post	  2-­‐way	  ANOVA	  analysis).	  
All	  experiments	  repeated	  at	  least	  3	  times.	  
4.3.2	  R.	  crenulata	  inhibition	  is	  cytoplasmic	  in	  MDA.MB.231	  cells.	  
R. crenulata	  inhibition	  of	  the	  canonical	  WNT	  pathway	  could	  be	  occurring	  at	  several	  
levels.	  It	  could	  upregulate	  the	  secretion	  of	  known	  antagonists,	  it	  could	  stabilize	  the	  
Axin/GSK3/APC	  degradation	  complex,	  it	  could	  inhibit	  nuclear	  translocation,	  or	  it	  could	  block	  
interactions	  required	  for	  transcriptional	  activity	  in	  the	  nucleus.	  To	  narrow	  down	  the	  mechanism	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of	  inhibition	  by	  which	  R. crenulata	  affects	  WNT/β−catenin	  signaling,	  we	  first	  aimed	  to	  eliminate	  
extracellular	  signaling	  effectors	  by	  utilizing	  LiCl	  to	  activate	  β−catenin	  transcription	  in	  a	  β−catenin	  
reporter	  assay.	  LiCl	  activates	  β−catenin	  transcription	  by	  inhibiting	  GSK3β,	  hence	  interrupting	  the	  
complex	  that	  phosphorylates	  β−catenin.	  The	  outcome	  is	  β−catenin	  transcriptional	  activity	  that	  
bypasses	  the	  upstream	  ligand	  activation	  of	  the	  extracellular	  receptors.	  As	  expected,	  LiCl	  
treatment	  significantly	  increased	  luciferase	  activity	  the	  increased	  luciferase	  levels	  were	  
significantly	  repressed	  when	  R. crenulata	  was	  included	  in	  the	  treatment	  (Figure	  2A).	  The	  
observed	  results	  suggest	  that	  the	  inhibition	  by	  R. crenulata	  must	  be	  happening	  in	  the	  
cytoplasm. To	  rule	  out	  if	  R. crenulata	  inhibited	  β-­‐catenin	  nuclear	  translocation	  we	  performed	  an	  
immunocytochemistry	  (ICC)	  analysis	  using	  the	  active	  β−catenin	  antibody	  on	  MDA-­‐MB-­‐231	  cells	  
stimulated	  with	  Wnt3a	  media	  in	  the	  presence	  or	  absence	  of	  R. crenulata.	  Fluorescent	  
immunocytochemistry	  images	  reveal	  the	  expected	  increase	  in	  nuclear	  β-­‐catenin	  accumulation	  
(Figure	  2B,	  left	  lower	  panel),	  however	  this	  was	  not	  observed	  in	  the	  R. crenulata	  treated	  cells	  
(Figure	  2B,	  Right	  lower	  panel).	  There	  was	  a	  low	  level	  of	  detectable	  active	  β-­‐catenin,	  but	  this	  
appeared	  to	  be	  sequestered	  in	  discrete	  locations	  in	  the	  cytoplasm.	  	  Therefore,	  these	  results	  
clearly	  demonstrate	  a	  marked	  decrease	  in	  β-­‐catenin	  nuclear	  accumulation	  in	  response	  to	  R. 
crenulata	  treatment,	  confirming	  that	  the	  inhibition	  is	  occurring	  in	  the	  cytoplasm,	  more 




Figure	  4	  2:	  R.	  crenulata	  inhibition	  is	  cytoplasmic	  in	  MDA.MB.231	  cells.	  A.	  R.	  crenulata	  
inhibits	  β−catenin	  transcriptional	  activation	  upon	  1µM	  LiCl	  treatment	  in	  MDA-­‐MB-­‐231	  
cells.Bar	  representation	  of	  luciferase	  reporter	  assay	  mean	  ±	  SEM	  of	  the	  difference	  
4.4	  Discussion	  
The	  previously	  observed	  anti-­‐neoplastic	  effects	  with	  the	  R. crenulata	  extract	  on	  breast	  
cancer	  cells	  were	  encouraging	  [1];	  however,	  no	  mechanism	  was	  implicated	  with	  the	  R. 
crenulata	  extract	  produced	  effects.	  In	  this	  study,	  our	  results	  demonstrate	  that	  R.crenulata	  
inhibits	  β−catenin	  activity	  transcription	  activation.	  Since	  canonical	  WNT	  signaling	  is	  a	  well	  
established	  mitogen	  and	  leads	  to	  increased	  in	  proliferation	  [11],	  we	  examined	  R.crenulata	  
effects	  on	  this	  WNT	  mediate	  function	  and	  our	  results	  demonstrate	  a	  repression	  in	  the	  induced	  
proliferation.	  Hence,	  it	  is	  plausible	  to	  hypothesize	  that	  R.crenulata	  inhibits	  other	  WNT	  related	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functions	  such	  as	  invasion,	  and	  the	  maintenance	  of	  stem	  cell	  characteristics	  [8]	  In	  MDA-­‐MB-­‐231	  
cancer.	  We	  have	  previously	  shown	  that	  R.	  crenulata	  treatment	  inhibits	  β−catenin	  transcriptional	  
activity	  in	  an	  aggressive	  glioblastoma	  cells	  (Mora	  et	  al,2015),	  hence	  R.crenulata	  induced	  
β−catenin	  inhibition	  could	  occur	  in	  other	  cancer	  cells.	  	  
Rhodiola	  root	  extract	  is	  composed	  of	  multiple	  chemical	  compounds	  such	  as	  phenols,	  
organic	  acids,	  flavonoids,	  and	  alkaloids	  [3];	  [12].	  Diverse	  cellular	  pathways	  and	  proteins	  have	  
been	  reported	  to	  be	  affected	  by	  Rhodiola	  constituents	  such	  as	  ROS-­‐AMPK-­‐PKC𝜉  [13,14],	  and	  
these	  multifarious	  effects	  are	  most	  likely	  due	  to	  the	  complex	  nature	  of	  the	  R. crenulata	  root	  
extract.	  It	  still	  remains	  unclear	  which	  component	  (or	  fraction)	  of	  R.	  crenulata	  mediates	  canonical	  
WNT	  signaling	  inhibition,	  however,	  results	  from	  this	  study	  suggest	  that	  the	  inhibition	  is	  
occurring	  in	  the	  cytoplasm	  (figure	  2).	  This	  narrows	  down	  the	  span	  of	  possibilities	  of	  how	  
bcatenin	  transcriptional	  inhibition	  immensely,	  however	  further	  research	  will	  lead	  to	  
understanding	  the	  inhibitory	  mechanism	  and	  hopefully	  the	  fraction	  mediating	  this	  important	  
event.	  Future	  studies	  will	  focus	  examining	  whether	  the	  anti	  cancer	  effects	  described	  in	  vitro	  and	  
whether	  manipulation	  of	  the	  canonical	  WNT	  signaling	  would	  affect	  xenograph	  growth	  and	  
development	  in	  MDA-­‐MB-­‐231	  .	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RHODIOLA	  CRENULATA	  INDUCES	  AN	  EARLY	  ESTROGENIC	  RESPONSE	  AND	  REDUCES	  
PROLIFERATION	  AND	  TUMORSPHERE	  FORMATION	  OVER	  TIME	  IN	  MCF7	  BREAST	  CANCER	  CELL	  
LINES	  
The	  work	  presented	  in	  this	  chapter	  was	  done	  in	  collaboration	  with	  Cody	  Jacobs,	  Kelly	  Gauger	  
(Gregory),	  Elizabeth	  M.	  Henchey	  and	  Jennifer	  Ser-­‐Dolansky	  
5.1	  Introduction	  
Breast	  cancer	  is	  the	  most	  common	  type	  of	  cancer	  among	  women.	  It	  has	  been	  estimated	  
that	  each	  year	  more	  than	  200,000	  new	  cases	  are	  diagnosed	  in	  the	  United	  States	  [2].	  Over	  70%	  of	  
all	  diagnosed	  breast	  cancer	  cases	  are	  positive	  for	  the	  estrogen	  receptor	  (ER)	  [3],	  where	  it	  is	  
typically	  upregulated,	  allowing	  the	  cells	  to	  be	  more	  responsive	  to	  endogenous	  estrogen	  in	  the	  
body.	  	  
Estrogen	  is	  a	  critical	  regulator	  of	  mammary	  growth	  and	  differentiation.	  The	  estrogen	  
receptors	  found	  in	  the	  mouse	  mammary	  gland	  are	  primarily	  located	  on	  epithelial	  cells	  and	  
adipocytes.	  	  In	  the	  developing	  mammary	  buds,	  pubertal	  estrogen	  drives	  the	  proliferation	  and	  
extension	  of	  the	  ducts.	  Estrogen	  can	  also	  increase	  the	  progesterone	  receptor	  (PR)	  leading	  to	  
enhanced	  progesterone	  responsiveness.	  Importantly,	  uncontrolled	  estrogenic	  activity	  can	  also	  
drive	  breast	  cancer	  risk.	  For	  example,	  overexpression	  of	  ERα	  stimulates	  tumors	  in	  mice	  [4]	  and	  
in	  women,	  the	  risk	  of	  breast	  cancer	  increases	  with	  higher	  circulating	  levels	  of	  E2	  [5],	  [6],	  [7],	  [8]	  	  
The	  use	  of	  complementary	  and	  alternative	  medicine	  to	  treat	  ailments	  ranging	  from	  
depression	  to	  glucose	  homeostasis	  [9]	  has	  gradually	  increased	  as	  an	  approach	  to	  benefit	  
personal	  health	  and	  complement	  conventional	  medicine.	  	  Rhodiola	  sp.	  is	  a	  perennial	  herbaceous	  
plant	  that	  grows	  primarily	  at	  high	  altitudes	  in	  the	  arctic	  areas	  of	  Europe	  and	  Asia.	  Rhodiola	  sp.	  
roots	  have	  been	  traditionally	  used	  to	  increase	  physical	  endurance,	  reduce	  fatigue,	  prevent	  high	  
altitude	  sickness,	  and	  to	  relieve	  mild	  to	  moderate	  depression	  [9].	  Over	  the	  past	  decade,	  several	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studies	  have	  documented	  that	  Rhodiola	  sp.	  possess	  anti-­‐neoplastic	  effects.	  R.	  rosea,	  the	  most	  
studied	  sp.	  of	  Rhodiola,	  decreases	  DNA	  damage	  in	  bone	  marrow	  cells	  from	  mice	  in	  response	  to	  
the	  mutagen	  N-­‐nitroso-­‐N-­‐methylurea	  [10]	  and	  increases	  cell	  death	  in	  several	  cancer	  cell	  lines	  
[11].	  Rhodiola	  Rosea	  and	  salidroside,	  an	  active	  compound	  in	  the	  plant,	  have	  also	  been	  shown	  to	  
induce	  autophagy	  in	  bladder	  cancer	  cell	  lines	  [12].	  Previously,	  we	  have	  demonstrated	  that	  R.	  
crenulata	  can	  decrease	  tumor	  growth	  in	  mice	  harboring	  a	  syngeneic	  triple	  negative	  breast	  	  
(TNBC)	  tumors	  [13]	  .	  Furthermore,	  we	  have	  shown	  that	  R.	  crenulata	  treatment	  decreases	  
tumorsphere	  formation	  as	  well	  as	  invasion,	  and	  increases	  sensitivity	  to	  anoikis	  (cell	  death	  in	  
response	  to	  loss	  of	  attachment)	  in	  human	  TNBC	  breast	  cancer	  lines	  [14].	  However,	  the	  
phytoestrogenic	  effects	  of	  Rhodiola	  sp.	  have	  not	  been	  carefully	  studied	  in	  ER+	  normal	  or	  breast	  
cancer	  cells.	  A	  unique	  study	  suggests	  that	  R.	  rosea	  is	  able	  to	  bind	  to	  the	  estrogen	  receptor	  [1],	  
but	  ER	  transcriptional	  activity	  has	  not	  been	  described.	  It	  is	  imperative	  to	  elucidate	  ER	  
transcriptional	  activity	  because	  Rhodiola	  rosea,	  commonly	  used	  to	  alleviate	  depression,	  might	  
have	  deleterious	  mitogenic	  effects	  in	  the	  mammary	  gland	  of	  patients	  with	  ER+	  breast	  cancer.	  In	  
the	  work	  described	  here,	  we	  sought	  to	  determine	  whether	  an	  R.	  crenulata	  root	  extract	  exhibits	  
estrogenic	  activity	  in	  ER+	  breast	  cancer	  cells	  in	  vitro	  and	  whether	  it	  affects	  normal	  mammary	  
epithelial	  proliferation	  and	  ER	  target	  gene	  expression	  in	  vivo.	  	  Our	  results	  suggest	  that	  R.	  
crenulata	  extract	  contains	  estrogenic	  components,	  however,	  continuous	  treatment	  leads	  to	  
decreases	  in	  MCF7	  cell	  proliferation	  and	  tumorsphere	  formation.	  	  
5.2	  Methods	  
5.2.1	  Treatments	  
R.	  crenulata	  root	  extract	  powder	  (Barrington	  Chemical	  Corporation,	  Harrison,	  NY),	  
containing	  a	  total	  of	  132.0	  mg/g	  dry	  weight	  (dw)	  of	  	  phenolic	  compounds	  (2.07±0.08	  mg/g	  	  dw	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of	  Tyrosol,	  	  Coumaric	  0.33±0.01	  mg/g	  	  dw,	  and	  6.17±0.31	  of	  	  Gallic	  acid)	  as	  described	  in	  [15],	  
was	  dissolved	  in	  10%	  ethanol	  and	  filter	  sterilized.	  All	  treatments	  were	  at	  100	  μg/ml	  
concentration	  or	  equivalent	  volume	  of	  vehicle	  control	  (10%	  EtOH).	  Continuously	  treated	  MCF7	  
Cells	  were	  supplemented	  with	  R.	  crenulata	  or	  vehicle	  every	  2	  days	  for	  the	  length	  of	  the	  study.	  
For	  estrogen	  transcription	  activity	  assessments,	  cells	  were	  plated	  and	  treated	  in	  charcoal	  
stripped	  serum	  and	  phenol	  free	  medium	  (DMEM,	  Life	  Technologies,	  Grand	  Island,	  NY)	  to	  reduce	  
background	  estrogenic	  activity.	  As	  a	  positive	  control,	  cells	  were	  stimulated	  with	  10	  nM	  of	  17-­‐
βestradiol	  (Cat	  #	  E8875,	  Sigma	  Aldrich).	  	  Inhibitor	  ICI	  182,780	  (Tocris	  ,Ellisville,	  MO,	  USA)	  was	  
used	  at	  a	  concentration	  of	  20	  nM.	  Lithium	  Cloride	  (LiCl)	  (	  Sigma	  Aldrich)	  was	  used	  at	  a	  
concentration	  of	  20	  mM	  dissolved	  in	  sterile	  filtered	  distilled	  water.-­‐	  Cell	  Culture	  	  
MCF7	  cells	  (ATCC,	  Manassas,	  VA,	  USA)	  were	  maintained	  at	  37°C	  with	  5%	  CO2	  in	  
Dulbecco’s	  Modified	  Eagle’s	  medium	  (DMEM,	  Life	  Technologies,	  Grand	  Island,	  NY)	  
supplemented	  with	  10%	  FBS	  and	  20	  µg/ml	  Gentamycin	  (Life	  Technologies,	  Grand	  Island,	  NY)	  and	  
0.01	  mg/ml	  of	  recombinant	  insulin.	  	  	  
5.2.2	  Cell	  Proliferation	  Assay	  
MCF7	  cells	  (3x105	  cells/well)	  in	  60	  mm	  plates	  (N=3	  per	  group),	  and	  treated	  as	  described	  
above.	  Cells	  were	  collected	  by	  Trypsin	  (Life	  Technologies,	  Grand	  Island,	  NY),	  and	  counted	  using	  
Vi-­‐cell	  cell	  viability	  (Beckman	  Coulter	  Inc,	  Fullerton,	  CA).	  Cells	  were	  counted	  once	  a	  week	  for	  a	  
period	  of	  3	  weeks.	  	  Doubling	  time	  for	  each	  read	  out	  period	  was	  calculated	  using	  the	  following	  
equation	  Doubling	  time=	  Time	  ln2/ln(X(cell	  number	  at	  the	  end	  of	  the	  incubation	  time	  )/X(cell	  
number	  at	  the	  beginning	  of	  the	  incubation	  time).	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5.2.3	  Dual	  reporter	  luciferase	  Assay	  	  
MCF7	  cells	  were	  transiently	  transfected	  with	  the	  pGL3-­‐Luc.3ERE	  Luciferase	  vector	  
(kindly	  provided	  by	  Fern	  Murdoch,	  Northwestern	  University,	  Evanston,	  IL)	  or	  with	  
Super8xTOPFlash	  reporter	  construct	  (graciously	  provided	  by	  Randall	  Moon)	  and	  pRL-­‐
CMV(Promega)	  using	  Lipofectamine	  2000	  (Sigma	  Aldrich®,	  St.	  Louis,	  MO),	  as	  per	  manufacturer	  
instructions.	  Cells	  were	  then	  washed	  with	  1X	  PBS	  and	  the	  Dual-­‐Luciferase®	  Reporter	  Assay	  
System	  (Promega)	  supplied	  protocol	  was	  followed	  for	  lysis	  and	  measurements.	  Recorded	  Firefly	  
and	  Renilla	  luciferase	  activity	  was	  measured	  using	  TD-­‐20/20	  Luminometer	  (Turner	  Designs,	  
Sunnyvale,	  CA).	  
5.2.4	  RNA	  Isolation	  and	  Real-­‐Time	  PCR	  
MCF7	  cells	  were	  treated	  as	  described	  above	  and	  the	  total	  RNA	  was	  extracted	  as	  per	  
manufacturer’s	  protocol	  (Trizol,	  Life	  Technologies,	  Carlsbad,	  CA).	  Relative	  mRNA	  levels	  were	  
quantified	  using	  quantitative	  real-­‐time	  Polymerase	  Chain	  Reaction	  (qPCR)	  (Strategene	  Mx3005P,	  
Agilent	  Technologies,	  La	  Jolla,	  CA).	  	  All	  values	  were	  normalized	  to	  the	  amplification	  of	  β−actin.	  
The	  PCR	  primer	  sequences	  used	  are	  as	  follows:	  ERα	  	  forward;	  5’-­‐ATCCACCTGATGGCCAAG-­‐3’;	  
ERα	  reverse;	  5’-­‐GCTCCATGCCTTTGTTACTCA-­‐3’,	  PS2	  forward;	  5’-­‐TCCCTCCAGAAGAGGAGTGT-­‐3’;	  
PS2	  reverse;	  5’-­‐CAGAAGCGTGTCTGAGGTGT-­‐3’.	  	  PR	  forward;	  5’-­‐TTACCATGTGGCAGATCCCACAG-­‐
3’;	  PR	  reverse;	  5’-­‐ACCATCCCTGCCAATATCTTGGG-­‐3’;	  β−actin	  forward;	  5’-­‐
GAGGCGTACAGGGATAGC-­‐3’;	  β−actin	  reverse;	  5’-­‐ATGGATATCGCC-­‐3’.	  Assays	  were	  performed	  
using	  the	  1-­‐step	  2X	  Brilliant	  SYBR	  Green	  qRT-­‐PCR	  Master	  Mix	  Kit	  (Agilent	  Technologies)	  
containing	  200nM	  forward	  primer,	  200nM	  reverse	  primer,	  and	  100ng	  total	  mRNA.	  The	  
conditions	  for	  target	  mRNA	  amplification	  were	  performed	  as	  follows:	  1	  cycle	  of	  50°C	  for	  30	  min;	  
1	  cycle	  of	  95°C	  for	  10	  min;	  35	  cycles	  each	  95°C	  for	  30s,	  55°C	  for	  1	  min,	  and	  72°C	  for	  30s.	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5.2.5	  Tumorsphere	  formation	  
3	  weeks	  R.	  crenulata	  or	  Vehicle	  treated	  MCF7	  cells	  were	  disassociated	  by	  Trypsin	  (Life	  
Technologies,	  Grand	  Island,	  NY)	  and	  cell	  pellets	  were	  collected	  by	  centrifugation	  (5min,	  1000g).	  
Cells	  were	  then	  suspended	  in	  MammocultTM	  human	  medium	  kit	  (STEMCELL	  Technologies	  Inc.,	  
Vancouver,	  BC,	  Canada)	  and	  pipetted	  repeatedly	  to	  ensure	  single	  cell	  suspension.	  A	  total	  of	  500	  
cells	  were	  plated	  on	  an	  AggreWellTM	  800	  plate	  (STEMCELL	  Technologies	  Inc.)	  and	  treated	  with	  
R.	  crenulata	  or	  vehicle	  control	  retreated	  every	  5	  days	  for	  3	  weeks.	  Captured	  representative	  
images	  were	  taken	  with	  a	  Nikon	  Eclipse	  TE2000-­‐U	  using	  MetaVueTM	  software	  (Universal	  
Imaging	  Corporation).	  	  	  
5.2.6	  Western	  Blot	  Analysis	  	  
MCF7	  cells	  were	  treated	  as	  described	  above	  and	  were	  lysed	  with	  RIPA	  buffer	  
supplemented	  with	  phosphatase	  inhibitors	  and	  protease	  inhibitors	  (Sigma	  Aldrich®,	  St.	  Louis,	  
MO).	  Lysate	  protein	  concentrations	  were	  measured	  by	  a	  BCATM	  Protein	  Assay	  Kit	  (Pierce,	  
Rockford,	  IL),	  50μg/ml	  of	  protein	  was	  run	  on	  a	  10%	  SDS-­‐PAGE	  and	  transferred	  onto	  a	  PVDF	  
membrane	  (Sigma	  Aldrich®,	  St.	  Louis,	  MO).	  Membrane	  was	  blocked	  for	  one	  hour	  with	  5%	  milk	  in	  
TBS-­‐T	  and	  primary	  antibodies	  	  (Rabbit	  non-­‐phospho	  (Active)	  β-­‐catenin	  (Ser33/37/Thr41)	  
(D13A1)	  1:1000	  5%	  BSA	  in	  TBS-­‐T	  (Cell	  Signaling	  Technology,	  Danvers,	  MA);	  Rabbit	  β-­‐actin	  1:2000	  
(Abcam,	  Cambridge,	  MA)	  were	  incubated	  over	  overnight.	  Secondary	  antibody	  [goat	  anti-­‐rabbit	  
IgG-­‐HRP	  1:5000	  (Santa	  Cruz	  Biotechnology,	  Dallas,	  TX)	  was	  incubated	  for	  2	  hours	  at	  room	  
temperature.	  The	  blot	  was	  washed	  and	  developed	  using	  a	  Western	  Blot	  Luminol	  Reagent	  (Santa	  
Cruz	  Biotechnology)	  and	  imaged	  with	  a	  Synopics	  4.2	  MP	  camera	  and	  G:Box	  Chemi-­‐XT4	  GENESys	  
software	  (SYNGENE,	  Frederick,	  MD).	  Image	  J	  software	  was	  used	  for	  band	  density	  quantification.	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5.2.7	  Animal	  care	  and	  treatment 
This	  study	  was	  carried	  out	  in	  strict	  accordance	  with	  the	  recommendations	  in	  the	  
Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  of	  the	  National	  Institutes	  of	  Health.	  
The	  protocol	  was	  approved	  by	  the	  Baystate	  Medical	  Center	  Institutional	  Animal	  Care	  and	  Use	  
Committee.	  Female129/C57Blk6	  c	  (n=20)	  were	  split	  into	  two	  groups:	  1.	  Vehicle	  treated	  group	  (	  
N=10)	  and	  R.	  crenulata	  treated	  group.	  Each	  group	  was	  individually	  housed	  in	  plastic	  cages	  with	  
food	  and	  water	  provided	  continuously,	  and	  maintained	  on	  a	  12:12	  light	  cycle.	  Mice	  were	  placed	  
on	  a	  chow	  diet	  [Harlan	  Teklad	  global	  18%	  protein	  rodent	  diet	  (#2018)	  containing	  2.8%	  fat,	  18.6%	  
protein]	  for	  12	  weeks.	  Treatment	  was	  supplemented	  in	  the	  water	  at	  a	  20	  mg/kg/day	  
concentration	  of	  R.	  crenulata	  or	  equivalent	  volume	  of	  vehicle	  control.	  Upon	  completion	  of	  the	  
treatment,	  mice	  were	  euthanized	  by	  CO2	  followed	  by	  cervical	  dislocation.	  Mammary	  glands	  
(3rd,	  4th,	  and	  5th	  inguinal	  glands	  were	  harvested	  and	  fixed	  in	  10%	  buffered	  formalin.	  	  
5.2.8	  Immunohistochemistry	  (IHC)	  	  
IHC	  was	  performed	  on	  a	  DakoCytomation	  autostainer	  using	  the	  Envision	  HRP	  Detection	  
system	  (Dako,	  Carpinteria,	  CA).	  Each	  tissue	  block	  was	  sectioned	  at	  4	  μm	  on	  a	  graded	  slide,	  
deparaffinized	  in	  xylene,	  rehydrated	  in	  graded	  ethanols,	  and	  rinsed	  in	  Tris-­‐phosphate-­‐buffered	  
saline	  (TBS).	  Heat	  induced	  antigen	  retrieval	  was	  performed	  in	  a	  microwave	  at	  98ºC	  in	  0.01	  M	  
citrate	  buffer.	  After	  cooling	  for	  20	  minutes,	  sections	  were	  rinsed	  in	  TBS	  and	  subjected	  to	  the	  
following	  primary	  antibodies	  [ER	  (sc-­‐542,	  Santa	  Cruz	  Biotechnology,	  Dallas,	  TX)	  ,PR	  (sc-­‐538,	  
Santa	  Cruz	  Biotechnology,	  Dallas,TX)	  and	  anti-­‐BrdU	  (Rat	  monoclonal,	  Abcam,	  Cambridge	  MA)	  for	  
45	  minutes.	  Immunoreactivity	  was	  visualized	  by	  incubation	  with	  chromogen	  diaminobenzidine	  
(DAB)	  for	  5	  minutes.	  Tissue	  sections	  were	  counterstained	  with	  hematoxylin,	  dehydrated	  through	  
graded	  ethanols	  and	  xylene,	  and	  cover-­‐slipped.	  Images	  were	  captured	  with	  an	  Olympus	  BX41	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light	  microscope	  using	  SPOT	  Software	  5.1	  (SPOT™Imaging	  Solutions,	  Detroit,	  MI).	  Total	  and	  
positively	  stained	  epithelial	  cells	  from	  mammary	  glands	  were	  quantified	  and	  the	  percentage	  of	  
positively	  labeled	  cells	  was	  calculated.	  
5.2.9	  Statistical	  Analysis	  	  
For	  single	  treatments,	  results	  were	  analyzed	  using	  Student’s	  t-­‐test	  for	  R.	  crenulata	  
treatment	  and	  combination	  treatments	  were	  analyzed	  by	  Two	  way	  ANOVA.	  Graphpad	  Prism	  
statistical	  analysis	  software(San	  Diego,	  CA)	  was	  used	  in	  this	  analysis	  and	  figure	  generation.	  
Grubb’s	  test	  was	  used	  on	  all	  data	  to	  identify	  statistical	  outliers	  
(http://www.graphpad.com/quickcalcs).	  	  
5.3	  Results	  
5.3.1	  R.	  Crenulata	  induces	  Estrogen	  transcription	  activity	  upon	  24	  hours	  of	  treatment.	  	  
To	  investigate	  whether	  the	  R.	  crenulata	  extract	  exhibits	  estrogenic	  activity,	  we	  treated	  
ER+	  MCF7	  breast	  cancer	  cells	  expressing	  an	  ERE-­‐Luc	  plasmid	  with	  100	  µg/ml	  of	  R.crenulata	  or	  
vehicle	  control	  for	  24	  hours.	  A	  dual	  luciferase	  reporter	  assay	  showed	  that	  after	  24	  hours,	  R.	  
crenulata	  significantly	  activates	  ER-­‐mediated	  transcription	  in	  MCF7	  cells	  (fig	  5.1A).	  To	  determine	  
whether	  these	  results	  corroborate	  with	  endogenous	  ER	  transcriptional	  activity,	  we	  performed	  a	  
quantitative	  real-­‐time	  PCR	  analysis	  of	  ERα	  target	  genes,	  PR	  and	  PS2.	  Our	  results	  demonstrate	  
that	  the	  mRNA	  transcript	  levels	  of	  PR	  and	  PS2	  are	  significantly	  increased	  in	  response	  to	  
treatment	  with	  R.	  crenulata	  compared	  with	  vehicle	  treated	  cells	  (fig.	  5.1B).	  Considering	  that	  	  
estrogen	  is	  a	  potent	  mitogen	  in	  MCF7	  cells,	  we	  examined	  proliferation	  in	  response	  to	  R.	  
crenulata	  treatment	  in	  MCF7	  cells	  using	  an	  automated	  cell	  counter.	  As	  expected,	  24	  hours	  
following	  treatment	  with	  R.	  crenulata,	  we	  observed	  a	  significant	  increase	  in	  the	  number	  of	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viable	  cells	  (fig	  5.1C).	  Taken	  together,	  these	  results	  suggest	  that	  the	  R.	  crenulata	  extract	  contains	  
estrogenic	  compounds	  capable	  of	  activating	  an	  ER-­‐mediated	  response	  in	  MCF7	  cells.	  	  
	  
Figure	  5.1.	  R.	  crenulata	  treatment	  induces	  ER	  transcriptional	  activation	  in	  MCF7	  cells	  in	  
vitro.	  MCF7cells	  were	  plated	  and	  after	  24	  hours,	  the	  media	  was	  replaced	  with	  charcoal	  
stripped	  and	  phenol	  free	  media	  and	  cells	  were	  treated	  with	  100	  µg/ml	  R.	  crenulata	  or	  
vehicle	  (10%	  EtOH)	  in	  the	  presence	  or	  absense	  of	  10	  nM	  	  17 β−estradiol	  (positive	  
control)	  for	  24	  hours.	  A.	  Bar	  graph	  representation	  of	  ERE-­‐Luc	  plasmid	  luciferase	  reporter	  
assay	  mean	  ±	  SEM	  (n=4)	  of	  the	  difference	  in	  fold	  change	  compared	  with	  control	  vehicle	  
treated	  cells.	  B.	  Bar	  graph	  representation	  for	  qPCR	  analysis	  of	  ER	  target	  genes	  PR	  and	  
PS2	  mRNA	  levels	  normalized	  to	  βactin	  mRNA	  in	  response	  to	  R.	  crenulata	  and	  17	  β-­‐
estradiol	  treatment	  (n=3).	  Bars	  represent	  mean	  ±	  SEM	  of	  N=3.	  Results	  are	  expressed	  as	  
relative	  expression	  of	  vehicle	  treated	  control	  cells.	  C.	  Bar	  graph	  representation	  of	  the	  
mean	  	  ±	  SEM	  of	  MCF7	  cell	  counts	  (n=3)	  cells	  after	  24	  hours	  treatment	  with	  R.	  crenulata	  	  
or	  vehicle	  	  (*p	  <	  0.05,	  **p	  <	  0.01,	  ****p<0.0001).	  	  
5.3.2	  Increased	  exposure	  time	  to	  R.	  crenulata	  diminishes	  the	  proliferative	  response	  observed	  
in	  MCF7	  cells	  and	  abolishes	  ER-­‐mediated	  activity.	  	  
Since	  Rhodiola	  supplements	  are	  typically	  consumed	  over	  a	  period	  of	  time,	  we	  surmised	  
that	  it	  would	  be	  more	  physiologically	  relevant	  to	  measure	  the	  growth	  pattern	  of	  MCF7	  cells	  
treated	  with	  R.	  crenulata	  over	  time.	  To	  that	  end,	  cells	  were	  plated	  at	  equal	  densities,	  treated	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with	  R.	  crenulata	  or	  vehicle,	  counted	  over	  a	  period	  of	  2	  weeks,	  and	  the	  doubling	  time	  was	  
calculated	  to	  assess	  changes	  in	  proliferation	  patterns.	  After	  24	  hours	  of	  treatment,	  results	  show	  
that	  the	  doubling	  time	  of	  	  R.	  crenulata	  treated	  cells	  was	  14.78	  hours	  compared	  to	  25.25	  hours	  
for	  the	  control	  vehicle	  treated	  cells	  (fig.	  5.2A)	  in	  agreement	  with	  our	  previous	  study.	  
Paradoxically,	  the	  later	  time	  points	  revealed	  a	  reverse	  in	  the	  proliferative	  pattern,	  a	  significant	  
increase	  in	  doubling	  time	  in	  the	  R.	  crenulata	  treated	  cells	  was	  noted	  as	  early	  as	  1	  week.	  	  
Considering	  that	  R.	  crenulata	  reduced	  doubling	  times	  in	  MCF7	  cells,	  we	  wanted	  to	  
investigate	  whether	  ER	  transcriptional	  activity	  was	  also	  reduced	  following	  continuous	  treatment	  
with	  R	  .crenulata.	  Therefore,	  we	  transfected	  an	  ERE-­‐Luc	  plasmid	  into	  MCF7	  cells	  which	  had	  been	  
continuously	  treated	  with	  R.	  crenulata	  for	  2	  weeks.	  	  A	  dual	  luciferase	  reporter	  assay	  revealed	  
that	  R	  crenulata	  treatment	  had	  reduced	  basal	  and	  17-­‐βestradiol	  -­‐induced	  ER	  transcriptional	  
activity	  (fig.	  5.2B).	  Treatment	  	  with	  10	  nM	  	  17-­‐βestradiol	  significantly	  increased	  luciferase	  
activity	  in	  both	  R.	  crenulata	  and	  vehicle	  treated	  cells	  suggesting	  that	  the	  receptor	  was	  still	  
functional.	  Furthermore,	  the	  estrogen	  receptor	  antagonist,	  ICI	  182,780,	  reduced	  luciferase	  
activity	  in	  all	  treatments.	  	  This	  experiment	  suggests	  that	  ERα	  remains	  functional	  after	  a	  2	  week	  
treatment	  with	  R.	  crenulata	  extract. Together	  these	  results	  indicate	  that	  longer	  treatment	  with	  
R.	  crenulata	  reduces	  the	  overall	  proliferation	  and	  estrogenic	  response	  in	  ER+	  MCF7	  cancer	  cells,	  





Figure	  5.2.	  Continuous	  R.	  crenulata	  treatment	  alters	  MCF7	  cell	  doubling	  time	  and	  
abolishes	  ER-­‐mediated	  activity.	  A.	  MCF7	  cells	  were	  plated	  at	  100,000	  cells	  per	  well	  and	  
treated	  with	  100 µg/ml	  R	  .crenulata	  or	  vehicle	  (10%	  EtOH).	  Cells	  were	  counted	  at	  1,	  7,	  
and	  14	  days	  and	  doubling	  time	  was	  calculated.	  Depicted	  results	  represent	  experiments	  
performed	  in	  triplicate	  ±	  SEM.	  (*p	  <	  0.05,	  **p	  <	  0.01,	  ***	  <	  0.001).	  B.	  MCF7	  cells	  treated	  
with	  R.	  crenulata	  and	  vehicle	  for	  2	  weeks	  were	  plated	  in	  24	  well	  plates	  and	  24	  hours	  
later,	  the	  media	  was	  replace	  with	  charcoal	  stripped	  and	  phenol	  free	  media	  treated	  with	  
100	  µg/ml	  R.	  crenulata	  or	  vehicle	  (10%	  EtOH)	  in	  the	  presense	  or	  absense	  of	  10	  nMof	  17	  
β-­‐estradiol	  (positive	  control)	  and	  or	  20	  nM	  ICI	  182,780	  (	  for	  24	  hours.	  Bar	  graph	  
representation	  of	  ERE-­‐Luc	  plasmid	  luciferase	  reporter	  assay	  mean	  ±	  SEM	  (N=3)	  (*p	  
value<	  0.05,	  **p	  value<	  0.01,	  .	  	  All	  depicted	  significance	  is	  from	  adjusted	  p	  values	  from	  
Bonferroni	  test	  post	  2-­‐way	  ANOVA	  analysis).	  
5.3.3	  R.	  crenulata	  reduces	  the	  formation	  and	  maintenance	  of	  	  MCF7	  tumorspheres.	  	  
The	  ability	  of	  cells	  to	  survive	  independent	  of	  attachment	  to	  surfaces	  and	  the	  ability	  to	  
form	  tumorspheres	  are	  characteristics	  of	  resilient	  cancer	  cells.	  Our	  previous	  work	  with	  triple	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negative	  breast	  cancer	  cells	  lines	  has	  suggested	  that	  R.	  crenulata	  reduces	  the	  tumorsphere	  
generating	  abilities	  in	  these	  aggressive	  cell	  lines	  [14].	  To	  assess	  this	  capability	  in	  less	  aggressive	  
ER+	  MCF7	  cells,	  we	  plated	  a	  single	  cell	  suspension	  of	  MCF7	  cells	  which	  had	  been	  previously	  
treated	  with	  R.	  crenulata	  or	  vehicle	  for	  2	  weeks	  in	  low	  attachment	  plates	  and	  tumorsphere	  
formation	  was	  monitored	  over	  21	  days.	  Within	  the	  first	  week,	  both	  R.	  crenulata	  and	  vehicle	  
treated	  cells	  were	  able	  to	  form	  small	  tumorspheres	  under	  the	  described	  conditions	  (Week	  1,	  fig.	  
5.3).	  However,	  over	  time,	  there	  were	  fewer	  R.	  crenulata	  treated	  tumorspheres	  compared	  to	  
vehicle	  treated	  MCF7	  cells.	  Additionally,	  vehicle	  treated	  tumorspheres	  increased	  in	  size	  
compared	  to	  R.	  crenulata	  treated	  cells,	  an	  observation	  that	  persisted	  for	  the	  duration	  of	  the	  
study	  (Week	  2	  ,3	  fig.	  5.3).	  	  These	  data	  suggest	  that	  treatment	  with	  a	  hydroalcoholic	  R.	  crenulata	  
root	  extract	  reduces	  tumorsphere	  formation	  in	  ER+	  MCF7	  cells.	  
	  
Figure	  5.3.	  MCF7	  tumorsphere	  formation	  is	  reduced	  in	  response	  to	  R.crenulata	  
treatment.	  A	  total	  of	  500	  MCF7	  cells	  were	  plated	  in	  an	  AggreWellTM	  800	  plate,	  treated	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with	  vehicle	  or	  R.	  crenulata	  and	  retreated	  every	  5	  days	  for	  3	  weeks.	  Phase	  contrast	  
images	  were	  captured	  at	  weeks	  1,	  2	  and	  3.	  Images	  were	  captured	  at	  20X	  magnification.	  
5.3.4	  R.	  crenulata	  alters	  ERα 	  expression	  and	  reduces	  β−catenin	  activity	  over	  time.	  
A	  24	  hour	  treatment	  with	  R.	  crenulata	  increased	  proliferation	  and	  ER	  activity	  while	  
continuous	  treatment	  resulted	  in	  a	  decrease	  in	  proliferation	  and	  dampened	  the	  estrogenic	  
response	  as	  well.	  Since	  ERα	  regulates	  the	  mitogenic	  effect	  of	  estrogen,	  we	  wanted	  to	  test	  
whether	  R.	  crenulata	  treatment	  could	  alter	  ERα gene	  expression	  levels.	  Quantitative	  real-­‐time	  
PCR	  analysis	  revealed	  that	  ERα mRNA	  transcript	  levels	  were	  significantly	  increased	  in	  R.	  
crenulata	  treated	  cells	  when	  compared	  with	  vehicle	  treated	  cells	  after	  24	  hours	  of	  treatment	  
(fig.	  5.4A).	  However,	  ERα	  mRNA	  levels	  were	  decreased	  after	  2	  weeks	  of	  continous	  treatment	  
(fig.	  5.4B).	  These	  results	  suggest	  that	  longer	  treatments	  with	  R.	  crenulata	  reduces	  estrogenic	  
responses	  in	  ER+	  MCF7	  cancer	  cells	  by	  reducing	  the	  expression	  of	  ERα.	  
Since	  ER	  transciptional	  activity	  is	  known	  to	  be	  regulated	  by	  β-­‐catenin	  and	  we	  have	  
previously	  demonstrated	  that	  R.	  crenulata	  treatment	  inhibts	  β-­‐catenin	  and	  decreases	  stem-­‐like	  
behaviors	  in	  more	  aggressive	  cancer	  cells	  	  [14]	  (Mora	  et	  al	  2015,	  in	  press)	  we	  wanted	  to	  
determine	  whether	  R.	  crenulata	  regulates	  β−catenin	  activity	  in	  these	  cells	  as	  well.	  To	  investigate	  
whether	  there	  was	  a	  change	  in	  the	  β−catenin	  activity	  as	  defined	  by	  level	  of	  phosphorylation	  at	  
(Ser33/37/Thr41),	  we	  probed	  protein	  extracts	  of	  	  24	  hour	  	  R.	  crenulata	  or	  vehicle	  treated	  cells	  
via	  Western	  Blot	  analysis	  with	  a	  non-­‐phospho	  (active)	  β−catenin	  antibody.	  	  To	  enhance	  active	  
β−catenin	  levels,	  cells	  were	  treated	  with	  the	  GSK3	  inhibitor,	  LiCl.	  As	  expected,	  LiCl	  treatment	  
resulted	  in	  an	  increase	  in	  the	  amount	  of	  active	  β−catenin	  in	  MCF7	  cells	  whereas	  R.	  crenulata	  
treatment	  marginaly	  reduced	  it	  (fig.	  5.4C,	  upper	  panel).	  	  To	  further	  confirm	  this	  observation,	  we	  
transfected	  MCF7	  cells	  with	  a	  β−catenin	  luciferase	  reporter	  construct	  (Super	  8xTOPFlash	  
Reporter)	  and	  treated	  the	  cells	  with	  R.	  crenulata	  or	  vehicle	  and	  stimulated	  β−catenin	  activity	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with	  LiCl	  for	  24	  hrs.	  As	  expected,	  LiCl	  treatment	  resulted	  in	  increased	  β−catenin	  transcriptional	  
activity	  and	  R.	  crenulata	  treatment	  significantly	  reduced	  this	  activity	  (fig	  4.4C,	  lower	  panel).	  	  
Thus,	  R.	  crenulata	  treatment	  inhibits	  β−catenin	  transcriptional	  activation	  in	  MCF7	  cells.	  	  Finally	  
we	  wanted	  to	  determine	  whether	  R.	  crenulata	  treatment	  reduced	  the	  amount	  of	  active	  
β−catenin	  after	  2	  weeks	  of	  treatment.	  	  Western	  blot	  analysis	  probed	  with	  active	  β−catenin	  
demonstrates	  a	  decrease	  in	  the	  level	  of	  active	  β−catenin	  in	  the	  MCF7	  cells	  treated	  with	  R.	  
crenulata	  for	  2	  weeks	  (fig.	  4.4D,upper	  panel).	  Densitometry	  analysis	  	  normalizing	  the	  proteins	  to	  
β-­‐actin	  confirms	  a	  signifcant	  reduction	  in	  active	  β−catenin	  levels	  as	  well	  (fig.	  4.4D,	  lower	  panel).	  	  
Hence,	  these	  results	  suggest	  a	  possible	  mechanism	  by	  which	  R.	  crenulata	  negatively	  affects	  
MCF7	  neaoplastic	  behaviors.	  
	  
Figure	  5.4.	  R.crenulata	  alters	  ERα expression	  and	  reduces	  β−catenin	  activity	  over	  time.	  
A.	  &	  B.	  Bar	  graph	  representation	  for	  qPCR	  analysis	  of	  ERα mRNA	  levels	  normalized	  to	  
β−actin	  mRNA	  in	  response	  to	  R.	  crenulata	  and	  17	  β-­‐estradiol	  treatment	  (n=3)	  at	  A.	  24	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hours	  or	  B.	  2	  weeks.	  	  Bars	  represent	  mean	  ±	  SEM	  of	  n=3.	  Results	  are	  expressed	  as	  
relative	  expression	  of	  vehicle	  treated	  control	  cells.	  C.	  R.crenulata	  reduces	  LiCl	  induced	  
β−catenin	  activity	  Upper	  panel:	  representative	  image	  of	  total	  protein	  lysates	  immuno-­‐
blotted	  with	  anti-­‐(active) β−catenin	  and	  normalizer βactin.	  Lower	  panel:	  Bar	  graph	  
representation	  of	  β−catenin	  luciferase	  reporter	  assay	  mean	  ±	  SEM	  of	  the	  difference	  in	  
fold	  change	  compared	  with	  control	  vehicle	  treated	  cells	  (N=4	  *p	  value<	  0.05).	  	  D.	  Upper	  
panel:	  representative	  image	  of	  total	  protein	  lysaetes	  from	  MCF7	  cells	  treated	  with	  
R.crenulata	  or	  vehicle	  for	  2	  weeks	  immuno-­‐blotted	  with	  anti-­‐(active)	  β−catenin	  and	  
normalizer	  βactin(N	  of	  2	  per	  treatment	  group).	  Lower	  panel:	  Bar	  representation	  of	  band	  
densities	  quantified	  and	  normalized	  to	   actin.	  Bars	  represent	  mean	  ±	  SEM	  of	  N=4	  (****p	  
value	  <	  0.0001).	  
5.3.5	  R.	  crenulata	  does	  not	  change	  ER	  expression	  or	  activity	  in	  murine	  mammary	  glands.	  	  
R.	  crenulata	  is	  often	  taken	  as	  an	  anti-­‐depressant	  and	  to	  date	  no	  known	  toxicities	  have	  
not	  been	  noted.	  Given	  the	  short	  term	  estrogenic	  effect	  of	  R.	  crenulata	  on	  MCF7	  cells,	  we	  wished	  
to	  examine	  whether	  the	  expression	  of	  estrogen	  associated	  targets	  could	  be	  noted	  in	  the	  
mammary	  glands	  of	  mice	  fed	  R.	  crenulata	  for	  12	  weeks.	  	  Ten	  week	  old	  129/C57BLK6	  female	  
mice	  were	  provided	  R.	  crenulata	  in	  their	  water	  for	  12	  weeks.	  	  The	  amount	  of	  water	  imbibed	  was	  
measured	  and	  calculated	  to	  be	  20	  mg/kg/day	  of	  R.	  crenulata.	  At	  the	  end	  of	  the	  study,	  we	  
examined	  the	  expression	  of	  ER	  and	  PR	  by	  IHC.	  The	  number	  of	  positively	  stained	  cells	  was	  
counted	  and	  our	  results	  reveal	  that	  there	  was	  no	  significant	  change	  with	  the	  inclusion	  of	  R.	  




Figure	  5.5.	  Estrogen	  receptor	  and	  progesterone	  receptor	  expression	  in	  mammary	  fat	  
pads	  from	  129/C57BLK6	  female	  mice	  treated	  with	  R.	  crenulata.	  	  Image	  representation	  of	  
IHC	  analysis	  performed	  on	  paraffin	  embedded	  mammary	  fat	  pads	  from	  mice	  treated	  
with	  R.	  crenulata	  or	  vehicle	  for	  12	  weeks.	  A.	  ERα	  B.	  PR.	  Associated	  bar	  graphs	  represent	  
the	  quantification	  of	  percentage	  of	  positively	  stained	  epithelial	  cells	  normalized	  to	  total	  
of	  epithelial	  cells. 
5.4	  Discussion	  
The	  present	  study	  demonstrates	  that	  the	  R.crenulata	  extract	  contains	  components	  with	  
estrogenic	  activity	  (fig.	  5.1).	  However,	  these	  effects	  changed	  with	  prolonged	  treatment	  with	  R.	  
crenulata.	  Cell	  doubling	  times	  were	  longer	  than	  the	  vehicle	  treated	  cells.	  After	  2	  weeks	  of	  R.	  
crenulata	  treatment,	  MCF7	  cells	  exhibited	  a	  decreased	  response	  to	  R.	  crenulata	  estrogenic	  
response,	  but	  still	  remained	  responsive	  to	  activators	  and	  inhibitors	  (17	  βestradiol	  and	  ICI 
182,780),	  suggesting	  that	  the	  ERα	  receptor	  remains	  functional.	  	  In	  association	  with	  the	  changes	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in	  doubling	  time,	  we	  found	  that	  prolonged	  exposure	  to	  R.	  crenulata	  reduced	  ERα	  mRNA	  (fig.	  
4A,B)	  levels	  and	  reduced	  β-­‐catenin	  activation(fig.	  5.4C,D).	  
β−catenin	  transcriptional	  activity	  ,via	  canonical	  WNT	  signaling,	  is	  implicated	  in	  the	  
regulation	  of	  cell	  fate,	  proliferation,	  morphology,	  and	  migration	  during	  normal	  development	  
[16].	  Dysregulation	  of	  this	  signaling	  pathway	  has	  been	  implicated	  in	  breast	  cancer	  [17];	  more	  
specifically	  as	  a	  critical	  factor	  in	  cancer	  stem	  like	  behavior	  and	  tumorsphere	  initiating	  activity.	  
Therefore,the	  R.crenulata	  effects	  on	  β−catenin	  support	  a	  mechanism	  to	  explain	  the	  inhibition	  of	  
tumorsphere	  formation	  with	  extended	  R.crenulata	  treatment	  .	  
Additionally,	  ERα transcriptional	  activity	  has	  been	  shown	  to	  be	  affected	  by	  the	  levels	  of	  
β−catenin	  levels.	  Specifically,	  Gupta	  et.	  al	  has	  demonstrated	  that	  β−catenin	  knockdown	  results	  
in	  reduced	  ERα	  responsiveness	  to	  17	  βestradiol	  [18].	  In	  our	  laboratory,	  we	  previously	  showed	  
that	  in	  cells	  deficient	  in	  WNT	  signaling	  antagonist	  Secreted	  frizzeled	  related	  protein	  1(SFRP1),	  
where	  β−catenin	  transcriptional	  activity	  is	  increased,	  the	  cells’	  estrogenic	  transcriptional	  
response	  to	  17	  βestradiol	  is	  enhanced	  (Gregory	  et	  al.,in	  press).	  	  	  Hence,	  a	  second	  explanation	  for	  
the	  reduced	  estrogenic	  effects	  could	  be	  a	  result	  of	  delayed	  influence	  of	  R.	  crenulata	  on	  β-­‐
catenin	  levels	  and	  activity.	  
The	  safety	  and	  toxicity	  of	  Rhodiola	  sp.	  have	  been	  examined	  in	  several	  studies.	  For	  mild	  
to	  moderate	  depression	  up	  to	  400-­‐700	  mg	  R.	  rosea	  containing	  3%	  rosavins	  and	  1%	  salidroside	  
has	  been	  given	  without	  noted	  side	  effects	  [19]	  .	  Since	  Rhodiola	  sp.	  supplements	  have	  gained	  
popularity,	  we	  felt	  it	  was	  important	  to	  show	  that	  Rhodiola	  sp.	  contain	  estrogenic	  
phytochemicals	  that	  can	  act	  on	  ER	  +	  cancer	  cells.	  However,	  our	  assessment	  in	  normal	  mammary	  
glands	  of	  mice	  treated	  for	  12	  weeks	  with	  R.crenulata	  	  resulted	  in	  no	  changes	  in	  ER	  levels	  or	  
activity.	  	  Future	  studies	  will	  have	  to	  be	  performed	  to	  determine	  whether	  this	  lack	  of	  effect	  in	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vivo	  is	  due	  to	  low	  level	  of	  accumulation	  in	  the	  breast,	  a	  lack	  of	  effect	  on	  normal	  cells,	  or	  	  
because	  of	  the	  extended	  treatment	  time.	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6.1	  Sfrp1	  obesity	  model:	  Further	  direction	  to	  understand	  the	  effects	  of	  R.	  crenulata	  
In	  chapter	  2,	  we	  investigated	  the	  effects	  of	  HFD	  feeding	  on	  adiposity,	  glucose	  
metabolism	  and	  inflammation	  in	  mice	  lacking	  expression	  of	  SFRP1.	  Our	  results	  demonstrate	  that	  
SFRP1	  is	  an	  important	  protein	  required	  for	  maintaining	  appropriate	  cellular	  signaling	  in	  response	  
to	  the	  onset	  of	  obesity.	  As	  shown	  by	  the	  results,	  Sfrp1	  deficiency	  affected	  several	  factors	  as	  it	  
exacerbated	  weight	  gain,	  dysregulated	  glucose	  homeostasis	  in	  several	  tissues	  (decreased	  
expression	  of	  glucose	  transporters	  [Slc2a2	  and	  Slc2a4],	  aberrantly	  upregulated	  hepatic	  
gluconeogenesis	  regulators	  [G6pc	  and	  Pck1],	  aberrant	  insulin	  secretion),	  and	  increased	  
inflammation	  marked	  by	  an	  increase	  in	  macrophage	  infiltration	  and	  an	  expression	  of	  pro-­‐
inflammatory	  genes,	  in	  mice	  in	  response	  to	  diet	  induced	  obesity	  (DIO)	  [1].	  Collectively	  these	  
results	  mimic	  an	  extreme	  obesity	  model,	  however	  further	  characterization	  of	  the	  role	  of	  SFRP1	  
in	  vitro	  would	  be	  of	  advantage,	  to	  delineate	  the	  different	  factors.	  	  
Our	  results	  showed	  that	  glucose	  clearance	  was	  dysregulated	  as	  early	  as	  2	  weeks	  of	  HFD	  
feeding,	  and	  that	  occurred	  independent	  of	  weight	  gain	  at	  that	  time	  point	  (fig.	  2.1,	  2.2).	  This	  
suggested	  that	  glucose	  metabolism	  occurred	  first	  and	  was	  further	  exacerbated	  by	  increased	  
adiposity.	  	  Inflammation	  is	  an	  important	  contributor	  to	  insulin	  resistance	  and	  glucose	  
homeostasis.	  A	  sustained	  pro-­‐inflammatory	  state	  was	  noted	  in	  our	  animals,	  however,	  the	  time	  
frame	  for	  induction	  of	  inflammation	  remains	  unknown.	  It	  is	  possible	  that	  HFD	  feeding	  lead	  to	  an	  
early	  inflammation	  which	  contributed	  to	  the	  dysregulation	  of	  glucose	  metabolism.	  	  This	  could	  be	  
tested	  by	  examining	  animal	  tissues	  as	  early	  as	  two	  weeks,	  and	  by	  including	  a	  third	  group	  treated	  
with	  a	  commercially	  available	  anti-­‐inflammatory	  drug.	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Another	  organ	  system	  that	  should	  be	  examined	  is	  the	  gastrointestinal	  tract.	  It	  has	  been	  
long	  shown	  that	  insulin	  stimulation	  is	  increased	  through	  Incretins,	  a	  hormone	  released	  by	  
enteroendocrine	  cells	  present	  in	  intestinal	  epithelium	  [2].	  A	  study	  has	  shown	  that	  incretin	  
production	  is	  regulated	  by	  the	  WNT/β−catenin	  signaling	  pathway	  [3].	  	  We	  did	  not	  determine	  
whether	  canonical	  WNT	  signaling	  is	  increased	  in	  the	  intestinal	  tissue	  in	  response	  to	  Sfrp1	  
deficiency,	  subsequently	  affecting	  incretin	  levels.	  	  We	  noted	  that	  insulin	  levels	  were	  consistently	  
higher	  in	  the	  Sfrp1	  -­‐/-­‐	  mice,	  and	  an	  increase	  in	  incretin	  levels	  could	  be	  a	  possible	  factor	  
contributing	  to	  this	  observation,	  in	  addition	  to	  the	  increase	  Sfrp1	  -­‐/-­‐	  islets	  sensitivity	  to	  high	  
glucose	  stimulation	  (fig.	  2.S2.A).	  	  
Understanding	  the	  discussed	  factors	  would	  be	  beneficial	  in	  understanding	  how	  
R.crenulata	  treatment	  ameliorated	  glucose	  clearance	  and	  increased	  insulin	  sensitivity	  	  	  in	  Sfrp1	  -­‐
/-­‐	  at	  the	  early	  time	  point	  in	  the	  study	  (2	  	  weeks)(fig.	  3.3)	  The	  study	  described	  in	  chapter	  3	  of	  this	  
dissertation,	  shows	  that	  R.	  crenulata	  attenuated	  DIO	  induced	  liver	  inflammation,	  hence	  if	  the	  
inflammation	  induction	  is	  an	  event	  that	  occurs	  early	  in	  the	  HFD	  Sfrp1	  -­‐/-­‐	  fed	  mice,	  R.	  crenulata	  
could	  attenuate	  inflammation	  in	  the	  livers	  of	  these	  mice,	  which	  were	  shown	  to	  have	  an	  increase	  
in	  pro-­‐inflammatory	  cytokines	  and	  steotosis.	  Hence,	  further	  understanding	  of	  the	  Sfrp1	  -­‐/-­‐	  on	  DIO	  
would	  be	  beneficial.	  
6.2	  R.	  crenulata	  and	  obesity	  complications:	  Future	  directions	  
	  It	  was	  previously	  shown	  that	  R.	  crenulata	  can	  inhibit	  adipogenesis	  in	  vitro	  [4],	  however	  
our	  results	  demonstrate	  that	  there	  was	  no	  change	  in	  body	  fat	  percentage	  in	  mice	  on	  HFD	  
treated	  with	  R.crenulata	  or	  vehicle.	  Additionally,	  studies	  have	  shown	  that	  salidroside	  improved	  
glucose	  uptake	  in	  skeletal	  muscle	  and	  adipocytes[5,6]	  and	  lowered	  fasting	  insulin	  levels	  in	  ZDF	  
diabetic	  rats[7].	  The	  referenced	  studies	  [5-­‐7]	  used	  concentrations	  of	  Rhodiola	  sp.	  or	  salidroside	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of	  80	  µg/ml	  for	  in	  vitro	  salidroside	  study,	  and	  500	  mg/kg	  for	  the	  in	  vivo	  RC	  study.	  Our	  
observations	  in	  both	  Sfrp1-­‐/-­‐	  mice	  and	  129/C57Bl6	  mouse	  models	  occurred	  using	  a	  dose	  of	  20	  
mg/kg.	  We	  used	  this	  dose	  since	  Sfrp1-­‐/-­‐	  became	  very	  sensitive	  to	  insulin	  during	  the	  ITT	  analysis,	  
and	  this	  dose	  was	  kept	  for	  the	  129/C57Bl6	  mice	  in	  order	  to	  compare	  between	  both	  studies.	  	  	  
Therefore,	  dose	  analysis	  would	  be	  beneficial	  since	  the	  beneficial	  effects	  vary	  depending	  on	  the	  
dosage.	  Since	  our	  dose	  is	  considerably	  lower	  than	  the	  published	  studies,	  and	  we	  only	  noted	  
improvement	  in	  liver	  inflammation,	  we	  rationalize	  that	  the	  liver	  has	  higher	  exposure	  to	  the	  R.	  
crenulata	  since	  it	  is	  known	  to	  be	  an	  organ	  responsible	  for	  processing	  and	  metabolizing	  nutrients.	  
Hence	  further	  analysis	  with	  higher	  dosage	  could	  affect	  other	  organs	  and	  result	  in	  an	  earlier	  
improvement	  in	  glucose	  metabolism.	  
6.3	  R.crenulata	  and	  WNT	  signaling:	  How	  does	  it	  occur?	  
In	  chapter	  4,	  we	  demonstrated	  for	  the	  first	  time	  that	  R.crenulata	  treatment	  inhibits	  
β−catenin	  transcriptional	  activity	  (fig.	  4.1).	  We	  further	  attempted	  to	  define	  the	  mechanism	  of	  
inhibition	  in	  MDA-­‐MB-­‐231	  cells,	  and	  we	  were	  able	  to	  narrow	  the	  possible	  targets	  and	  
demonstrate	  that	  it	  occurs	  in	  the	  cytoplasm.	  	  We	  first	  hypothesized	  that	  this	  inhibition	  is	  
occurring	  due	  to	  increased	  GSK3β. 	  When	  WNT/β−catenin	  signaling	  is	  on,	  GSK3β	  is	  
phosphorylated	  on	  Ser9,	  which	  renders	  it	  unable	  to	  phosphorylate.	  As	  a	  result,	  β−catenin	  
accumulates	  in	  the	  cytoplasm	  and	  translocate	  to	  the	  nucleus	  where	  it	  transcribes	  WNT	  target	  
genes.	  	  This	  phosphorylation	  event	  is	  decreased	  when	  WNT/β−catenin	  signaling	  is	  off.	  However,	  
using	  monoclonal	  antibodies	  against	  GSK3βpSER9,	  we	  were	  unable	  to	  detect	  a	  change	  in	  
phosphorylation	  levels	  (data	  not	  shown).	  	  
Current	  data	  from	  our	  laboratory	  suggests	  that	  R.	  crenulata	  affects	  cellular	  respiration	  
of	  MDA-­‐MB-­‐231	  breast	  cancer	  cells.	  	  Respiration	  at	  the	  cellular	  level	  is	  based	  on	  the	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consumption	  of	  glucose.	  A	  recent	  study	  in	  MDA-­‐MB-­‐231	  cells	  demonstrated	  that	  β−catenin	  
nuclear	  translocation	  is	  dependent	  on	  its	  acetylation,	  which	  is	  regulated	  by	  glucose	  availability	  
[8].	  Our	  results	  simply	  indicate	  that	  inhibition	  by	  R.	  crenulata	  occurs	  upstream	  of	  the	  nuclear	  
translocation,	  hence	  acetylation	  could	  conceivably	  be	  part	  of	  this	  mechnaism.	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